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Haematopoietic stem cells (HSCs) emerge during embryogenesis and maintain 
hematopoiesis in the adult organism. Qualitative and quantitative assessment of 
HSCs can only be performed functionally using the in vivo long-term repopulation 
assay. Due to the lack of such data, little is known about the development of HSCs in 
the human embryo, which is a prerequisite for the development of new therapeutic 
strategies. Employing the xenotransplantation assay, I have performed here the 
spatio-temporal mapping of HSC activity within the human embryo and have shown 
that human HSCs emerge first in the aorta-gonad-mesonephros (AGM) region, 
specifically in the ventral wall of the dorsal aorta, and only later appear in the yolk 
sac, liver and placenta. Human AGM region HSCs transplanted into 
immunodeficient mice provide long-term high-level multilineage haematopoietic 
repopulation. These cells, although present in the AGM region in low numbers, 
exhibit a very high self-renewal potential. A single HSC derived from the AGM 
region generates around 600 daughter HSCs in primary recipient mice, which 
disseminate throughout the entire recipient bone marrow and are retransplantable. 
These findings highlight the vast regenerative potential of the earliest human HSCs 
and set a new standard for in vitro generation of HSCs from pluripotent stem cells for 
the purpose of regenerative medicine. I have also established a preliminary 
immunophenotype of the earliest human HSC. These data will be useful for my 
future studies on the mechanisms underlying the high potency of human embryonic 
HSCs and on the characterisation of embryonic HSC niche.  
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LIST OF ABBREVIATIONS 
7-AAD – 7-amino-actinomycin 
AGM region – the aorta-gonad-mesonephros region 
ALDH – aldehyde dehydrogenase 
AoD – the dorsal domain of the dorsal aorta 
AoV – the ventral domain of the dorsal aorta 
BFU-E – burst-forming unit erythroid 
CAFC – cobblestone area-forming cell 
CFSE – carboxyfluorescein diacetate succinimidyl ester 
CFU-C – colony-forming unit-culture 
CFU-G – colony-forming unit-granulocyte 
CFU-GEMM – colony-forming unit-granulocyte, erythroid, macrophage, 
megakaryocyte 
CFU-GM – colony-forming unit-granulocyte, macrophage 
CFU-M – colony-forming unit-macrophage 
CFU-S – colony-forming unit-spleen 
CI – confidence interval 
CLP – common lymphoid progenitor 
CMP – common myeloid progenitor 
CS – Carnegie stage 
DPBS – Dulbecco’s phosphate buffered saline 
ES cell – embryonic stem cell 
FACS – fluorescence-activated cell sorting 
FBS – foetal bovine serum 
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GMP – granulocyte and monocyte progenitor 
hpf – hours post fertilisation 
HSC – haematopoietic stem cell 
LTC-IC – long-term culture-initiating cell 





Ly5.2/Ly5.2 mouse – C57BL/6 mouse 
MEP – megakaryocyte and erythrocyte progenitor 
MLP – multilymphoid progenitor 
MPP – multipotent progenitor 
NK cell – natural killer cell 
NOD/SCID mouse – NOD.CB17-Prkdc
scid 
mouse 





SCID – severe combined immunodeficiency 
SD – standard deviation 
STR analysis – short tandem repeat analysis 
UGR – urogenital ridge   
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1.1. General Introduction 
Due to a very limited access to early human embryonic tissues, the embryonic 
development of the human haematopoietic system remains a largely unexplored area 
of research. A better understanding of this process is not only of academic interest 
but also of potential practical importance. Although bone marrow and umbilical cord 
blood-derived HSC transplantation is performed for a number of therapeutic 
indications in the clinic, the availability of suitable donors is inadequate. Therefore, 
many research laboratories are investigating the possibility of generating HSCs under 
controlled conditions in the laboratory. Embryonic and induced pluripotent stem cells 
can differentiate in vitro into the majority of cell types, including various 
haematopoietic cells. Theoretically, pluripotent stem cells could become an unlimited 
source of customised HSCs suitable for clinical application (reviewed by Kaufman, 
2009). However, the generation of transplantable HSCs has not been achieved so far. 
A better understanding of the embryonic development of human HSCs may be 
instrumental in developing novel protocols for their generation in the laboratory 
since without a deep understanding of the process in vivo it is hardly possible to 
replicate it in vitro. 
 
Although in vertebrate embryos the first haematopoietic cells, primitive 
erythroblasts, emerge in the yolk sac (Moore and Metcalf, 1970), a growing body of 
evidence suggests that the AGM region plays a key role in the generation of adult-
type or the so-called definitive HSCs (Boisset et al., 2010; de Bruijn et al., 2002; 
Dieterlen-Lievre, 1975; Medvinsky and Dzierzak, 1996; Medvinsky et al., 1993; 
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Muller et al., 1994; Zovein et al., 2008), possibly through the endothelio-
haematopoietic transition of endothelial cells in the dorsal aorta, which has been 
most convincingly shown in the zebrafish embryo employing in vivo imaging 
techniques (Bertrand et al., 2010; Kissa and Herbomel, 2010). The mouse AGM 
region is capable of autonomous initiation and expansion of HSCs (Cumano et al., 
2001; Medvinsky and Dzierzak, 1996; Taoudi et al., 2008). The early umbilical cord 
and the placenta are also involved in HSC development (de Bruijn et al., 2000; 
Gekas et al., 2005; Ottersbach and Dzierzak, 2005; Robin et al., 2009). Since in the 
mouse embryo the first definitive HSCs are detected at approximately the same time 
in different embryonic locations (de Bruijn et al., 2000; Gekas et al., 2005; 
Kumaravelu et al., 2002; Muller et al., 1994; Ottersbach and Dzierzak, 2005), their 
primary origin still remains a debatable issue (reviewd by Medvinsky et al., 2011). 
 
The generation of the first immunodeficient mice capable of accepting human tissue 
grafts (McCune et al., 1988) gave rise to studies on human HSCs, which were 
usually sourced from the adult bone marrow and the umbilical cord blood (Conneally 
et al., 1997; Larochelle et al., 1996; Wang et al., 1997). Human HSCs at early 
embryonic stages were detected only in the liver (Oberlin et al., 2010) and the 
placenta (Robin et al., 2009). Since human AGM and yolk sac cells have never been 
tested for HSC activity, it is not clear whether the previous observations in the mouse 
embryo can be extended to the human embryo. Therefore, considering the potential 
practical relevance to regenerative medicine, a detailed characterisation of the 
development of HSCs in the human embryo is the major scientific question 
addressed by the present thesis.  
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1.2. Central Terms of This Thesis 
HSC is a multipotent stem cell that emerges early during embryogenesis and 
maintains haematopoiesis during the entire lifespan of the organism through 
continuous self-renewal and differentiation. It is considered that fully-developed 
adult-type or the so-called definitive HSCs are capable of long-term high-level 
haematopoietic repopulation upon direct transplantation into preconditioned adult 
wild-type (immunocompetent) recipients (reviewed by Medvinsky et al., 2011). 
Therefore, qualitative and quantitative assessment of definitive HSCs can only be 
performed in vivo using the long-term repopulation assay (Jones et al., 1990; 
Ploemacher and Brons, 1989; Spangrude et al., 1988; Szilvassy et al., 1990). It 
should be noted that when discussing mouse embryonic HSCs I use the term 
‘definitive’; however, to be formal, I omit using this term for human embryonic 
HSCs since they were tested by transplantation into irradiated adult immunodeficient 
mice. In theory, the ideal recipient to test the definitive status of human embryonic 
HSCs would be a preconditioned adult human recipient. 
 
Pre-HSC is a haematopoietic precursor cell in the embryo that precedes the 
formation of definitive HSCs. Pre-HSCs, unlike definitive HSCs, are not yet mature 
enough to provide haematopoietic repopulation upon direct transplantation into 
irradiated adult wild-type recipients (reviewed by Medvinsky et al., 2011). These 
cells can mature into definitive HSCs in vitro (Rybtsov et al., 2011; Taoudi et al., 
2008) and can possibly engraft preconditioned neonatal (Ferkowicz et al., 2003; 




The AGM region is an intraembryonic tissue consisting of the dorsal aorta and 
urogenital ridges (UGRs). Data obtained in the mouse embryo suggest that the AGM 
region is the site where the first definitive HSCs emerge. The AGM region originates 
from the para-aortic splanchnopleura, which combines the dorsal aorta, vitelline 
artery (also called the omphalomesenteric artery), gut and splanchnopleura (reviewed 
by Medvinsky et al., 2011). 
 
The yolk sac is a membranous extra-embryonic tissue consisting of extra-embryonic 
endoderm and mesoderm. In various vertebrate embryos, the differentiation and 
production of the first primitive nucleated erythroblasts and myeloid cells occur in 
the yolk sac. Therefore, it was long considered that the yolk sac also produces 
definitive HSCs. However, the current consensus is that it is more likely that this role 
belongs to the AGM region (reviewed by Medvinsky et al., 2011). 
 
Primitive haematopoiesis is the first wave of haematopoiesis. It originates in the 
yolk sac and is characterised by a transient production of primitive erythroblasts and 
some myeloid cells serving the needs of the embryo before mature haematopoietic 
cells are produced by definitive HSCs (reviewed by Medvinsky et al., 2011). 
 
Definitive haematopoiesis is the second and the last wave of haematopoiesis 
emerging during embryogenesis and persisting in the adult organism. Although a 
growing body of data suggests that definitive haematopoiesis originates in the AGM 




1.3. Haematopoietic Hierarchy 
1.3.1. Adult Haematopoietic Hierarchy 
The majority of cells forming the adult haematopoietic system are mature 
haematopoietic cells including megakaryocytes and platelets, erythrocytes, 
neutrophil, eosinophil and basophil granulocytes, monocytes and macrophages, T, B 
and natural killer (NK) cells and myeloid and plasmacytoid dendritic cells. All these 
cells are derived from HSCs through multistep differentiation (Figure 1.3.1). 
Although this process is a continuum, different types of haematopoietic progenitors 
can be distinguished during the transition from HSCs to mature haematopoietic cells. 
The maturational relationship between HSCs, immature haematopoietic progenitors, 
committed haematopoietic progenitors and mature haematopoietic cells can be 
viewed as a hierarchy (reviewed by Seita and Weissman, 2010). 
 
At the foundation of the definitive haematopoietic hierarchy are definitive HSCs, 
which in adult vertebrates usually reside in the bone marrow. HSCs in the bone 
marrow are present at a very low frequency. In the mouse bone marrow, there is one 
HSC in 10000 nucleated cells (Kumaravelu et al., 2002). Isolating by fluorescence-















the mouse bone marrow, HSCs can be enriched almost to a single cell level 
(Adolfsson et al., 2001; Kiel et al., 2005; Osawa et al., 1996; Spangrude et al., 1988; 
Wilson et al., 2008). The precise frequency of HSCs in the human bone marrow is 
not known since the limiting dilution analysis by direct transplantation of 
unfractionated cells has not been done. However, recalculation of data obtained with 





Figure 1.3.1. Adult haematopoietic hierarchy (classical model). The multistep 
differentiation of definitive HSCs results in the formation of progeny with descending 
haematopoietic lineage plasticity and self-renewal capacity. Mature haematopoietic cells are 
terminally differentiated. The dotted lines indicate that intermediate haematopoietic 




human bone marrow cells (Majeti et al., 2007; Notta et al., 2011; Pang et al., 2011). 












 cells with frequency 1:10. (Notta et al., 2011). 
Interestingly, in contrast to mouse HSCs, human HSCs express CD34
 
and Flt3 
(Doulatov et al., 2010). 
 
Immediately downstream of HSCs in the haematopoietic hierarchy, multipotent 
progenitors (MPPs) have been identified. Similar to HSCs, these cells possess full 
multilineage differentiation potential; however, they lack unlimited self-renewal 
capacity (reviewed by Seita and Weissman, 2010). The mouse MPP population is 
heterogeneous and contains cells with different immunophenotypes listed below in a 


























































(Adolfsson et al., 2001; Boyer et al., 
2011; Christensen and Weissman, 2001; Forsberg et al., 2006; Wilson et al., 2008). 

















al., 2010; Majeti et al., 2007).  
 
Further downstream of MPPs in the haematopoietic hierarchy, common myeloid 
progenitors (CMPs) and common lymphoid progenitors (CLPs) have been identified. 
Similar to MPPs, these cells possess limited self-renewal capacity. Their 
differentiation potential is restricted either to the myeloid or lymphoid lineage, 
respectively. CMPs give rise to megakaryocyte and erythrocyte progenitors (MEPs) 
and granulocyte and monocyte progenitors (GMPs), which generate platelets and 
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erythrocytes and granulocytes, monocytes and myeloid dendritic cells, respectively. 
CLPs give rise to lymphoid lineage-restricted progenitors finally producing T, B, NK 
and plasmacytoid dendritic cells (reviewed by Seita and Weissman, 2010). By 























































































(Galy et al., 1995). Recently, it has 
been proposed that CLPs do not exist in the human adult haematopoietic hierarchy 














multilymphoid progenitors (MLPs) have been identified. In contrast to CLPs, MLPs 
are not lymphoid-lineage restricted and give rise not only to all mature lymphoid 












cells, which previously were considered as 
human CLPs, they lacked T cell differentiation potential and could generate in vitro 
only B and NK cells (Doulatov et al., 2010). Studies in the mouse have also 
suggested that adult haematopoietic hierarchy may differ from the model described 
above (Adolfsson et al., 2005; Lai and Kondo, 2006; Mansson et al., 2007). 
 
1.3.2. Embryonic Haematopoietic Hierarchy 
In the developing mouse embryo, the haematopoietic hierarchy evolves in the reverse 
sequence compared to that of the adult haematopoietic hierarchy. The first fully 
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mature haematopoietic cells, primitive erythroblasts, are found in the mouse yolk sac 
at day 8–8.5 of development (Silver and Palis, 1997). Around the same time, the first 
mouse committed haematopoietic progenitors detected in vitro as colony-forming 
units-culture (CFU-Cs) emerge in the yolk sac (Moore and Metcalf, 1970). The first 
immature haematopoietic progenitors detected in vivo as colony-forming units-spleen 
(CFU-Ss) appear in the mouse embryo around day 9.5–10 (Medvinsky et al., 1993), 
and the first definitive HSCs are detected in the mouse AGM region approximatelly 
at day 11.5 of development (Muller et al., 1994). 
 
To explain the emergence of mature haematopoietic cells and haematopoietic 
progenitors before HSCs, two models have been proposed. The first model suggests 
that two haematopoietic hierarchies, primitive and definitive, coexist during 
embryogenesis. The primitive transitory haematopoietic hierarchy emerges early in 
embryogenesis in the yolk sac and exists temporally until the permanent definitive 
haematopoietic hierarchy is established by AGM region-derived definitive HSCs. 
The second model suggests that a single haematopoietic hierarchy persists in the 
embryo. In this model, some embryonic haematopoietic ancestor cells give rise to the 
definitive HSC lineage. As HSC specification requires time, the same haematopoietic 
ancestor cells give rise to haematopoietic progenitors and mature haematopoietic 
cells to assure the ongoing development of the embryo. When definitive HSCs 
emerge, the haematopoietic hierarchy finally becomes established. If this model is 
correct, it cannot be ruled out that the above mentioned haematopoietic ancestor cells 
emerge in the yolk sac, but that final HSC maturation requires the AGM region 
environment (reviewed by Medvinsky et al., 2011). 
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1.4. Assessment of Haematopoietic Potential 
As discussed above, the haematopoietic cell population represents a diverse pool of 
cells that includes HSCs, immature haematopoietic progenitors, committed 
haematopoietic progenitors and mature haematopoietic cells. To evaluate this diverse 
population, different assays are used. Assays can be classified according to the cell 
type that they measure (HSCs, immature haematopoietic progenitors or committed 
haematopoietic progenitors) and the experimental conditions utilised (in vivo or in 
vitro, short-term or long-term). In this section, the main methods used to assess cell 
haematopoietic potential are described. 
 
1.4.1. Assessment of HSCs 
Qualitative (long-term self-renewal and multipotency) and quantitative assessment of 
HSCs can be performed only in vivo using long-term repopulation assays, which can 
be divided into two major groups: primary and secondary. These can further be 
categorised as competitive and noncompetitive. Human HSCs are assayed in 
xenotransplantation models (reviewed by Herbert et al., 2008). 
 
The primary long-term repopulation assay is accepted as the gold standard and the 
only tool to qualify and quantify HSCs within a transplanted cell population. The 
competitive assay measures the long-term ability of tested cells to engraft the bone 
marrow of irradiated recipients, relative to cotransplanted competitor HSCs, which 
are usually obtained from the bone marrow of a congenic donor with a phenotype 
distinguishable from the recipient and the tested donor (Szilvassy et al., 1990). The 
cotransplanted bone marrow cells have a dual role. Firstly, bone marrow 
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haematopoietic progenitors provide short-term radioprotection to the recipient before 
long-term HSC engraftment. Secondly, bone marrow HSCs are necessary for 
semiquantitative assessment of tested HSCs. Homing ability is often considered as an 
additional HSC defining criterion together with unlimited self-renewal and 
multilineage engraftment (reviewed by Ema and Nakauchi, 2004; reviewed by 
Harrison et al., 1993). 
 
The noncompetitive transplantation assay involves transplantation of tested HSCs 
without competitor cells. This assay more closely reflects allogeneic and autologous 
transplantation performed in clinical haematology. To provide recipient survival 
shortly after irradiation, a large number of HSCs need to be transplanted. 
Alternatively, recipients may be irradiated with a lower dose to ensure the 
regeneration of their own haematopoietic system. The assay allows evaluation of the 
myeloablation protection ability of HSCs (reviewed by Herbert et al., 2008). 
 
The secondary repopulation assay is usually performed six months after primary 
transplantation. To this end, primary recipient bone marrow cells are transplanted 
into a congenic irradiated secondary recipient that are phenotypically distinguishable 
from the primary donor. After 4–6 months, the presence of primary donor HSC-
derived haematopoietic cells in the secondary recipient is assessed. This gives some 
indication about HSC long-term self-renewal (reviewed by Herbert et al., 2008). 
 
The xenotransplantation assay is currently the most adequate method to study human 
HSCs. The first studies were performed using severe combined immunodeficiency 
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(SCID) recipient mice, which display T and B cell defects (McCune et al., 1988). As 
SCID mice often mediate the immunorejection of xenograft, they were backcrossed 
to nonobese diabetic (NOD) mice, which are deficient for NK and antigen-presenting 
cells (Shultz et al., 1995). Currently, NOD.CB17-Prkdc
scid
 (NOD/SCID) mice are the 
most widely used recipients to study human haematopoiesis in vivo. However, a low 
proportion of human HSCs engraft these animals. In addition, in these mice there is a 
bias towards B cell differentiation, and the development of T cells is rare. Also, the 










 (NSG) mice (Shultz et al., 2005) were created. The former strain 
supports a relatively high level of human HSC engraftment but, due to thymic 
lymphomagenesis, has a short life span. The latter strain supports a higher level of 
human HSC engraftment and is long-lived. Therefore, NSG mice are the best 
available xenogeneic recipients able to engraft human HSCs. It is accepted that these 
mice are considered as engrafted with human HSCs if at least 0.1% of total bone 
marrow CD45
+
 cells are of human origin (Notta et al., 2010). This criterion was 
selected to assess the engraftment of human bone marrow, mobilised peripheral 
blood and umbilical cord blood-derived HSCs. 
 
1.4.2. In Vivo Assessment of Immature Haematopoietic Progenitors 
To assess immature haematopoietic progenitors in vivo, the CFU-S assay is utilised 
(Till and McCulloch, 1961). Briefly, lethally irradiated mice are transplanted with a 
tested sample. After seven to 13 days, their spleens are dissected and fixed, and 
macroscopic spleen colonies are counted. This assay detects the cells that are capable 
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of short-term self-renewal and myelo-erythroid differentiation. In the definitive 
haematopoietic hierarchy, CFU-Ss reside downstream of HSCs. CFU-Ss can be 
divided into early (e.g. day 7) and late (e.g. day 13) CFU-Ss. Spleen colonies 
generated 7 days after transplantation contain mainly megakaryocytes and 
erythrocytes. Spleen colonies generated 13 days after transplantation are usually 
composed of granulocytes, macrophages, megakaryocytes and erythrocytes. 
Therefore, the late spleen colonies are generated by more immature haematopoietic 
precursors than the early ones. It is assumed that the number of CFU-Ss is a rough 
reflection of HSC numbers in a tested cell fraction (reviewed by Herbert et al., 
2008). However, pre-CFU-Ss (noncycling bone marrow-repopulating cells that 
survive cytostatic treatment) were shown to be a better indicator of the number of 
HSCs in the cell population being transplanted (Hodgson and Bradley, 1979). 
 
1.4.3. In Vitro Assessment of Immature Haematopoietic Progenitors 
There are two main in vitro assays to detect immature haematopoietic progenitors: 
the long-term culture-initiating cell (LTC-IC) assay and the cobblestone area-
forming cell (CAFC) assay. 
 
The LTC-IC assay is a submersed culture system that uses feeder cells to provide 
substrate and growth factors for the propagation and maturation of primitive 
haematopoietic progenitors. The LTC-IC is defined as a cell that is able to produce 
daughter cells that are detectable as colony-forming units-culture CFU-Cs (Dexter et 
al., 1977). Although LTC-ICs represent a subset of cells that share phenotypic and 
functional properties with HSCs, these cell types are distinct. Indeed, while human 
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 (Bhatia et al., 1997). 
 
The CAFC assay is also based on a submersed culture system that involves the use of 
feeder cells. In this assay, immature haematopoietic progenitors migrate underneath 
the feeder cell layer and at specific time points (defined by their primitiveness) begin 
to proliferate and form phase-dark haematopoietic colonies or the so-called 
‘cobblestone areas’. A cell that gives rise to one cobblestone area is called the 
CAFC. In the mouse CAFC assay, the frequency of day 10 CAFCs correlates with 
the frequency of day 12 CFU-Ss, and the frequency of day 28 CAFCs correlates with 
the frequency of HSCs within a tested cell population (Ploemacher et al., 1991). In 
the human CAFC assay, the frequency of week 6–12 CAFCs correlates with the 
frequency of HSCs (van Hennik et al., 1998). 
 
1.4.4. Assessment of Committed Haematopoietic Progenitors 
The late stages of haematopoiesis correspond to the persistence of committed 
haematopoietic progenitors that are an intermediate stage between immature 
haematopoietic progenitors and haematopoietic cells with morphologically visible 
features of differentiation. Generally, committed myelo-erythroid progenitors are 
assessed in short-term semisolid medium culture and are called CFU-Cs. When 
grown in these conditions, they form colonies of different types according to their 
maturity. The following committed haematopoietic progenitors are usually assessed: 
colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte (CFU-
GEMM), burst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte, 
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macrophage (CFU-GM), colony-forming unit-granulocyte (CFU-G) and colony-
forming unit-macrophage (CFU-M) (Nissen-Druey et al., 2005). 
 
1.5. Embryonic Development of Haematopoiesis in the Mouse 
There are several intra- and extra-embryonic sites of haematopoiesis in the mouse 
embryo (Figure 1.5.1). In accordance with current views, these sites are the yolk sac, 
the AGM region, the placenta, the umbilical and vitelline arteries and the liver. 
Although the mouse is the best characterised in vivo model in experimental 
haematology, the precise site where definitive HSCs emerge in the mouse embryo is 
still a debatable issue as the first mouse definitive HSCs can be detected at 
approximately the same time in different intra- and extra-embryonic tissues (de 
Bruijn et al., 2000; Gekas et al., 2005; Kumaravelu et al., 2002; Muller et al., 1994; 
Ottersbach and Dzierzak, 2005). This may be explained either by HSC emergence in 
different tissues or by HSC migration between different sites of the embryo. As 
mouse definitive HSC lineage specification involves pre-HSC maturation (Rybtsov 
et al., 2011; Taoudi et al., 2008), possible migration of these cells may complicate 
the analysis (reviewed by Medvinsky et al., 2011). 
 
1.5.1. Role of the Yolk Sac in Mouse HSC Development 
In the mouse embryo, the first sign of haematopoietic differentiation, βH1-globin 
gene expression, is detected in the yolk sac mesoderm around day 7.5 of 
development. By day 8, proliferating and differentiating extra-embryonic mesoderm 
cells form blood islands consisting of primitive haematopoietic cells surrounded by 




Figure 1.5.1. Multisite development of the haematopoietic system in the mouse embryo. 
In the mouse embryo, the first definitive HSCs are detected at day 11–11.5 of development 
in the dorsal aorta, the yolk sac, the umbilical and vitelline arteries and the placenta. Then, 
HSCs from the above intra- and extra-embryonic sites are believed to migrate to the 
embryonic liver (day 12.5 of development) and finally to the bone marrow (day 16.5 of 
development). In meantime, HSCs and/or haematopoietic progenitors colonise the thymus 
and spleen. The image was taken from Medvinsky et al., 2011. 
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primitive erythroblasts, are detected in the yolk sac (Silver and Palis, 1997). In 1970, 
it was reported that the mouse yolk sac harbours significant CFU-C, CFU-S and HSC 
activity (Moore and Metcalf, 1970). Considering this and the fact that the yolk sac is 
the earliest site of haematopoiesis in the mouse embryo, it was reasonable to suggest 
that mouse definitive HSCs emerge in the yolk sac. In addition, earlier observations 
in the chicken embryo supported this idea (Moore and Owen, 1965; Moore and 
Owen, 1967). 
 
A few years later, experiments performed with chimeric quail and chicken embryos 
provided solid evidence against the origin of definitive haematopoiesis in the yolk 
sac and suggested that definitive HSCs emerge in the embryo proper (Dieterlen-
Lievre, 1975). Shortly after that, it was reported that yolk sac cells derived from the 
day 8 mouse embryo contribute to adult haematopoiesis upon intrauterine 
transplantation into embryonic recipients (Weissman et al., 1978). Dieterlen-Lievre’s 
finding was interpreted as a peculiarity of the avian but not the mammalian embryo. 
However, the results of Irving Weissman’s experiments have not been independently 
confirmed. 
 
The ability of the mouse yolk sac to give rise to definitive HSCs was repeatedly 
questioned in 1990s. Employing a more stringent recipient mouse irradiation 
protocol to prevent the regeneration of endogenous CFU-Ss, it has been shown that 
the mouse yolk sac lacks CFU-Ss prior to day 9.5 of development and, of more 
importance, that the AGM region contains a higher number of CFU-Ss than the yolk 
sac (Medvinsky et al., 1993). Subsequent studies, have shown that the AGM region 
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but not the yolk sac is capable of definitive HSC generation through the maturation 
of pre-HSCs starting from day 10.5 of development and that the first definitive HSCs 
are detected in the yolk sac only at day 11.5 of development (Medvinsky and 
Dzierzak, 1996; Muller et al., 1994). 
 





 yolk sac cells from the day 9 mouse embryo were shown to 
contribute to adult haematopoiesis upon transplantation into pre-conditioned neonatal 
recipient mice (Yoder et al., 1997). However, at day 9 of development the circulation 
in the mouse embryo has already been established, it is unclear whether these cells 
originate in the yolk sac or in the para-aortic splanchnopleura. To answer this 
question, definitive HSCs precursors need to be assesses functionally in the early day 
8 mouse embryo, when the heart is not yet contracting. As this is not currently 
possible, only CFU-C migration through the embryonic circulation has been assessed 
so far (Lux et al., 2008). For this, Ncx1
-/-
 mouse embryos, which fail to initiate 
cardiac contractions and therefore the circulation, were used. It has been reported 
that the vast majority of CFU-Cs in Ncx1
-/-
 mouse embryos reside in the yolk sac, 
suggesting that intra-embryonic CFU-Cs found in wild-type embryos migrate from 
the yolk sac. The assessment of HSCs was not possible as the mutant embryos die in 
utero at day 10.5 of development, a day before the first mouse definitive HSCs can 
be detected. An attempt to show that the HSC lineage emerges in the yolk sac has 
been made employing genetic labelling of Runx1-expressing cells (Samokhvalov et 
al., 2007; Tanaka et al., 2012). However, considering the unclear duration of 
labelling, it is difficult to draw firm conclusions from these studies. 
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The lack of intra-embryonic CFU-Cs in Ncx1
-/-
 mouse embryos may be a secondary 
effect related to the lack of physical stress created by blood flow. It has been shown 
that shear stress applied in vitro improves both haematopoietic differentiation of 
mouse embryonic stem cells and propagation of mouse para-aortic splanchnopleura 
and AGM region-derived CFU-Cs in vitro. Additionally, intra-embryonic CFU-Cs in 
Ncx1
-/-
 mouse embryos can be rescued by applying shear stress during cell culture 
(Adamo et al., 2009). The pro-haematogenic effect of blood flow shear stress was 
also confirmed in the zebrafish embryo (North et al., 2009). As for a mechanistic 
insight into this phenomenon, the induction of nitric oxide signalling has been 
suggested as a molecular pathway to stimulate intra-embryonic haematopoiesis in 
both the mouse and zebrafish embryo (Adamo et al., 2009; North et al., 2009). 
 
Some observations have suggested that there is no controversy as to whether mouse 
definitive HSC lineage emerges in the yolk sac or the para-aortic splanchnopleura 
since both tissues are capable of generating definitive HSCs autonomously 
(Matsuoka et al., 2001). To this end, the yolk sac and the para-aortic splanchnopleura 
from the day 8 mouse embryo were individually cocultured for 4 days with AGM-S3 
stromal cells. This resulted in the production of definitive HSCs both by the yolk sac 
and by the para-aortic splanchnopleura, suggesting that definitive HSC precursors 
were present in both tissues prior to the onset of circulation. Despite the exceptional 
potential of AGM-S3 cells to induce definitive haematopoiesis in the precirculation 
mouse embryo, no further studies employing this cell line have been published since 




1.5.2. Role of the AGM Region in Mouse HSC Development 
Although experiments in the avian embryo had already suggested an intra-embryonic 
origin of definitive HSCs in 1975 (Dieterlen-Lievre, 1975), the view that mammalian 
HSCs originate in the yolk sac  dominated the field until the early 1990s. In 1993, a 
novel intra-embryonic source of haematopoietic activity, the AGM region, was 
described. It was reported that at day 9.5 of development the AGM region is the only 
source of CFU-S activity in the mouse embryo. During day 10, CFU-Ss appear in the 
yolk sac, with approximately fourfold lower frequency than in the AGM region. The 
liver does not develop CFU-S activity until day 11–11.5 of development (Medvinsky 
et al., 1993). 
 
Although the AGM region contains more CFU-S than the yolk sac, it does not 
necessarily mean that mouse definitive HSCs emerge in the AGM region. When the 
long-term repopulation assay was employed to assess the spatio-temporal distribution 
of HSCs in the mouse embryo, it was found that the first definitive HSCs can be 
easily detected at day 11–11.5 of development both in the AGM region and in the 
yolk sac. In both sites, only one HSC per tissue was found (Kumaravelu et al., 2002; 
Muller et al., 1994). It is worth mentioning that definitive HSCs were occasionally 
detected in the day 10.5 mouse AGM region and never in the day 10.5 yolk sac. To 
repopulate three irradiated adult recipient mice, 112 day 10.5 AGM regions were 
required (Muller et al., 1994). This finding was used to favour the AGM region as a 
primary source of definitive HSCs. However, this did not look like a very convincing 
argument due to the infrequency of the observation, which more likely could be 
explained with asynchronous development of some mouse embryos. Since HSCs 
32 
 
were detected in both the AGM region and the yolk sac at approximately the same 
time of development, it remained unclear in which embryonic site definitive HSCs 
emerge. 
 
To answer this question, an ex vivo organ explant culture system was developed 
(Medvinsky and Dzierzak, 1996). At day 10.5 of development, definitive HSCs are 
extremely rare in the mouse embryo (Muller et al., 1994). Dissecting and 
individually culturing the AGM region, the yolk sac and the liver from the day 10.5 
mouse embryo, it has been shown that only cultured AGM region cells are capable of 
providing robust long-term multilineage haematopoietic repopulation in irradiated 
adult recipient mice, suggesting that the AGM region but not the yolk sac generates 
the first mouse definitive HSCs (Medvinsky and Dzierzak, 1996). 
 
The same conclusion was drawn using an in vitro myelo-lymphoid differentiation 
assay. The para-aortic splanchnopleura and the yolk sac from day 7.5–8.5 mouse 
embryos were individually cocultured with mouse bone marrow-derived S17 stromal 
cells in the presence of cytokines. After 5 days, cells were transferred either onto 
fresh S17 stromal cells and cultured for 10–15 days to assess myeloid, B and NK cell 
potential, or cocultured with mouse thymic lobes for 10–15 days to assess T cell 
potential. It has been found that the para-aortic splanchnopleura possesses both 
myeloid and lymphoid differentiation potential prior to the onset of circulation, while 
the yolk sac produced only myeloid cells. Although the analysis was not performed 
at a clonal level, it has been suggested that cells with multilineage differentiation 
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potential, presumably definitive HSCs, emerge in the para-aortic splanchnopleura 
(Cumano et al., 1996). 
 
After it had been discovered that the mouse AGM region is capable of autonomous 
HSC generation (Medvinsky and Dzierzak, 1996), further steps were taken to 
localise the source of HSC activity within the AGM region. Various vertebrate 
embryos contain endothelium-associated haematopoietic cell clusters attached 
mainly to the ventral wall of the dorsal aorta (Dantschakoff, 1909; Emmel, 1916; 
Garcia-Porrero et al., 1995; Jaffredo et al., 1998; Jordan, 1917; Minot, 1912; Tavian 
et al., 1996). Also, it has been shown that Runx1, a key transcription factor essential 
for definitive HSC embryonic development (reviewed by Swiers et al., 2010), is 
expressed in the haematopoietic cell clusters and some endothelial cells lining the 
ventral wall of the dorsal aorta (North et al., 1999). The above observations indicated 
that the dorsal aorta might be a source of HSC activity within the mouse AGM 
region. Subdissecting the day 11.5 mouse AGM region into the dorsal aorta and the 
UGRs and individually transplanting cell suspensions prepared from these tissues 
into irradiated adult recipient mice, it has been found that only the dorsal aorta 
harbours HSCs (de Bruijn et al., 2000). Subdissecting the day 11.5 mouse dorsal 
aorta and surrounding mesenchyme along the midline into the ventral domain (AoV) 
and the dorsal domain (AoD) and testing these two tissues for HSC activity in the 
long-term repopulation assay, it has been found that the vast majority of definitive 
HSCs reside in the AoV. Moreover, it has been shown that exclusively the AoV is 
capable of HSC generation and expansion in the organ explant culture system 
(Taoudi and Medvinsky, 2007). 
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As it has already been mentioned, at day 11.5 of development the mouse AGM 
region contains one definitive HSC (Kumaravelu et al., 2002; Muller et al., 1994). 
After 3–5 days of culture in the organ explant culture system, the number of 
definitive HSCs increases up to 12 (Kumaravelu et al., 2002). A striking 150-fold 
increase of HSC numbers occurs in the reaggregate culture system after 4 days of 
culture in the presence of cytokines. The method involves the dissociation of the 
AGM region, purification of the cell population of interest, reaggregation of this 
population with primary AGM region stromal cells and culture at the gas-liquid 
interface (Sheridan et al., 2009; Taoudi et al., 2008). Using the fluorescent dye 
carboxyfluorescein diacetate succinimidyl ester (CFSE), it has been shown that the 
most of HSC within the reaggregated AGM region cultured for 4 days underwent no 
more than four divisions. In order to generate 150 HSCs from a single HSCs present 
in the mouse AGM region before culture, eight symmetrical divisions would be 
required. Therefore, the generation of mouse definitive HSCs in vitro and 
presumably in vivo occurs through the maturation of HSC ancestors termed pre-
HSCs (Taoudi et al., 2008), the existence of which was already suspected by 
Medvinsky and Dzierzak (1996).  
 
The mouse pre-HSCs described by Taoudi et al. (2008) are now called type II pre-
HSCs in order to distinguish them from type I pre-HSCs, which were described later 
(Rybtsov et al., 2011). Mouse type II pre-HSCs share the same phenotype with 




 (Taoudi et al., 2008; Taoudi et al., 2005). 
Developing a new coaggregate culture system in which the population of interest is 
coagregated with mouse OP9 stromal cells instead of primary AGM region stromal 
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 pre-HSCs have been discovered. 
These pre-HSCs were termed type I pre-HSCs because they mature into definitive 




type II pre-HSC phenotype 
(Rybtsov et al., 2011). 
 
Considering that mouse definitive HSCs, unlike pre-HSCs, are capable of long-term 
high-level haematopoietic repopulation upon direct transplantation into irradiated 
adult wild-type (immunocompetent) recipient mice, type I and type II pre-HSCs 
(Rybtsov et al., 2011; Taoudi et al., 2008) may not be the only pre-HSCs described 






 long-term repopulating haematopoietic 
cells found in the yolk sac and the para-aortic splanchnopleura of the day 9 mouse 
embryo can repopulate preconditioned neonatal but not adult recipient mice 
(Ferkowicz et al., 2003; Yoder et al., 1997). This suggests that these cells are not yet 
fully developed HSCs, and to become definitive HSCs they require some 











 long-term repopulating haematopoietic 
cells found in the intra-aortic cell clusters and subaortic patches in the day 10.5 
mouse embryo can be mentioned. Importantly, these cells repopulate irradiated 
immunodeficient but not wild-type adult recipient mice (Bertrand et al., 2005). This 
suggests that they are not definitive HSCs since to achieve successful haematopoietic 
engraftment they lack mechanisms to resist the immune system of wild-type hosts. 
Moreover, even in immunodeficient recipients, these cells are not capable of high-
level haematopoietic repopulation (Bertrand et al., 2005). Therefore, the described 
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above long-term repopulating haematopoietic cells may be pre-HSCs; however, the 
link between them and type I and type II pre-HSCs remains to be established. 
 
1.5.3. Role of Extra-Embryonic Arteries in Mouse HSC Development 
It has been found that during days 11.5 and 12.5 of development the mouse umbilical 
and vitelline arteries contain some numbers of definitive HSCs. The number of HSCs 
in these blood vessels was estimated as one HSC per two combined arteries, which is 
comparable to HSC frequency in the day 11.5 AGM region (de Bruijn et al., 2000). 
The first HSCs could be detected in the umbilical and vitelline arteries already at day 
10.5 of development, but HSC frequency is as low as in the day 10.5 mouse AGM 
region (de Bruijn et al., 2000; Muller et al., 1994). Although definitive HSCs are 
detected in the umbilical and vitelline arteries, these vessels failed to generate HSC 
in the organ explant culture system (de Bruijn et al., 2000). Thus, the ability of these 
vessels to initiate definitive haematopoiesis autonomously remains unclear. 
 
Recently, it has been suggested that the vitelline artery (also termed the 
omphalomesenteric artery) plays a role in the establishment of mouse definitive 
haematopoiesis through extravascular emergence of haematopoietic cell clusters and 
presumably definitive HSCs (Zovein et al., 2010). At day 9 of development, the 
vitelline artery is directly connected to the umbilical arteries. This connection is lost 
by day 11, when the vitelline artery establishes a connection to the dorsal aorta. In 
order to achieve this, between days 9 and 11 of development the vitelline artery 
undergoes significant remodelling. At the beginning, the link to the dorsal aorta 
occurs through a network of multiple small blood vessels. When these blood vessels 
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undergo remodelling to establish a single connection to the dorsal aorta, large 
endothelium-associated haematopoietic cell clusters, previously termed mesenteric 
blood islands, emerge (Garcia-Porrero et al., 1995; Zovein et al., 2010). By 
analysing this process in two dimensions, Zovein et al. (2010) have concluded that 
the haematopoietic cell clusters containing definitive HSCs emerge through 
extravasation. It is important to know whether emerging HSCs are located inside or 
outside blood vessels since this can shed light on the mechanism of HSC migration 
to the liver. Importantly, the above conclusion regarding the extravasation of 
haematopoietic cell clusters was declined when three-dimensional whole embryo 
immunostaining and imaging technique was employed. All endothelium-associated 
haematopoietic cell clusters observed around the vitelline artery of day 10–10.5 
mouse embryos were intra-arterial (Yokomizo et al., 2011).  
 
1.5.4. Role of the Placenta in Mouse HSC Development 
When, 35 years ago, long-term chronic anaemia correction was achieved in c-Kit
W/Wv 
mice transplanted with wild-type placental cells, it was suggested for the first time 
that the mouse placenta harbours HSCs (Dancis et al., 1977). A renewed interest in 
the placenta as a haematopoietic organ emerged again in 2000s, after two research 
groups had independently shown that between days 11.5 and 15.5 of development 
the mouse placenta serves as a reservoir for definitive HSCs (Gekas et al., 2005; 
Ottersbach and Dzierzak, 2005). 
 
The first HSCs can be detected in the mouse placenta at day 10.5 of development; 
however, these HSCs are extremely rare and provide only low-level repopulation 
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(Gekas et al., 2005). The first high-level repopulating HSCs are detected in the 
mouse placenta at day 11.5 of development (Gekas et al., 2005; Ottersbach and 
Dzierzak, 2005), approximately at the same time when they are detected in the AGM 
region, the yolk sac and the umbilical and vitelline arteries (de Bruijn et al., 2000; 
Kumaravelu et al., 2002; Muller et al., 1994). At day 11.5, there are no more than 2.5 
definitive HSCs per one mouse placenta (Gekas et al., 2005). By day 12.5 of 
development, the number of placental HSCs peaks. The actual number of definitive 
HSCs in the mouse placenta at day 12.5 is unclear and has been reported to vary 
from 12 (Ottersbach and Dzierzak, 2005) to 50 (Gekas et al., 2005). At day 13.5, 
placental HSC numbers begin do decline and reach 2–3 HSCs per one mouse 
placenta by day 15.5 of development, which may be explained by the relocation of 
placental HSCs to the liver (Gekas et al., 2005).  
 
Since the circulation in the mouse embryo is established 3 days before the first HSCs 
can be detected in the placenta, it is unclear whether mouse placental HSCs originate 
in the placenta, the AGM region or the yolk sac. The mouse placenta, unlike the day 
10.5–11.5 AGM region (Kumaravelu et al., 2002; Medvinsky and Dzierzak, 1996) 
and the day 12.5 yolk sac (Kumaravelu et al., 2002), was unable to produce HSCs in 
the organ explant culture system (Ottersbach and Dzierzak, 2005; Robin et al., 
2006). Therefore, it is possible that either the mouse placenta does not contain pre-
HSCs and is colonised by HSCs emerging elsewhere or that due to some technical 




The role of the circulation in the establishment of placental haematopoiesis was 
assessed in vivo employing the same approach as in the case with the yolk sac. It has 
been shown that in Ncx1
-/-
 mouse embryos, which fail to initiate cardiac contractions 
and therefore the circulation, CD41
+
 haematopoietic cell clusters emerge in the 
vessels of the chorioallantoic mesenchyme and developing labyrinth. Furthermore, 
placental cells from the mutant embryos are capable of myelo-erythroid and 
lymphoid differentiation in vitro (Rhodes et al., 2008). All this suggests that the 
mouse placenta possesses independent haematopoietic activity. However, it was not 
possible to assess if the mouse placenta can independently generate definitive HSCs 
as Ncx1
-/-
 mouse embryos die in utero at day 10.5 of development, before the 
appearance of transplantable HSCs. Importantly, organ explant culture experiments 
have suggested that the mouse placenta cannot generate HSCs (Ottersbach and 
Dzierzak, 2005; Robin et al., 2006). Additionally, it has been reported that definitive 
HSCs in the mouse placenta are CD41
- 
(Robin et al., 2011). This suggests that the 
emergence of CD41
+
 cell clusters in the placental vasculature and other signs of 
independent haematopoietic activity may not be related to the emergence of 
definitive HSCs. 
 
1.6. Embryonic Development of Haematopoiesis in Birds 
The first systematic studies addressing the embryonic origin of HSCs were 
performed on the chicken embryo. Parabiosis and cell transplantation between 
chicken embryos of opposite sexes, suggested that the yolk sac is the most likely 
source of the first HSCs (Moore and Owen, 1965; Moore and Owen, 1967). The first 
study that has brought this dogma into a question was also performed on avian 
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embryos (Dieterlen-Lievre, 1975). Grafting 2-day-old quail embryos onto chicken 
yolk sacs of the comparable developmental stage and employing morphological 
differences between quail and chicken cell nuclei showed that after 6–11 days of 
incubation all haematopoietic cells in the chimeric embryos were of quail origin, 
suggesting that HSCs emerge in some intra-embryonic site but not in the yolk sac. 
An intracoelomic grafting of quail spleen or thymus rudiments into the chicken 
embryo confirmed that these organs can be colonised by chicken haematopoietic 
cells, excluding inter-species incompatibility in the system (Dieterlen-Lievre, 1975). 
 
To find the possible intra-embryonic source of HSCs, the avian embryo was 
examined at 4–5 days of development, and some basophilic cells were found in the 
dorsal mesentery. These cells were proposed to be the earliest haematopoietic 
precursors. After 2–3 days, haematopoietic cells have been found to form dense foci 
at the level of the cardinal veins infiltrating the wall of blood vessels and lymph 
spaces and protruding into the lumen of the dorsal aorta. The intra-embryonic origin 
of the haematopoietic cells was confirmed in the chimeric embryo system (Dieterlen-
Lievre and Martin, 1981). The study suggested that HSCs in the avian embryo may 
originate from underneath the luminal layer of the dorsal aorta. However, later the 
same research group proposed a revised scenario for the embryonic development of 
HSCs in birds. By labelling the vasculature of the chicken embryo with DiI-
conjugated acetylated low-density lipoproteins at the time when intra-aortic 
haematopoietic cell clusters were not yet present, it was found that after the 
emergence of the clusters haematopoietic cells within the clusters retain DiI dye. As 





endothelial cells with no evidence of CD45
+
 haematopoietic cells present, it was 
concluded that haematopoietic cell clusters and presumably HSCs and/or pre-HSCs 
within these clusters were derived from endothelial cells at day 3–3.5 of development 
(Jaffredo et al., 1998). Subsequently, the labelled haematopoietic cells form the intra-
aortic clusters ingressed in the dorsal mesentery ventral to the dorsal aorta, 
propagated and formed para-aortic haematopoietic cell foci. This observation was 
confirmed using cell labelling with nonreplicative LacZ-bearing retroviruses 
(Jaffredo et al., 2000).  
 
Shortly after the emergence of HSCs in the dorsal aorta, the thymus, bursa of 
Fabricius and bone marrow of the avian embryo are colonised by haematopoietic 
cells. The colonisation of the thymus occurs during several short periods, with the 
first between days 5 and 6 in the quail embryo and between days 7 and 8.5 in the 
chicken embryo. The bursa of Fabricius is colonised by haematopoietic cells during a 
single period between days 7 and 11 in the quail embryo and days 8 and 14 in the 
chicken embryo. The bone marrow is colonised by haematopoietic cells on day 9 in 
the quail embryo and on day 10 in the chicken embryo (reviewed by Dieterlen-Lievre 
and Le Douarin, 2004). 
 
1.7. Embryonic Development of Haematopoiesis in Lower 
Vertebrates 
Due to external embryonic development, a high embryo tolerance for manipulations, 
prolific reproduction and comparatively low maintenance cost, frogs and fish are 
powerful tools in developmental biology. To study haematopoiesis during 
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embryogenesis, the African clawed frog (Xenopus laevis) and the zebrafish (Danio 
rerio) are frequently used (reviewed by Ciau-Uitz et al., 2010; reviewed by Paik and 
Zon, 2010). 
 
1.7.1. Haematopoiesis in the Frog Embryo 
In the frog embryo, primitive haematopoiesis occurs in the ventral blood island 
(Turpen et al., 1981). Its anterior portion starts producing haematopoietic cells, 
mainly of myeloid lineage, at 24 h post fertilisation (hpf) (Ohinata et al., 1990). The 
posterior portion of the ventral blood island gives rise to embryonic erythrocytes, 
myeloid cells and short-lived T cells at 35 hpf (Maeno et al., 1985). 
 
As for definitive haematopoiesis in the anuran embryo, it originates in the dorso-
lateral plate mesoderm giving rise to the trunk portion of the dorsal aorta, where cell 
clusters containing presumably definitive HSCs are formed at 80–92 hpf (Ciau-Uitz 
et al., 2000; Maeno et al., 1985; Turpen et al., 1981). Importantly, the ventral blood 
island and the dorso-lateral plate mesoderm derive from different blastomeres, 
suggesting that definitive HSCs emerge independently of primitive haematopoietic 
cells. (Ciau-Uitz et al., 2000). During the larval period, the main haematopoietic 
organ in the frog becomes the liver populated by HSCs from the dorsal aorta (Chen 
and Turpen, 1995). The bone marrow takes this function over after metamorphosis 






1.7.2. Haematopoiesis in the Zebrafish Embryo 
Being almost transparent, the zebrafish embryo provides a unique opportunity to 
study the development of haematopoiesis in vivo in real time (Bertrand et al., 2010; 
Kissa and Herbomel, 2010). There are two sites of primitive haematopoiesis in the 
zebrafish embryo: the rostral blood island, which develops from the anterio-lateral 
plate mesoderm and gives rise to myeloid cells, mainly macrophages, starting from 
10 hpf (Herbomel et al., 1999), and the intermediate cell mass, which develops from 
the posterio-lateral plate mesoderm and gives rise to erythroid cells entering the 
circulation around 24 hpf (Long et al., 1997). 
 
It is believed that definitive HSCs in the zebrafish embryo emerge in the dorsal aorta 
through the so-called endothelio-haematopoietic transition at 35–36 hpf (Bertrand et 
al., 2010; Kissa and Herbomel, 2010). The endothelio-haematopoietic transition 
starts about 30 hpf with aortic floor endothelial cell contractions and bending 
towards the subaortic space (Figure 1.7.1). After 1–2 h, the bent cells contract 
through the medio-lateral axis and loose contacts with adjacent lateral cells retaining 
contacts with rostral and caudal cells. Then, the distal contacts also disrupt and the 
cells undergoing the endothelio-haematopoietic transition acquire haematopoietic 
progenitor morphology and enter first the subaortic space, then the axial vein and 
finally the circulation (Kissa and Herbomel, 2010). It is believed that after emerging 
in the dorsal aorta definitive HSCs migrate into the caudal haematopoietic tissue and 
expand there. Starting from the second week of development, HSCs migrate from the 
caudal haematopoietic tissue into the kidney marrow, which is the main
44 
 
   
Figure 1.7.1. Endothelio-haematopoietic transition in the zebrafish embryo. GFP 
fluorescence highlights the whole vasculature in the KDR-GFP zebrafish embryo. The 
sequential stages of the endothelio-haematopoietic transition are explained in the text. 
Arrowheads point to haematopoietic precursor cells. DA, dorsal aorta. AV, axial vein. The 
image was taken from Kissa and Herbomel, 2010. 
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haematopoietic organ in the late larva and adult zebrafish (Bertrand et al., 2008; 
Murayama et al., 2006). 
 
1.8. Embryonic Development of Haematopoiesis in the Human 
For a long time, it was almost impossible to access the early human embryo for 
research purposes. Therefore, the investigation on the embryonic development of the 
human haematopoietic system has not been performed systematically. In the late 
1980s, the antiprogestative compound mifepristone became routinely used 
worldwide to terminate early pregnancies, which allowed obtaining relatively intact 
early human embryos for research purposes (Vervest and Haspels, 1985). At the 
same time, the first immunodeficient mice able to accept human HSC grafts were 
generated (McCune et al., 1988). This enabled the start of studies investigating the 
embryonic development of the human haematopoietic system and focusing on the 
origin of definitive HSCs. 
 
Until now, the development of the haematopoietic system in the early human 
embryos was characterised mainly by immunohistochemical methods and in vitro 
assays (Bloom and Bartelmez, 1940; Huyhn et al., 1995; Luckett, 1978; Migliaccio 
et al., 1986; Oberlin et al., 2002; Tavian et al., 1996; Tavian et al., 1999; Tavian et 
al., 2001). Human HSCs have been extensively studied in foetal, neonatal and adult 
cell sources by transplantation into immunodeficient mice (Conneally et al., 1997; 
Larochelle et al., 1996; Wang et al., 1997), but at early embryonic stages HSCs were 
assayed only in the liver (Oberlin et al., 2010) and the placenta (Robin et al., 2009). 
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Notably, neither the human AGM region nor the yolk sac has ever been assessed for 
HSC activity. 
 
1.8.1. Intra-Aortic Haematopoietic Cell Clusters 
Similar to other vertebrate embryos, the first human haematopoietic cells, primitive 
erythroid cells, are produced in the yolk sac between days 16 and 18.5 of 
development (Bloom and Bartelmez, 1940; Luckett, 1978). Classical experiments in 
the avian model system performed by Dieterlen-Lièvre (1975) and in the mouse 
model system performed by Medvinsky et al. (1993) demonstrated intra-embryonic 
haematopoietic activity. Bruno Peault and colleagues made the first attempt to extend 
these observations to the human embryo (Oberlin et al., 2002; Tavian et al., 1996; 
Tavian et al., 1999; Tavian et al., 2001). 
 
Employing immunohistochemistry, Tavian et al. (1996) have shown the existence of 




 cell clusters on the ventral wall of 
the dorsal aorta in the 30- to 37-day-old human embryo. A similar anatomic 
localisation display endothelium-associated haematopoietic cell aggregates on the 
ventral wall of the dorsal aorta in the avian and the mouse embryo at equivalent 
stages of embryonic development (Jaffredo et al., 1998; Taoudi et al., 2008; 
Yokomizo and Dzierzak, 2010). Although it has never been tested directly, it is 
assumed that these cell clusters contain HSCs. Tavian et al. (1996) assessed the 
haematogenic potential of the dorsal aorta by its ability to generate CFU-Cs in 
methylcellulose medium after primary short-term coculture with bone marrow 
stromal cells. Although in current literature Bruno Peault and colleagues are credited 
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for the description of human intra-aortic haematopoietic cell clusters, it should be 
noted that the presence of such clusters on the ventral wall of the human dorsal aorta 
was reported for the first time in the beginning of the last century (Minot, 1912). 
 
1.8.2. Chronology of the Emergence of Haematopoietic Progenitors 
Employing immunohistochemistry and in vitro assays, Tavian et al. (1999) have 
described the chronology of the emergence of haematopoietic progenitors in the 
human embryo. Primitive haematopoietic cells, erythroblasts and some unspecified 
CD45
+
 cells, were found in the human yolk sac at day 21 of development (the 
earliest stage described in the paper). At this embryonic age, there were no CD45
+
 
cells detected in the embryo proper. However, some primitive erythroblasts were 
found inside the cardiac cavity, suggesting that at day 21 circulation had already 
been established. The first CD45
+
 cells were detected inside the human embryo at 
day 22 of development. The authors have suggested that these cells migrated from 
the yolk sac. 
 
As for definitive haematopoiesis, it has been established that at day 27 of 




 cells emerged in the pre-umbilical region of the 
dorsal aorta. After 3 days, these cells were detected in the vitelline artery and liver. 




 cells in the dorsal aorta 
reaches several hundred. These cells disappeared from the dorsal aorta by day 40. 




The chronology described above is based on the assumption that the earliest 
haematopoietic progenitors in the human embryo are CD34
+
. Although the authors 
demonstrated that the CD34
+
 cell population possesses haematopoietic activity 
giving rise to haematopoietic colonies in methycellulose, it was not shown that 
CD34
- 
cells in the early human embryo are void of haematopoietic potential (Tavian 
et al., 1999). If the earliest human embryonic haematopoietic progenitors are indeed 
CD34
-
, their spatio-temporal distribution in the human embryo may differ from the 
described above. 
 
1.8.3. Dorsal Aorta but not the Yolk Sac Contains Multilineage Haematopoietic 
Progenitors 
To assess further the beginning of the development of definitive haematopoiesis in 
the human embryo, Tavian et al. (2001) employed a multistep in vitro assay. To this 
end, the dorsal aorta and the yolk sac were dissected and individually seeded intact 
on monolayers of confluent mouse bone marrow-derived MS-5 stromal cells and 
cultured in the presence of cytokines for 3 days. Then, tissues were dissociated and 
cultured for 10 additional days under the same conditions. Finally, cells were 
transferred either onto fresh MS-5 stromal cells and cultured for 4–5 weeks to assess 
myeloid, B and NK cell differentiation potential, or cocultured with mouse thymic 
lobes for 20 days to assess T cell differentiated potential. 
 
Using this in vitro assay, it has been demonstrated that the yolk sac at all stages 
assessed is capable of generating only myloid and NK cells whereas the dorsal aorta 
starting from day 24 of development can give rise to myeloid, B, T and NK cells. 
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The authors proposed that human multipotent haematopoietic progenitors and 
presumably HSCs emerge in the dorsal aorta (Tavian et al., 2001). Since the analysis 
was not performed at a clonal level, one cannot be sure that the progenitors described 
were indeed multipotent but not separate myeloid and lymphoid haematopoietic 
progenitors. Additionally, considering possible coexistence of the embryonic and 
adult haematopoietic hierarchies during development, in vitro assays cannot inform 
on the development of true HSCs, which can be assessed only in vivo using long-
term repopulation assays. 
 
1.8.4. Haematopoietic Potential of the Vascular Endothelium 
Employing in vitro assay described in the previous section, Oberlin et al. (2002) 
made an attempt to establish the haematogenic potential of the aortic and vitelline 
endothelium in 28- to 44-day-old human embryos. The authors have found that all 
vascular endothelial cells in the human embryo express CD34. None of the CD45
+
 
cells were ever found to be positive for CD34 expression before day 28 of 




 cell clusters were found on the ventral wall 
of the dorsal aorta. It was concluded that all vascular endothelial cells in the human 
embryo express CD34 and can be distinguished from haematopoietic progenitors as 





purified from the human aorta and the vitelline artery gives rise to myeloid and 
lymphoid cells. The authors concluded that a subset of human embryonic endothelial 




Considering recent findings in other model systems, especially in the zebrafish 
embryo (Bertrand et al., 2010; Kissa and Herbomel, 2010), it is very likely that the 
haematogenic endothelium also exists in the human embryo. However, the data 
obtained by Oberlin et al. (2002) are ambiguous in this respect. During human 
embryonic stem (ES) cell in vitro haematopoietic differentiation, CD43 marks 
emerging haematopoietic progenitors before CD45 (Vodyanik et al., 2006). In the 
mouse embryo, the earliest haematopoietic progenitors express CD41 but not CD45 
(Ferkowicz et al., 2003; Mikkola et al., 2003). The same is true for in vitro 
haematopoietic differentiation of mouse ES cells (Eilken et al., 2009; Lancrin et al., 
2009). Therefore, the conclusion regarding the haematogenic potential of the human 





lack the expression of CD43 or CD41.  
 
1.8.5. Role of the Placenta in Human HSC Development 
In the mouse placenta, definitive HSCs are detected at the same developmental age 
as in the AGM region, the yolk sac and the umbilical and vitelline arteries. 
Therefore, the placenta is considered to be one of the HSC sources in the mouse 
embryo (de Bruijn et al., 2000; Gekas et al., 2005; Kumaravelu et al., 2002; Muller 
et al., 1994; Ottersbach and Dzierzak, 2005). In the human embryo, the placenta also 
possesses haematopoietic activity. Already at week 5–6 of development (the earliest 
age studied), the human placenta contains comparatively high numbers of cells with 





cell population (Barcena et al., 2009; Robin et al., 2009). It has also been reported 
that the placenta harbors HSCs from at least week 6 of development, as was assessed 
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by highly sensitive PCR analysis (Robin et al., 2009). However, this method is not 
specific for haematopoietic cells and in principal can detect any donor-derived 
placental cells that survived after transplantation. The presence of true multipotent 
HSCs in the placenta was convincingly shown only starting from week 9 of 
development, when human haematopoietic engraftment in NSG recipient mice was 
assessed by flow cytometry (Robin et al., 2009). Thus, the exact timing of HSC 
appearance in the placenta remains to be clarified. 
 
1.9. Cellular Origin of Definitive HSCs 
More than a century ago, it has been noted that in the embryo the development of the 
haematopoietic and endothelial lineages is tightly linked together. The observation 
that during early embryogenesis proliferating and differentiating yolk sac mesoderm 
cells form blood islands consisting of primitive haematopoietic cells surrounded by 
endothelial cells led to an idea that both haematopoietic and endothelial lineages 
arise from common precursor termed haemangioblasts (Sabin, 1920). Around the 
same time, endothelium-associated intra-aortic haematopoietic cell clusters have 
been described, and it has been suggested that definitive HSCs emerge from the 
haematogenic endothelium (Dantschakoff, 1909; Emmel, 1916; Jordan, 1917; Minot, 
1912). During the last century, scientific data supporting the above two and some 
other scenarios have been presented; however, the cellular origin of definitive HSCs 






1.9.1. Haemangioblasts as HSC Lineage Precursors 
Early observations in the chicken embryo have suggested that yolk sac blood islands 
are clonal structures emerging from individual haemangioblasts as a result of their 
haemato-endothelial differentiation (Murray, 1932; Sabin, 1920). Therefore, it was 
reasonable to hypothesise that definitive HSCs develop in the yolk sac from 
haemangioblasts (Moore and Metcalf, 1970; Moore and Owen, 1965; Moore and 
Owen, 1967). Although the clonal origin of blood islands in the chicken yolk sac was 
suggested by morphological observations (Minko et al., 2003), blood islands in the 
mouse yolk sac have been reported to be multiclonal (Ueno and Weissman, 2006). In 
fact, there are no blood islands in the mouse yolk sac itself but a 
noncompartmentalised belt-like structure that encircles the whole yolk sac 
(Ferkowicz and Yoder, 2005). Furthermore, it is currently widely accepted that 
definitive HSCs originate intra-embryonically but not in the yolk sac (Dieterlen-
Lievre, 1975; Medvinsky et al., 1993). Therefore, the haemangioblast theory of the 
origin of definitive HSCs has been transformed to be in line with the concept that 
definitive HSCs emerge in the embryo proper, and it has been speculated that 
haemangioblasts reside in the para-aortic splanchnopleura (Huber et al., 2004). 
 
Initially, experiments performed with embryonic tissues have provided limited 
scientific evidence to support the existence of haemangioblasts. In the chicken 
embryo, hypothetical haemangioblasts (VEGFR2
+
 cells sorted from extra-embryonic 
mesoderm) produced in vitro either haematopoietic or endothelial colonies but never 
mixed haemato-endothelial colonies (Eichmann et al., 1997). Observations in the 
mouse embryo have not provided clear-cut evidence for the existence of 
53 
 
haemangioblasts either. Orthotopic transplantations have shown that haematopoietic 
and endothelial cells in the mouse yolk sac originate from different regions of the 
primitive streak, excluding their origin from a single haemato-endothelial precursor 




progenitors giving rise in vitro to haematopoietic, endothelial and smooth muscle 
cells have been identified mainly in the posterior region of the primitive streak of the 
mouse embryo. Importantly, these cells were rarely detected in the yolk sac, 
indicating that the yolk sac is colonised by haematopoietic and endothelial 





 ‘haemangioblasts’ needs to be elucidated further (Huber et 
al., 2004). 
 
An additional in vivo proof for the existence of haemangioblasts was obtained in the 
zebrafish embryo. Employing single cell fate maps obtained upon laser activation of 
caged fluorescein dextran, it has been demonstrated that haemangioblasts reside in 
the ventral margin of the gastrulating zebrafish embryo. These cells have been shown 
to be truly bipotent since they gave rise to haematopoietic and endothelial cells only. 
However, not all haematopoietic and endothelial cells arise from common 
progenitors, suggesting that some other mechanisms for the emergence of 
haematopoietic cells may exist during embryogenesis. It is also not clear whether 
definitive HSCs arise from haemangioblasts in the zebrafish (Vogeli et al., 2006).  
 
Another line of evidence to support the existence of haemangioblasts comes from 
studies employing in vitro haematopoietic differentiation of mouse ES cells. 
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Although this system may misrepresent true in vivo situation, Flk-1
+
 in vitro 
haemangioblasts termed blast colony-forming cells have been identified (Choi et al., 
1998; Kennedy et al., 1997). The blast colony-forming cells transiently exist within 
embryoid bodies, three-dimensional aggregates of cells derived from ES cells. When 
cells from embryoid bodies differentiated for 3–3.25 days were plated in 
methylcellulose medium supplemented with VEGF and SCF, blast cell colonies 
developed within 2–3 days. Upon transfer into liquid culture medium supplemented 
with growth factors, individual blast colonies could give rise to both haematopoietic 
and endothelial cells. Employing two distinct mouse ES cell lines, it has been shown 
that blast colonies are clonally derived but do not arise through cell migration and/or 
aggregation (Choi et al., 1998). 
 
The studies discussed in this section aimed to provide evidence for the existence of 
bipotent progenitors capable of haemato-endothelial differentiation. Unfortunately, 
the relationship of these cells to definitive HSCs has not been shown, and the 
emergence of definitive HSCs from haemangioblasts remains to be proven. 
 
1.9.2. Haematogenic Endothelial Cells as HSC Lineage Precursors 
The existence of haematogenic endothelium was suggested almost a century ago 
after endothelium-associated intra-aortic haematopoietic cell clusters had been 
described in different vertebrate embryos (Dantschakoff, 1909; Emmel, 1916; 
Jordan, 1917; Minot, 1912). The first experiments exploring the production of 
haematopoietic cells by the aortic endothelium were performed in the avian embryo. 
Labelling the vasculature of the chicken embryo with DiI-conjugated acetylated low-
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density lipoproteins or nonreplicative LacZ-bearing retroviruses resulted in the 
formation of labelled intra-aortic haematopoietic cell clusters. It is not entirely clear 
whether only endothelial but not circulating haematopoietic cells were labelled at the 
beginning (Jaffredo et al., 2000; Jaffredo et al., 1998). 
 
The existence of the haematogenic endothelium has been most convincingly shown 
in the zebrafish embryo. By employing in vivo time-lapse imaging of Flk-1, c-Myb, 
CD41 and Runx1 reporter transgenic zebrafish embryos, the production of 
haematopoietic cells by aortic endothelial cells has been visualised (Bertrand et al., 
2010; Kissa and Herbomel, 2010). The haematogenic endothelium cells become 
evident around 30 hpf when they start to contract and bend towards the subaortic 
space. After 5–6 h, these cells loose contacts with adjacent endothelial cells, acquire 
haematopoietic progenitor morphology and enter first the subaortic space, then the 
axial vein and finally the circulation (Kissa and Herbomel, 2010). Since long-term 
tracing of these cells was not done, it needs to be established that they are indeed 
HSCs but not multipotent progenitors (Bertrand et al., 2010; Kissa and Herbomel, 
2010). 
 
To prove the existence of the haematogenic endothelium in the mouse embryo, 
CD144 gene expression-specific Cre-mediated in vivo labelling was employed. In 
this experimental model, it has been found that the majority of haematopoietic cells 
in adult mice are labelled (Zovein et al., 2008). Since mouse adult HSCs are CD144
- 
(Taoudi et al., 2005), the haematopoietic lineage labelling should occur during 
embryogenesis. Based on the assumption that CD144 is an exclusive endothelial 
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marker, which is the case in the adult organism (Lampugnani et al., 1992), it was 
claimed that mouse definitive HSCs emerge from endothelial cells (Zovein et al., 
2010). However, in the mouse embryo, CD144 marks not only endothelial cells but 
also HSC lineage cells (North et al., 2002; Rybtsov et al., 2011; Taoudi et al., 2008; 
Taoudi et al., 2005). In fact, the labelling of haematopoietic lineage can be easily 







type I pre-HSCs or some earlier CD144
+
 haematopoietic precursors (reviewed by 
Medvinsky et al., 2011). However, Zovein et al. (2008) performed in vitro tamoxifen 
induction of Cre-ERT2 expressed under the control of the CD144 gene promoter in 




, and did not 
observe the labelling of haematopoietic cells due to the recombination of the 
Rosa26R-LacZ reporter gene. They concluded that the CD144 gene is not transcribed 
in CD144
+
 haematopoietic cells and that the CD144 protein is carried over from their 
endothelial ancestors. 
 
However, studies on the specification of HSC lineage in the mouse embryo from our 
















 type II pre-HSC stage takes 4 days. By the end of 
this period, CD144 remains expressed on the surface of definitive HSCs at a high 
level, which is unlikely to be possible without CD144 gene transcription. 
Furthermore, pre-HSC maturation into definitive HSCs involves several cell 
divisions, suggesting that the CD144 gene should be transcribed in HSC lineage cells 
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in order to maintain the constant level of CD144 protein expression (Rybtsov et al., 
2011; Taoudi et al., 2008). 
 
The aim of another study employing CD144 gene expression-specific Cre-mediated 
in vivo recombination was to establish the role of the Runx1 gene in the development 
of mouse definitive HSCs and its link to the haematogenic endothelium. When 
Runx1 was excised with CD144 gene promoter-driven Cre, definitive HSCs in the 
mouse embryo did not develop. In contrast, Runx1 deletion with Cre expressed in 
haematopoietic cells under the control of the Vav1 gene promoter did not affect the 
development of mouse definitive HSCs (Chen et al., 2009). Since Runx1 ablation in 
haematopoietic cells does not affect the development of definitive HSCs, based on 
the assumption that CD144 is an exclusive endothelial marker it has been concluded 
that Runx1 is required for the endothelio-haematopoietic transition during the 
production of definitive HSCs from the haematogenic endothelium (Chen et al., 
2009). However, Runx1 excision affecting the development of definitive HSCs could 
also occur in CD144-expressing pre-HSCs and/or definitive HSCs (Rybtsov et al., 
2011; Taoudi et al., 2008; Taoudi et al., 2005). Although it is known that Vav1 
expression is restricted to haematopoietic cells (Ogilvy et al., 1999), the evidence 
that the Vav1 gene promoter is active in HSC lineage cells would support the idea 
that CD144 gene expression-specific Cre-mediated Runx1 deletion occurs prior 
CD144
+
 cells acquire haematopoietic identity. In this case, the existence of the 




The existence of haematogenic endothelium has also been demonstrated in vitro. It 






 mesodermal cells, 







cells capable of producing haematopoietic cells (Nishikawa et al., 1998a). 
Importantly, cells with a similar phenotype and functional properties have been 
isolated from the day 9.5 mouse yolk sac and the embryo proper (Nishikawa et al., 
1998b). The above observations have been reinforced employing live cell imaging 
combined with single cell tracking (Eilken et al., 2009). 
 
Recently, a model combining both the haemangioblast and the haematogenic 
endothelium concepts has been proposed using the mouse ES cell differentiation 
model. Following the development of individual blast colonies using live cell 












haematopoietic cells (Lancrin et al., 2009). Thus, it is possible that haemangioblasts 







endothelial cells capable of producing 
haematopoietic cells in vitro can be found in the mouse embryo; however, it remains 
to be confirmed if these haematogenic endothelium cells originate from 
haemangioblasts. 
 
As for the human embryo, the only attempt to demonstrate the haematogenic 





cells considered to be endothelial (Oberlin et al., 2002). As 
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 cells from the human 
dorsal aorta and the vitelline artery do not express such early haematopoietic markers 
as CD43 (Vodyanik et al., 2006) or CD41 (Eilken et al., 2009; Ferkowicz et al., 
2003; Lancrin et al., 2009; Mikkola et al., 2003); therefore, it is still not confirmed 
that in the human embryo endothelial cells give rise to haematopoietic cells. 
 
Although some of the in vitro studies discussed above have convincingly shown that 
haematopoietic cells can be produced by endothelial cells (Eilken et al., 2009; 
Lancrin et al., 2009), the relationship of these endothelial and haematopoietic cells to 
definitive HSCs is not clear. The studies employing cell fate tracking upon in vivo 
labelling have not provided unambiguous evidence for the emergence of definitive 
HSCs from the haematogenic endothelium either. Thus, the haematogenic 
endothelium concept remains just one of the possible theories attempting to explain 
the embryonic development of definitive HSCs. 
 
1.9.3. Mesodermal Cells as HSC Lineage Precursors 
It is possible that the HSC lineage emerges not from haemangioblasts or 
haematogenic endothelium cells but directly from mesodermal precursors. It has 
been shown that in the mouse embryo between days 8.5 and 12 of development 
underneath the aortic floor persist the so-called subaortic patches formed by Gata3
+
 
mesodermal cells (Bertrand et al., 2005; Manaia et al., 2000). It was suggested that at 











 long-term repopulating haematopoietic cells 
detectable only by transplantation into immunodeficient adult recipient mice 
60 
 
(Bertrand et al., 2005). These cells can be considered as pre-HSCs since they are not 
mature enough to repopulate wild-type hosts (reviewed by Medvinsky et al., 2011). 











pre-HSCs emerge in the subaortic patches and 
migrate towards the lumen of the dorsal aorta and form intra-aortic haematopoietic 
cell clusters where pre-HSCs mature into definitive HSCs, which are released into 
the circulation. The recent study on mouse embryonic pre-HSCs and definitive HSCs 
from our laboratory has suggested that the above scenario may be true. While 
definitive HSCs are localised to the endothelial lining of the dorsal aorta, pre-HSCs 
reside both in the luminal and subluminal layers of the dorsal aorta (Rybtsov et al., 
2011). The subaortic patches have also been described in the human embryo 
(Marshall et al., 2000). 
 
1.10. Dorso-Ventral Polarity in Haematopoietic Activity within the 
Embryonic Dorsal Aorta 
In various vertebrate embryos, endothelium-associated haematopoietic cell clusters 
are found mainly on the ventral wall of the dorsal aorta (Emmel, 1916; Garcia-
Porrero et al., 1995; Jaffredo et al., 1998; Jordan, 1917; Minot, 1912; Tavian et al., 
1996). Furthermore, a number of key genes responsible for definitive haematopoietic 
specification during embryonic development, such as Runx1, Scl, c-Myb, Gata2, 
Gata3, Bmp4, Lmo2 and some others, are expressed in the ventral aortic endothelium 
and/or subaortic mesenchyme but not in the dorsal wall of the dorsal aorta (Bertrand 
et al., 2005; Ciau-Uitz et al., 2000; Durand et al., 2007; Elefanty et al., 1999; Manaia 
et al., 2000; Marshall et al., 2000; North et al., 1999; Thompson et al., 1998). These 
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observations led to functional testing of the dorso-ventral polarity in haematopoietic 
activity within the dorsal aorta and surrounding mesenchyme. 
 
Subdissecting the day 11.5 mouse dorsal aorta and surrounding mesenchyme along 
the midline into the AoV and the AoD and assessing the number of committed 
haematopoietic progenitors in each of these two tissues, it was unexpectedly shown 
that CFU-Cs are uniformly distributed in the wall of the dorsal aorta. However, in the 
long-term repopulation assay, the vast majority of definitive HSCs were found in the 
AoV. Testing the mouse dorsal aorta at day 10.5 of development, before appearance 
of definitive HSCs, it has been shown that in the organ explant culture system the 
AoV but not the AoD is capable of HSC generation and expansion (Taoudi and 
Medvinsky, 2007). 
 
At present, functional data on the existence of the dorso-ventral polarity in 
haematopoietic activity within the embryonic dorsal aorta are available only for the 
mouse embryo. Although in vivo imaging of the zebrafish embryo has provided 
rather convincing evidence that zebrafish definitive HSCs/multipotent progenitors 
emerge through the endothelio-haematopoietic transition of ventral aortic endothelial 
cells (Bertrand et al., 2010; Kissa and Herbomel, 2010). Beside the observations of 
the distribution of intra-aortic haematopoietic cell clusters (Minot, 1912; Tavian et 
al., 1996), no data to support the existence of the dorso-ventral polarity in 





1.11. Staging of Human Embryos 
Performing research on the embryonic development of the human haematopoietic 
system, it is important to stage human embryos properly to divide this continuous 
process into consecutive phases. Different staging approaches are used by different 
researchers. Researchers having different backgrounds understand the term 
‘gestational age’ differently. Embryologists by this term mean the postovulatory age 
of the human embryo (the age calculated based on the woman’s last ovulation). 
Gynaecologists-obstetricians under this term understand the menstrual age of the 
human embryo (the age calculated from the beginning of the woman’s last menstrual 
period). The difference between the two gestational ages is approximately two 
weeks; however, it cannot usually be determined precisely since the difference 
depends on the length of the woman’s menstrual cycle, which is frequently variable. 
When research is performed on early human embryos, the discrepancy in age may be 
sufficient enough to corrupt the results severely. Therefore, an accurate staging 
system of human embryos should be used (O’Rahilly and Muller, 2000). 
 
In present-day embryology, the Carnegie staging system, originally described by 
Streeter and refined by O’Rahilly and Muller (1987), is a gold standard to stage 
human embryos. Although this system has been accepted internationally and allows 
comparison between the findings of different researchers, the use of expressions as 
‘in a 22-day-old human embryo’ or ‘in a 6-week-old human embryo’ are not 
uncommon (Huyhn et al., 1995; Migliaccio et al., 1986; Oberlin et al., 2010; Oberlin 
et al., 2002; Robin et al., 2009; Tavian et al., 1996). Often it is not even specified 
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whether this is the postovulatory gestational age or the postmenstrual gestational age 
(Robin et al., 2009). 
 
The Carnegie staging system covers the whole human embryonic period (the first 56 
days of development), which starts with fertilisation and finishes with the onset of 
bone marrow formation in the humerus. The Carnegie staging system divides the 
human embryonic period into 23 Carnegie stages (CSs). Each CS is based on a 
complex of both external and internal morphological criteria and is not directly 
dependent on gestational age. Therefore, human embryos of the same gestational age 
can belong to different CSs, and vice versa, human embryos belonging to the same 
CS can be of different gestational ages. Embryos arranged only according to their 
gestational ages are not staged (O’Rahilly and Muller, 1987). 
 
1.12. Immunophenotype of Human Adult HSCs 
Haematopoiesis is usually considered as a hierarchy in which HSCs give rise to 
immature haematopoietic progenitors, which in turn give rise to committed 
haematopoietic progenitors producing mature haematopoietic cells. In this hierarchy, 
HSCs are the most challenging to study. The very low frequency of HSCs in 
haematopoietic tissue encourages the creation of methods of HSCs purification. 
Furthermore, some clinical applications require the isolation of HSCs. These 
questions can be addressed when the specific immunophenotype of human HSCs is 






The most widely used positive marker for human HSCs is CD34. Civin et al. (Civin 
et al., 1984) found this marker on approximately 1–2% of human bone marrow cells 
but not on peripheral mature haematopoietic cells. Berenson et al. (1988) showed 
that CD34
+
 baboon bone marrow cells are able to reconstitute the haematopoietic 
system of lethally irradiated recipients. In contrast, animals transplanted with CD34
+
 
cell-depleted bone marrow were either nonengrafted or demonstrated bone marrow 
aplasia and pancytopenia. Later, the same research group showed that CD34
+
 human 




 cell population is very heterogeneous. There is one HSC within about 
10000 CD34
+ 
cells sorted from human haematopoietic cell tissues. Only a small 
fraction of CD34
+ 
cells that are Lin
-
 (cells that do not express mature lineage markers 
such as CD2, CD3, CD4, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD33, 
CD56, CD66b, CD123, CD235a) and CD38
- 
possess HSC potential (reviewed by 
Bhatia et al., 1997; Kondo et al., 2003). In the umbilical cord blood, it has been 







one HSC (Bhatia et al., 1997). 
 
For a long time, it was assumed that CD34 marks all human HSCs. However, it was 
shown that some human HSCs are CD34
- 
(Bhatia et al., 1998; Zanjani et al., 1998). 
In umbilical cord blood, there is one CD34
-
 HSC in 1×10
8
 mononuclear cells 
compared with one CD34
+
 HSC in 1×10
6
 mononuclear cells (Bhatia et al., 1998). It 




 cells, which do not initially have 
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or have extremely low HSC potential, do acquire it after four days of coculture with 
bone marrow stromal cells,
 
which coincides with their conversion to a CD34
+
 
phenotype (Nakamura et al., 1999). Therefore, it was suggested that CD34
-
 HSCs are 
upstream of CD34
+
 HSCs and that patients transplanted with CD34
+
 cells do not 
receive essential CD34
-
 HSCs and may experience graft failure. Kato et al. (Kato et 
al., 2001) demonstrated that CD34
-
 bone marrow cells from patients transplanted 
with sorted CD34
+
 HSCs do not have potential to mature into CD34
+
 cells. In 
contrast, CD34
-
 bone marrow cells from healthy volunteers or from patients 
transplanted with unmanipulated bone marrow cells or T cell-depleted bone marrow 
possess this potential. The clinical significance of this finding remains to be clarified. 
 
1.12.2. CD133 
It was proposed that CD133 can provide an alternative to CD34 for the selection of 
human HSCs. CD133 is expressed on 20–60% of CD34
+ 
cells isolated from adult and 
foetal bone marrow, foetal liver, umbilical cord blood and mobilised peripheral 
blood. On CD34
+ 
cells obtained from adult haematopoietic tissues, the expression of 




 cells from the umbilical cord blood CD34
+
 cell population increases the 
proportion of CD133
+ 
up to almost 90%. It is important that on CD34
-
 cells CD133 is 
expressed at a very low level (CD133
+ 
cells are not detectable within the CD34
- 
cell 






 cell population 








cells can provide long-term multilineage 
human haematopoietic cell engraftment in foetal sheep and irradiated NOD/SCID 

















cell population have HSC potential. Thus, CD133 does not 















 cells are the only cells in adult 
and foetal bone marrow, foetal liver, umbilical cord blood and mobilised peripheral 
blood that are able to sustainably engraft irradiated SCID-hu mice (SCID mice 
transplanted with human foetal organs, including thymus, liver, bone with cavity, 
spleen and/or lymph nodes) (Baum et al., 1992). In clinical settings, it has been 




 cells with or without lineage 
depletion can reconstitute the haematopoietic system of preconditioned patients 
(Negrin et al., 2000). 
 
1.12.4. c-Kit 




 cells within human haematopoietic tissue 
CD34
+ 
cell population is arbitrary since c-Kit is expressed on these cells in a 




 and the c-Kit
high 
cell populations are gated. 




. Using the 







sufficient to show long-term multilineage engraftment of human haematopoietic cells 
in recipients. Due to a relatively small number of recipients used in the study, 
limiting dilution analysis was not possible (Kawashima et al., 1996). 
 
1.12.5. KDR (Flk-1) 
It has been reported that approximately 100 times higher enrichment for human 






 cell population can be achieved by 
isolating KDR
+









cells from human bone marrow, peripheral blood, mobilised 
peripheral blood and umbilical cord blood can generate long-term multilineage 
haematopoietic cell engraftment in irradiated NOD/SCID mice. It was estimated that 




cells. This cell population is Lin
-
 and 
represents about 0.1 to 0.5% of CD34
+ 













. This suggests that depletion of 
CD38
+ 
cells would further enrich this cell population for human HSCs. KDR is also 




 cell population (Ziegler et al., 1999). 
Surprisingly, following the report that KDR allows human HSC enrichment to a very 
high level, the marker has not been widely, if at all, employed. 
 
1.12.6. CD143 (Angiotensin-Converting Enzyme) 
Recently, it has been shown that CD143 marks human HSCs within the CD34
+
 cell 









umbilical cord blood generate long-term multilineage haematopoietic cell 
engraftment in irradiated NOD/SCID mice. Limiting dilution analysis of long-term 
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from human umbilical cord blood contain one HSC (Jokubaitis et al., 2008). 




 cell clusters on the ventral wall 
of the human embryonic dorsal aorta express CD143 (Sinka et al., 2012; Tavian et 
al., 1996).  
 
1.12.7. Hoechst 33342 Efflux 
Goodell et al. (1996) reported that staining mouse bone marrow cells with the 
fluorescent dye Hoechst 33342 allows isolating in a single step a cell population that 
is highly enriched for HSCs. Hoechst 33342
-
 cell population contains HSCs and is 
referred to as a ‘side population’. For mouse haematopoietic tissues, the side 
population assay allows over 1000-fold enrichment for HSC activity when compared 
to unmanipulated bone marrow. Although not all of the mouse HSCs belong to the 
side population, Hoechst 33342
+
 cells have approximately 500 times lower HSC 
activity than side population cells. 
 
The side population assay has also been applied to human haematopoietic tissues. 
Unlike mouse haematopoietic side population cells, human Hoechst 33342
- 
haematopoietic cells constitute a much more phenotypically and functionally 
heterogeneous population. For example, low-density human foetal liver cells contain 
around 0.15% of side population cells. Only about 20% of these cells are CD34
+
. 




 cells, express at least one 
of the lineage markers. Although all of the human HSCs present in foetal liver were 
shown to be Hoechst 33342
-
, due to significant heterogeneity it is not possible to 
69 
 
enrich the side population of human haematopoietic cells for HSC activity without 




 cells and enrichment for CD34
+







foetal liver cells are depleted from Hoechst 33342
+ 
cells, the 
frequency of HSCs increases only tenfold, but due to the toxic effect of exposing the 
cells to Hoechst 33342 there is observed an approximately threefold loss of HSCs 
(Uchida et al., 2001). 
 
1.12.8. High Cytosolic Aldehyde Dehydrogenase Activity 
Cytosolic aldehyde dehydrogenase (ALDH) is expressed at high levels in HSCs, as 
has been demonstrated first in the mouse. After counterflow centrifugal elutriation 
and Lin
+ 
cell depletion, mouse bone marrow cells were incubated with a fluorescent 
ALDH substrate dansyl aminoacetaldehyde, which diffuses across the cell membrane 
and after oxidation by ALDH forms dansyl glycine is retained intracellularly. 
ALDH
+ 
cells were identified by dansyl fluorescence. Every tenth cell in this 
population was shown to be an HSC (Jones et al., 1996). 
 
More recently, a newer fluorescent ALDH substrate BODIPY aminoacetaldehyde 
(Aldefluor) was used to select human HSCs. Both HSCs and haematopoietic 
progenitors reside within a fraction of human umbilical cord blood cells that exhibits 
low light scatter (SSC) properties, absence of the lineage markers and high 








cell population. Limiting dilution analysis estimated the frequency of HSCs to be 1 
























cells failed to 
generate long-term multilineage haematopoietic cell engraftment in irradiated 
NOD/SCID mice. This suggests that the majority of human HSCs are enriched 
within the cell population that expresses both CD34 and ALDH (Storms et al., 2005). 
 
1.12.9. Most Precise Immunophenotype of Human Adult HSCs to Date 
Studying HSCs derived from umbilical cord blood, Majeti et al. (2007) have isolated 










 cell population to as few 
as 10 cells. Later, this immunophenotype was confirmed (Doulatov et al., 2010) and 
an additional HSC marker, CD49f, was proposed (Notta et al., 2011). This allowed 
separating HSCs and transiently engrafting multipotent haematopoietic progenitors. 






















 cell population is still one in 10 cells (Notta et 
al., 2011). The use of more receptive for human HSCs neonatal but not adult NSG 
recipient mice by Majeti et al. (2007) may explain the discrepancy. Importantly, 
considerable HSC activity was also detected within Thy-1- cell population, which 
previously was considered as harbouring exclusively multipotent progenitors (Majeti 












 cell population are HSCs (Notta et al., 2011). This highlights that 
human HSCs are heterogeneous and no unique marker or marker combination have 





1.13. Summary and the Goal of the Present Study 
HSCs can only be truly assessed by using the long-term repopulation assay. Until 
now, the development of the haematopoietic system in the early human embryo was 
studied exclusively in vitro; therefore, only the emergence of cells with HSC 
immunophenotype, which are not necessarily HSCs, has been assessed. Considering 
this and the potential impact that a human subject study may have on the 
development of novel therapeutic strategies, the main goal of the present study was 
to elaborately describe the development of the earliest HSCs in the human embryo. 
The results of this study are organised in three subchapters: 
1. HSCs in the Early Human Embryo. Here, I describe the spatio-temporal 
distribution of HSC in the early human embryo and provide evidence for their 
stemness.   
2. Regenerative Potential of the Early Human Embryonic HSCs. In this result 
subchapter, I compare the regenerative potential of early human embryonic 
HSCs to that of HSC from other sources. 
3. Localisation and Immunophenotypic Characterisation of Human AGM 
Region HSCs. Here, I describe the dorso-ventral polarity in HSC activity 
within the human AGM region and provide the first data on the 




2. MATERIALS AND METHODS 
2.1. General Buffers 
Buffer 1 (dissection buffer) is a room temperature Dulbecco’s phosphate buffered 




 (Sigma-Aldrich) containing 7% of heat-
inactivated foetal bovine serum (FBS) (PAA Laboratories) and 100 IU/ml of 
penicillin and 100 μg/ml of streptomycin (Pen Strep solution from Invitrogen). 
 





7% of heat-inactivated FBS, 100 IU/ml of penicillin and 100 μg/ml of streptomycin. 
 





containing 2% of heat-inactivated FBS with or without 100 IU/ml of penicillin and 
100 μg/ml of streptomycin (the antibiotics were added in the case of a cell sorting). 
 
2.2. Source and Processing of Human Embryonic, Foetal and 
Neonatal Tissues 
Human embryonic and foetal tissues were obtained immediately after elective 
termination of pregnancy. The procedure was carried out by medical professionals at 
the Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK using mifepristone and 
misoprostol. Human umbilical cord blood samples were provided by the Scottish 
National Blood Transfusion Service (frozen mononuclear cells) and the Edinburgh 
Reproductive Tissue Biobank (full blood). In both cases, the samples were collected 
from full-term umbilical cords and placentas. The study was approved by the Lothian 
Research Ethics Committee (reference nos. 08/S1101/1 and 09/S1102/35). Before 
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tissue specimens were obtained and anonymised, each patient gave informed consent 
in writing for the use of human embryonic and foetal tissues in research.  
 
The developmental stage of human embryos was determined according to the 
Carnegie staging system (O’Rahilly and Muller, 1987). The postmenstrual 
gestational age of human foetuses was determined by obstetrician-gynaecologists 
using medical ultrasonography. 
 
Embryonic and foetal tissue dissection was performed in buffer 1. Whenever 
possible, my goal was to obtain from the same human embryo the AGM region, the 
yolk sac, the liver, the umbilical cord and the placenta, which were dissected under a 
Leica MZ8 stereomicroscope (Leica) using electrolysis-sharpened tungsten needles. 
In some cases, it was not possible to obtain all the above mentioned tissues as 
specimens were damaged. The dissection procedure was similar to that previously 
described for the mouse embryo and is described below (Medvinsky et al., 2008). 
 
For the enzymatic treatment of the human AGM region, yolk sac, liver and umbilical 
cord, 1 mg/ml of collagenase/dispase (Roche) and 0.12 mg/ml of DNase I (Roche) 
were added to tissues suspended in buffer 1 and incubated at 37° C for 40 min with 
gentle shaking. For the enzymatic treatment of placental tissue, two previously 
published protocols were employed with slight modifications (Barcena et al., 2009; 
Robin et al., 2009). After placentas were dissected free from maternal tissues and 
blood clots, they were minced with a surgical scissors. Then, either 181 U/ml of type 
I-A collagenase (Sigma-Aldrich), 0.7 mg/ml of type I-S hyaluronidase (Sigma-
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Aldrich) and 0.12 mg/ml of DNase I (Barcena et al., 2009) or 1 mg/ml of 
collagenase/dispase, 3 mg/ml of pancreatin (Sigma-Aldrich) and 0.12 mg/ml of 
DNase I (Robin et al., 2009) were added to placental tissues suspended in buffer 1 
and incubated at 37° C for 60 min with gentle shaking. At the end of enzymatic 
treatment, tissue digests were washed with buffer 2. In all instances, cells were 
centrifuged at 330×g for 5 min. For preparation of placental cells, in contrast to other 
tissues, 2 mM of EDTA (Sigma-Aldrich) were added to buffer 2. After the first wash 
with buffer 2, tissue digests were pipetted gently to prepare a single cell suspension. 
Human AGM region, yolk sac, liver and umbilical cord cells were washed an 
additional time with buffer 2. To remove cell clumps, placental cells were passed 
through a 40 μm nylon cell strainer (BD) and washed four more times. Finally, cells 
were resuspended in buffer 2 and kept on ice until transplantation, which was 
performed within 3–4 h of termination of pregnancy. In the majority of experiments 
with the human placenta, I omitted Ficoll-Paque density gradient separation step 
following the obtaining of a single cell suspension to minimise possible cell losses. 
 
Full umbilical cord blood obtained from the Edinburgh Reproductive Tissue Biobank 
was diluted 1:4 with buffer 2 supplemented with 2 mM of EDTA and layered over 
Ficoll-Paque (StemCell Technologies) and processed according to manufacturer’s 
instructions to separate mononuclear cells. Frozen mononuclear cells obtained from 
the Scottish National Blood Transfusion Service were removed from the liquid 
nitrogen, immediately thawed in a water bath at 37° C and washed twice in buffer 2 
supplemented with 2 mM of EDTA. Then, CD34
+
 cells were isolated employing the 
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Miltenyi Biotec magnetic cell separation technique. Finally, cells were resuspended 
in buffer 2 and kept on ice until transplantation. 
 
2.3. Xenogeneic Long-Term Repopulation Assay 
NSG mice (Shultz et al., 2005) were used as recipients for human HSCs. Animals 
were bred within the University of Edinburgh, Edinburgh, Scotland, UK according to 
the provisions of the Animal (Scientific Procedures) Act 1986 under the project 
license granted by the Home Office. All researchers who performed experiments 
with the mice held personal licenses granted by the Home Office. 
 
Mice were kept under specific pathogen-free conditions in isolators or individually-
ventilated cages. Autoclaved drinking water and γ-irradiated chow diet was provided 
ad libitum. During the first 4 weeks after irradiation, autoclaved drinking water was 
supplemented with 0.1 mg/ml of enrofloxacin (10% Baytril solution from Bayer) or 
1.67 mg/ml of neomycin (Invitrogen). Animals were exposed to 14-h light and 10-h 
dark cycle. 
 
Up to 6 h before transplantation with human cells, 6–8-week-old female NSG mice 
received a sublethal total body irradiation dose of 3.5 Gy at a rate of 0.75 Gy/min 
from a 
137
Cs source (GSR D1 γ-irradiator, Gamma-Service Medical). Animals were 
transplanted with cells intravenously via the tail vein. Some xenotransplantation 
experiments were performed by Dr Stanislav Rybtsov. The number of transplanted 
human embryonic cells were expressed in embryo equivalents (e.e.), defined as a unit 
of cells equivalent to the number of cells present in one tissue. Starting from week 6–
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8 after transplantation, NSG recipient mice were bled by tail vein nicking every 1–2 
months. Human HSC contribution was assessed by flow cytometry analysis cell  
immunolabelling with anti-human CD45 antibody. At the end of each experiment 
(usually 4–8 months after transplantation), all recipients (including those found 
nonengrafted after peripheral blood analysis) were killed by dislocation of the neck 
according to the Schedule 1 of the Animal (Scientific Procedures) Act 1986, and 
their bone marrow was collected. Bone marrow cells were labelled with anti-human 
CD45 antibody, and flow cytometry analysis was performed to detect the presence of 
human haematopoietic cells. The peripheral blood, bone marrow, spleen and thymus 
of engrafted NSG recipient mice were further analysed by flow cytometry analysis. 
The bone marrow and spleen from primary recipients were used in secondary 
transplantation experiments. On many occasions, xenotransplantation experiments in 
conjunction with the limiting dilution assay were also performed. 
 





/Boy mice (Ly5.1/Ly5.1) were used as recipients for HSCs from 
C57BL/6 mouse embryos (Ly5.2/Ly5.2) and bone marrow ‘carrier’ cells from F1 
hybrid mice (Ly5.1/Ly5.2). Ly5.1/Ly5.1, Ly5.2/Ly5.2 and Ly5.1/Ly5.2 mice were 
bred and kept under conditions similar to those for NSG mice, with the only 
difference being that the immunocompetent mice were housed in open-top cages. 
 
Up to 6 h before transplantation with mouse cells, 6–8-week-old female Ly5.1/Ly5.1 
mice received a split sublethal total body irradiation dose of 9.5 Gy (5 Gy and 4.5 Gy 
3 h apart) at a rate of 0.59 Gy/min from a 
137
Cs source. Animals were transplanted 
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with cells intravenously via the tail vein. The dose of transplanted mouse embryonic 
cells was expressed in e.e. At week 8 after transplantation, Ly5.1/Ly5.1 recipient 
mice were bled by tail vein nicking. Donor HSC contribution was assessed by flow 
cytometry analysis following cell immunolabelling with anti-mouse CD45.1 and 
CD45.2 monoclonal antibodies. 
 
2.5. Analysis of NSG Recipient Mouse Tissues 
To collect recipient mouse tissues, buffer 2 supplemented with 2 mM of EDTA was 
used. NSG mice transplanted with human AGM region, yolk sac, liver, umbilical 
cord, placental or bone marrow cells from primary recipients were bled by tail vein 
nicking, and erythrocytes were lysed using BD Pharm Lyse Buffer (BD) according to 
manufacturer’s instructions. To analyse haematopoietic tissues, the spleen, thymus, 
long bones, coxal bones and sternum were obtained. Spleen and thymus were gently 
mashed in a small volume of the buffer through a 40 μm nylon cell strainer. The 
bone marrow was flushed out from the bones, and a single cell suspension was 
prepared by gentle pipetting. A cell fraction associated with endosteum was obtained 
from bones after treatment with 1 mg/ml of collagenase/dispase and 0.12 mg/ml of 
DNase I at 37° C for 40 min with gentle shaking and added to the flushed-out bone 
marrow fraction. The cells were spun down, resuspended in buffer 2 and kept on ice 
until transplantation. To calculate the proportion of total bone marrow transplanted 
into secondary recipients, we used previously reported data on the distribution of 





2.6. Human CFU-C Assay 
Human CFU-C number in dissociated human embryonic tissues was detected by 
plating 0.1–0.05 e.e. of cells into the MethoCult H4034 Optimum Medium (StemCell 
Technologies) following manufacturer’s recommendations. Human CFU-Cs in the 
bone marrow of NSG recipient mice engrafted with human HSCs were detected by 
plating 10000–25000 bone marrow nucleated cells. The bone marrow from a 
nontransplanted NSG mouse was used as a negative control. Cells were incubated at 
37° C, in 5% CO2 and ≥95% humidity for 14 days. Haematopoietic colonies were 
enumerated microscopically. Some individual colonies were subject for cytospin 
analysis (May-Grunwald-Giemsa staining) and flow cytometry analysis 
(immunolabelling with anti-human CD45 and CD235a and anti-mouse CD45 and 
Ter119 antibodies). 
 
2.7. Cytospin Preparation and May-Grunwald-Giemsa Staining 
Fourteen days after the human CFU-C assay had been set up, individual 
haematopoietic colonies were harvested with a pipette under direct microscopic 
visualisation. Cells were washed from methylcellulose medium three times with 
buffer 3 and resuspended in 100 µl of the same buffer. Then, cells were loaded into 
individual cytospin chambers (Shandon) placed on top of a filter card (Thermo) and a 
poly-L-lysine-coated microscope slide (VWR International) and spun in a Cytospin 3 
centrifuge (Shandon) at 1000 rpm for 5 min. Microscope slides were removed from 
the cytospin chambers, air-dried, fixed with 100% methanol at room temperature for 




To stain cytospins, May-Grunwald-Giemsa staining was employed. May-Grunwald 





1:1 and 1:9, respectively. Both working solutions were 
prepared immediately before cell staining and were filtered through grade 1 filter 
paper (Whitman). Methanol-fixed cells were first stained with May-Grunwald stain 
for 14 min and then with Giemsa stain for 12 min. After this, microscope slides were 
washed with running tap water, immersed in distilled water and air-dried. Finally, 
cells were mounted in DPX mounting medium (Agar Scientific) and covered with a 
cover slip (VWR International). Cytospins were analysed next day using an Olympus 
BX61 compound microscope (Olympus). 
 
2.8. Flow Cytometry Analysis and FACS 
The following mouse anti-human monoclonal antibodies (all from BD) were used for 
flow cytometry analysis and/or FACS: CD3-APC, PE and PerCP (clones SK7 and 
SP34-2), CD4-APC and APC-Cy7 (clone RPA-T4), CD8-PE and PE-Cy7 (clone 
RPA-T8), CD11b-PE-Cy7 (clone ICRF44), CD13-APC (clone WM15), CD14-APC 
and APC-Cy7 (clones M5E2 and MφP9), CD19-PE (clone HIB19), CD33-PE (clone 
WM53), CD34-APC (clone 8G12), CD38-FITC and PE (clone HIT2), CD41a-FITC 
(clone HIP8), CD45-Biotin, FITC and V450 (clone HI30), CD66b-FITC (clone 
G10F5), CD94-APC (clone HP-3D9), CD235a-APC (clone GA-R2), IgM-Biotin 
(clone G20-127), αβ TCR-FITC (clone WT31) and γδ TCR-PE (clone 11F2). Mouse 
anti-human CD144-PE monoclonal antibody (clone TEA 1/31) was purchased from 
Beckman Coulter. Mouse anti-human c-Kit-APC (clone A3C6E2), Thy-1-APC 
(clone DG3) and CD105-APC (clone 43A4E1) monoclonal antibodies were a kind 
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gift from Miltenyi Biotec. Mouse anti-human CD45RA-eFluor 450 (clone HI100) 
and mouse anti-mouse CD45.1-APC (clone A20) and CD45.2-PE (clone 104) 
monoclonal antibodies were bought from eBioscience. Appropriate isotype controls, 
fluorochrome-conjugated streptavidin reagents and rat anti-mouse CD45-APC and 
FITC (clone 30-F11), Ter119-FITC and PE and in-house biotin-conjugated CD144 
(clone 11D4.1) monoclonal antibodies were purchased from BD. The Human FcR 
Blocking Reagent (Myltenyi Biotec) and anti-mouse CD16/32 purified monoclonal 
antibody (clone 93) (eBioscience) were used to prevent unwanted binding of 
antibodies to Fc receptors. All the antibodies and reagents listed above were used at 
final concentrations either recommended by manufacturers or determined by titration 
in-house. 
 
Cell immunolabelling and washes were performed in buffer 3. Up to 1×10
6
 cells 
were resuspended in 50 μl of the Human FcR Blocking Reagent and anti-mouse 
CD16/32 purified monoclonal antibody diluted 1:10 and 1:200, respectively, in 
buffer 3 and incubated on ice for 10 min. Then, 50 μl of antibody solution at the 
double concentration were added to the cells, making the final cell suspension 
volume to 100 μl. Cells were stained on ice and in the dark for 30 min. After this, 
cells were washed twice. If required, secondary staining with fluorochrome-
conjugated streptavidin was performed in a similar way. Otherwise, cells were 
resuspended in buffer 3 supplemented with 1.5 μg/ml of 7-amino-actinomycin (7-




A FACSCalibur, LSRFortessa (both from BD) or CyAn ADP (Dako) instruments 
were used for flow cytometry analysis. FACS and postsort purity checks were 
performed on a FACSAria II (BD) or Celula mvs360b (Celula) instruments. Sorted 
cells were spun down, resuspended in buffer 2 and kept on ice until transplantation. 
Flow cytometry data were analysed with FlowJo v7.6.1 software (Tree Star). 
 
2.9. Magnetic Cell Separation 
The magnetic cell separation technology developed by Miltenyi Biotec was 
employed to isolate CD34
+ 





 cells from human AGM region cell samples. All reagents and 
materials listed below were purchased from Miltenyi Biotec. Human CD34 and 







were isolated using anti-PE MicroBeads following cell immunolabelling with mouse 
anti-human CD144-PE monoclonal antibody (clone TEA 1/31) (Beckman Coulter). 
In all cases, magnetic cell separation was performed manually using a QuadroMACS 
separator and LS columns. Cell immunolabelling, washes and isolation were 
performed in buffer 3 according to manufacturer’s recommendations.   
   
2.10. Confocal Microscopy Analysis of the Mouse Bone Marrow 
Femurs were dissected from NSG recipient mice engrafted with human HSCs and 
immediately fixed in 10% neutral buffered formalin (Sigma-Aldrich). After 2 h, 
bones were decalcified in 0.4 M EDTA solution (pH=7.2) for 4 days at 4° C. Then, 





 and, after bones had sunk, into a 1:1 mixture of 30% sucrose solution 
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and OCT embedding medium (CellPath) and kept at 4° C for 1 day. For 
cryosectioning, bones were snap-frozen in OCT embedding medium on dry ice. 
Tissue sections were cut using a Leica CM1900 cryostat (Leica), transferred onto 
poly-L-lysine-coated microscope slides and kept at -20° C until immunolabelling. 
Individual tissue sections were encircled using a hydrophobic barrier pen (Vector 
Labs) and rehydratated in buffer 3 for 1 min. For antigen retrieval, tissue sections 
were incubated in 10 mM sodium citrate (Sigma-Aldrich) and 0.05% Tween 20 
(Sigma-Aldrich) buffer (pH=6) at 80° C for 20 min followed by a wash in buffer 3 
for 5 min. Then, the Human FcR Blocking Reagent and anti-mouse CD16/32 
purified monoclonal antibody diluted 1:10 and 1:200, respectively, in buffer 3 were 
added to tissue sections. After 10 min, this solution was discarded and mouse anti-
human CD45-FITC (clone HI30, BD) and unlabelled rat anti-mouse CD45 (clone 30-
F11, BD) antibodies diluted 1:10 and 1:100, respectively, in buffer 3 were added to 
tissues sections and incubated for 1 h in the dark followed by three washes, 5 min 
each, in buffer 3. After this, goat anti-rat IgG-Alexa Fluor 546 antibody (Invitrogen) 
diluted 1:100 in buffer 3 was added to tissue sections and incubated for 30 min in the 
dark followed by three washes, 5 min each, in buffer 3. Then, nuclei were stained by 
incubating tissue sections in buffer 3 containing 0.2% of DAPI (Invitrogen) for 10 
min in the dark followed by three washes, 5 min each, in buffer 3. Finally, tissue 
sections were mounted in VECTASHIELD mounting medium (Vector Labs) and 
covered with a cover slip. Microscope slides were analysed next day using Leica DM 





2.11. DNA Fingerprinting 
Short tandem repeat (STR) analysis to discriminate between embryonic versus 
maternal origin of haematopoietic repopulation was performed by Dr Lindsey Welch 
at the University of Strathclyde, Glasgow, Scotland, UK. Genomic DNA was 
extracted from human embryonic or foetal donor tissues and from peripheral blood, 
bone marrow and/or spleen cells obtained from corresponding NSG recipient mice 
repopulated with human haematopoietic cells. For this, the QIAamp DNA 
Investigator Kit (Qiagen) and a QIAcube robotic instrument (Qiagen) were used. 
DNA quantification was performed with the Plexor HY System (Promega) and an 
Mx3500P real-time PCR machine (Stratagene). DNA quantification values were 
determined using the Plexor
 
Data Analysis Software (Promega). DNA samples and 
PCR positive and negative controls were amplified with the AmpFlSTR SGM Plus 
PCR Amplification Kit (Applied Biosystems). PCR products were detected on a 
3130 Genetic Analyzer (Applied Biosystems). Handling of raw data and genotyping 
were carried out with GeneMapper ID v3.2.1 software (Applied Biosystems). All the 
reagents and instruments listed above were used according to manufacturers’ 
recommendations. DNA match probabilities were calculated based on allele 
frequencies in the Scottish Caucasian population. 
 
2.12. Statistical Analyses 
Data are presented as a mean±standard deviation (SD) or a 95% confidence interval 
(CI). Correlation between variables was assessed based on the Pearson product-
moment correlation coefficient or the Spearman rank correlation coefficient and two-
tailed test of significance. Selection of parametric versus nonparametric tests to 
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perform comparison between groups was based on the evaluation of normality using 
the Kolmogorov-Smirnov test. If data sets were normally distributed, comparison 
between groups was performed using the Independent-Samples T Test or the Paired-
Samples T Test. In the opposite case, the Mann-Whitney U Test or the Wilcoxon 
Signed Ranks Test were used. Statistical significance was attributed to probability 
value P<0.05. For the above statistical procedures, SPSS 15.0 for Windows software 
(SPSS) was used. Validity tests for the single-hit Poisson model and the limiting 
dilution analysis were performed using ELDA software (Hu and Smyth, 2009) 




3.1. HSCs in the Early Human Embryo 
3.1.1. Introduction 
It was long assumed that in vertebrate embryos the yolk sac is the unique provider of 
definitive HSCs (Moore and Metcalf, 1970; Moore and Owen, 1965; Moore and 
Owen, 1967). A paradigm shift occurred after the experiments with chimeric quail 
and chicken embryos had suggested the intra-embryonic origin of HSCs (Dieterlen-
Lievre, 1975). Shortly after, the same was confirmed for the amphibian embryo 
(Turpen et al., 1981). In the mouse embryo, the first HSCs were also detected in the 
intra-embryonic AGM region (Muller et al., 1994). Moreover, it has been shown that 
the mouse AGM region initiates and sustains the generation of definitive HSCs 
independently of the yolk sac (Medvinsky and Dzierzak, 1996). Considering that the 
qualitative and the quantitative assessment of HSCs can usually be performed 
employing the in vivo long-term repopulation assay (Jones et al., 1990; Ploemacher 
and Brons, 1989; Spangrude et al., 1988; Szilvassy et al., 1990), nothing has been 
reported regarding the development of HSCs in the human embryo. The fundamental 
understanding of this process is a prerequisite for the development of novel 
therapeutic strategies such as a guided in vitro differentiation of human pluripotent 
stem cells into transplantable HSCs and a controlled ex vivo expansion of human 
umbilical cord blood and adult bone marrow HSCs. 
 
Until now, the early embryonic development of the human haematopoietic system 
has been studied mainly by immunohistochemical methods and in vitro assays. 
Similar to other vertebrate embryos, in the human embryo, haematopoietic cells are 
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generated both in the yolk sac and in the embryo proper (Huyhn et al., 1995). In the 
yolk sac, the first haematopoietic cells, primitive erythroid cells, are produced in 
blood islands between days 16 and 18.5 of development (Bloom and Bartelmez, 





 haematopoietic cell clusters appear on the ventral wall of 
the human dorsal aorta between days 26 and 37 of development (Minot, 1912; 
Tavian et al., 1996; Tavian et al., 1999). This territory has never been tested for HSC 
activity, but it has been claimed that the first human HSCs emerge within these cell 
clusters. Later, it has been demonstrated that the AGM region contains 
haematopoietic progenitors able to give rise to myeloid, B, T and NK cells, whereas 
the yolk sac haematopoietic progenitors were able to produce myeloid and NK cells 
but not B and T cells (Tavian et al., 2001). Despite the fact that these data were 
obtained in vitro, it is speculated that the earliest human HSCs emerge in the AGM 
region as only this tissue showed unrestricted haematopoietic differentiation 
potential. Due to the lack of in vivo data, it is still not clear where and when the first 
HSCs arise in the human embryo. 
 
3.1.2. Experimental Approach 
Early human embryos were obtained immediately after elective termination of 
pregnancy. In the majority of cases, it was possible to dissect from the same embryo 
all tissues that, based on studies in the mouse, are considered to be involved in the 
embryonic development of the mammalian haematopoietic system (reviewed by 
Medvinsky et al., 2011). This approach in a combination with access to human 
embryos at different developmental stages allowed establishing the spatio-temporal 
87 
 
distribution of HSCs in the early human embryo. To assess HSC activity, single cell 
suspensions prepared from different dissected embryonic tissues were individually 
transplanted into sublethally irradiated NSG mice. In all experiments, female 
recipient mice were used since they are more receptive for human HSCs than male 
recipient mice (Notta et al., 2010). Human HSCs were detected by their capacity to 
provide long-term (>4 months) multilineage haematopoietic engraftment of human 
origin and to self-renew upon intravenous transplantation into sublethally irradiated 
NSG mice. 
 
3.1.3. Spatio-Temporal Distribution of HSCs in the Early Human Embryo 
To establish the spatio-temporal distribution of HSCs in the early human embryo, 
transplantation experiments were performed with dissected human AGM regions, 
yolk sacs, livers, umbilical cords and placentas from CS 12–17 human embryos 
(Figures 3.1.1 and 3.1.2). In total, 29 independent experiments were set up. 
Throughout the thesis, the term ‘independent’ refers to those experiments performed 
with different human embryos. The AGM region was obtained in all cases. The yolk 
sac, liver, umbilical cord and placenta were obtained in 20, 27, 17 and 19 
experiments, respectively (Table 3.1.1). 
 
HSCs in the AGM region were detected in 11 cases. In nine of these experiments, the 
AGM region was the only tissue containing HSCs, suggesting that the AGM region 
is the first generator of human HSCs. True multipotent HSCs in the human AGM 
region were detected from CS 14 until at least CS 17. Out of seven independent 
transplantations performed with CS 14 AGM regions, only one resulted in human
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Figure 3.1.1. Representative human embryos used in the present study to establish the 
onset of HSC activity during human embryogenesis. Embryos at CS 12–17 were obtained 






Figure 3.1.2. Embryonic tissues used in the present study to establish the spatial 
distribution of HSCs in the human embryo. In the majority of experiments, it was 
possible to dissect from the same human embryo all tissues that are considered to be 




  Table 3.1.1. Spatio-temporal distribution of HSCs in the early human embryo. Cell 
suspensions prepared from AGM regions, yolk sacs, livers, umbilical cords and placentas 
obtained from CS 12–17 human embryos were individually transplanted into sublethally 
irradiated NSG mice. Data shown are the number of tissues that gave human haematopoietic 
repopulation (long-term embryonic multilineage repopulation, long-term embryonic 
unilineage T cell repopulation or transient maternal unilineage T cell repopulation) 
compared to the total number of tissues transplanted. The numbers in parentheses indicate an 
approximate postovulatory gestational age in days accepted for each CS (O’Rahilly and 
Muller, 1987). NA, not assessed. 
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long-term multilineage repopulation of a recipient mouse. In contrast, every second 
CS 15–17 human embryos contained HSCs in the AGM region. It was not possible to 
establish when the human AGM region loses HSC activity since human embryos 
beyond CS 17 could not be obtained for the present study (Table 3.1.1). 
 
In the yolk sac, HSCs could be detected starting from CS 16. Thus, HSCs in the 
human yolk sac appear approximately 5 days later than in the AGM region. In total, 
there were observed only three cases when HSCs resided in the yolk sac. In two of 
these experiments, HSCs were also detected in the AGM region (Table 3.1.1). It is 
currently unclear whether the human yolk sac is able to produce HSCs independently 
or serves just as a reservoir for the HSCs produced in the AGM region and delivered 
to the yolk sac through the circulation. 
 
In one out of 27 experiments, HSCs were found in the human embryonic liver. The 
liver was obtained from a CS 17 human embryo. In this embryo, HSCs were also 
found in the AGM region. Additionally, some cells capable of long-term unilineage 
T cell repopulation were detected in two other CS 17 livers. The same outcome was 
also observed in one experiment with the AGM region dissected from a CS 16 
human embryo (Table 3.1.1). Importantly, the bone marrow from the NSG recipient 
mice exhibiting long-term unilineage T cell engraftment could never provide human 
haematopoietic repopulation in secondary recipients, excluding HSC origin of the 
repopulation. It can be speculated that cells capable of long-term unilineage T cell 
engraftment were early embryonic T cell progenitors. Alternatively, these cells might 
be human counterparts of mouse lymphopoiesis-biased γ and δ subtypes of long-term 
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repopulating haematopoietic cells found in the mouse adult bone marrow and the 
foetal liver (Dykstra et al., 2007b). 
 
Umbilical cords and placentas obtained from early human embryos contained no 
HSCs at all embryonic developmental stages tested. However, upon transplantation 
into sublethally irradiated NSG recipient mice, every third placenta irrespective of 
developmental stage could easily provide transient unilineage T cell repopulation of 
maternal origin (Table 3.1.1). Explicit details on the nature of this haematopoietic 
repopulation are provided in section 3.1.10. 
 
3.1.4. Dorsal Aorta Is the Source of HSC Activity within the Human AGM 
Region 
In the mouse embryo, definitive HSCs first appear in the dorsal aorta (de Bruijn et 
al., 2000; Taoudi and Medvinsky, 2007). In 10 independent transplantation 
experiments, it was tested whether this could be extrapolated to the human embryo. 
To increase the success rate of these experiments, CS 15–17 human embryos were 
used. In each case, the AGM region was subdissected into the dorsal aorta and the 
UGRs, as previously described for the mouse AGM region (de Bruijn et al., 2000; 
Taoudi and Medvinsky, 2007). Single cell suspensions prepared from these tissues 
were individually transplanted into sublethally irradiated NSG recipient mice. In 10 
independent experiments performed, HSCs were detected in six dorsal aortae and 





3.1.5. High-Level Haematopoietic Repopulation by Early Human Embryonic 
HSCs 
In NSG mice engrafted with HSCs from the human AGM region, the yolk sac and 
the embryonic liver, donor CD45
+
 haematopoietic cells could first be detected in the 
recipient blood around month 2 after transplantation, reaching on average 
0.22±0.15% of total blood leukocytes (Figure 3.1.3). Observing the recipient mice 
for up to 14 months after transplantation, it has been found that around month 5 after 
transplantation a substantial increase in the levels of donor haematopoietic 
contribution into the recipient peripheral blood usually occurs (Figure 3.1.3). The 
percentage of human CD45
+
 cells in the recipient mouse peripheral blood could 
reach up to 90% of total leukocytes by month 8 after transplantation (Figure 3.1.3 
and Table 3.1.2). By the end of the observation period, which lasted for 4–14 months 
after transplantation, on average 40±25% of total recipient blood leukocytes were of 
human origin. In the recipient mouse bone marrow and spleen, the percentage of 
human CD45
+
 cells was even higher than in the peripheral blood, reaching on 
average 76±20% and 70±29% of total bone marrow or spleen CD45
+
 cells, 
respectively (Table 3.1.2). In the recipient thymus, virtually all leukocytes were 
human T cells. 
 
3.1.6. Multilineage Differentiation Potential of Early Human Embryonic HSCs 
In general, the pattern of human multilineage haematopoietic repopulation observed 
upon the engraftment of early human embryonic HSCs was similar to that reported 
by others after engraftment of umbilical cord blood or adult bone marrow HSCs 







Table 3.1.2. High-level hematopoietic repopulation by early human embryonic HSCs. 
NSG mice transplanted with HSCs derived from the human AGM region, the yolk sac or the 
embryonic liver were observed for 4–14 months. At the end of each experiment, the 
percentage of human CD45
+
 cells in the recipient peripheral blood, bone marrow and spleen 
was assessed by flow cytometry. NA, not assessed as the recipients died. 
Figure 3.1.3 (on the previous page). Progressive growth of haematopoietic contribution 
in NSG recipient mice engrafted with early human embryonic HSCs. (A) Representative 
flow cytometry plots show hematopoietic cells in the peripheral blood and bone marrow of 
an NSG mouse transplanted with 0.33 e.e. of AGM region cells. In this case, the AGM 
region was obtained from a CS 16 embryo. The repopulation kinetics was monitored for 8 
months. BM, bone marrow. (B) Human hematopoietic engraftment kinetics in the peripheral 
blood of 14 NSG recipient mice transplanted with human AGM region, yolk sac or 
embryonic liver cells. The numbers at the end of the time series correspond to the recipient 
identification numbers in Table 3.1.2. 
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differentiation was usually biased towards lymphopoiesis. In NSG recipient mice 
engrafted with early human embryonic HSCs, human CD19
+ 
B lineage cells were the 
major human leukocyte population in the peripheral blood (43±27%) and spleen 
(59±25%). In the recipient mouse bone marrow the percentage of B lineage cells was 
on average 38±23% of total human leukocytes (Table 3.1.3). To characterise human 
B lymphopoiesis and to distinguish between pre-B cells and B cells, human B 
lineage cells were examined for the surface expression of IgM. In the bone marrow 
of NSG recipient mice, approximately one-third (27±1.5%) of human B lineage cells 
passed the pre-B cell stage, as indicated by the expression of IgM. In the spleen, the 
proportion of IgM
+ 
B lineage cells was approximately three times as high (83±6.5%) 
as in the bone marrow. In the peripheral blood, almost all (93±3.4%) human B 
lineage cells were IgM
+
. (Figure 3.1.4 A) These observations correspond to the 
normal development of B lineage cells (Nagasawa, 2006). 
 
As for T lymphopoiesis, human CD3
+
 T cells were observed in all main 
haematopoietic tissues of NSG mice engrafted with early human embryonic HSCs 
(Table 3.1.3). In the recipient blood, bone marrow and spleen, the percentage of 
these cells was 35±20%, 14±7.8% and 26±21% of total human leukocytes, 
respectively. In the thymus, all CD45
+
 haematopoietic cells were human T cells. The 













 T cells constituted 16±8.3% and 5.5±2.5% of 
total human T cells, respectively. As expected, only 2.1±0.64% of human thymic 
CD45
+




 T cells. Importantly, only rare 








Figure 3.1.4 (on the previous page). Human long-term multilineage haematopoietic 
repopulation in NSG recipient mice engrafted with early human embryonic HSCs. 
Representative flow cytometry plots show human B cells (A), T cells (B, C), NK and NKT 
cells (D), granulocytes and monocytes/macrophages (E), erythroid cells (F) and platelets 
(G) in the peripheral blood, bone marrow, spleen and/or thymus of an NSG mouse 7 months 
after it was transplanted with 0.5 e.e. of AGM region cells. In this case, the AGM region was 
obtained from a CS 17 human embryo. Note that the staining for CD4 and CD8 is shown in 
gated human CD45
+
 cells, and for TCRs in gated human CD3
+
 cells. For flow cytometry 














































































































































































































































































































































as is normally observed in human peripheral blood (Figure 3.1.4 B and Table 3.1.3). 
The above indicates that early human embryonic HSC-derived T cell progenitors are 
capable of normal intrathymic maturation (reviewed by Koch and Radtke, 2011). 
Additionally, 97±1.5% of human CD3
+
 cells in the peripheral blood of NSG 
recipient mice expressed αβ T cell receptors. Only 1.0±0.75% of T cells expressed γδ 
T cell receptors (Figure 3.1.4 C). The same is normally observed in the human 
peripheral blood (reviewed by Ciofani and Zuniga-Pflucker, 2010). 
 
To finalise the description of lymphopoiesis, it needs to be mentioned that early 









 NKT cells. These cells were present at a comparatively low frequency 
in the recipient NSG mouse peripheral blood (9.2±8.9%), bone marrow (1.4±1.1%) 
and spleen (3.7±3.4%) (Figure 3.1.4 D). 
 
As for myelopoiesis, the percentage of human CD33
+
 myeloid cells in the peripheral 
blood and spleen of NSG recipient mice engrafted with early human HSCs was 
comparatively low (14±7.8%). However, up to 95% of human leukocytes in the 
recipient bone marrow were of myeloid lineage. On average, this figure was 49±24% 









macrophages were observed (Figure 3.1.4 E). Human erythroid cells could never be 
detected in the peripheral blood and spleen of NSG mice engrafted with early human 
embryonic HSCs. However, human CD235a
+
 erythroid cells could easily be found in 
the recipient mouse bone marrow, reaching 6.2±3.2% of total bone marrow nucleated 
cells. On average, 18±7.2% of erythroid cells coexpressed CD45, indicating their 
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immature state (Figure 3.1.4 F). Mouse erythropoietin has a reduced activity on 
human cells (Nicolini et al., 1999). This may be one of the reasons for the lack of 
peripheralisation of human erythroid cells. Also, human erythrocyte release into the 
mouse peripheral blood may be hampered by recipient macrophages (Hu et al., 




platelets were easily 
detectable in the peripheral blood of NSG mice engrafted with early human 
embryonic HSCs (Figure 3.1.4 G). 
 
3.1.7. Human HSCs and Haematopoietic Progenitors in the Recipient Mouse 
Bone Marrow 
Flow cytometry analysis of the bone marrow from NSG recipient mice engrafted 
with HSCs from the human AGM region, the yolk sac and the embryonic liver have 
confirmed that human haematopoiesis in such recipients progressed from HSCs to 
mature haematopoietic cells through intermediate haematopoietic progenitor stages. 





population contains the vast majority, if not all, of HSCs and haematopoietic 





 cells in the bone marrow of recipient mice transplanted with early 
human embryonic HSCs was on average 1.0±0.71% of total bone marrow nucleated 
cells (Table 3.1.4), a value approximately 10 times higher than is usually observed in 
the normal human bone marrow (Pang et al., 2011). For recipient mice 4, 9, 10 and 
14, a more detailed flow cytometry analysis of the bone marrow human HSC and 





cell population was further subdivided into three cell subpopulations based on the 
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Table 3.1.4. Human CD34+CD38- cell frequency in the bone marrow of NSG recipient 
mice engrafted with early human embryonic HSCs. NSG mice transplanted with HSCs 
derived from the human AGM region, the yolk sac or the embryonic liver were observed for 




 cells in 
the recipient bone was assessed by flow cytometry. The recipient identification numbers are 
the same as in Table 3.1.2. NA, not assessed. 
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) could easily be identified in the recipient bone 





 cells, respectively. If we compare these figures to those for the normal 
human bone marrow (Majeti et al., 2007), MLPs but not MPPs were dominant 
haematopoietic progenitors in the NSG recipient mouse bone marrow. 
 
To assess human haematopoietic progenitors in the recipient mouse bone marrow 
functionally, the CFU-C assay was performed. Bone marrow cells from the recipient 
mice engrafted with early human embryonic HSCs were plated into methylcellulose 
medium supplemented with human cytokines. After 14 days of culture, human 
haematopoietic colonies could easily be detected (Figure 3.1.6 A–D). In the recipient 
mouse bone marrow, there were on average 31.8±10.3 human CFU-Cs per 10000 
nucleated cells (Table 3.1.5). The human origin of haematopoietic colonies was 
confirmed by flow cytometry analysis (Figure 3.1.6 E and F). 
 
3.1.8. Spatial Distribution of Haematopoietic Cells in the Recipient Mouse Bone 
Marrow 
In two experiments, femurs were collected from NSG recipient mice engrafted with 
HSCs from the human AGM region. The femurs were fixed, decalcified, snap-frozen 
in OCT embedding medium and sectioned. After staining with anti-human and anti-
mouse CD45 monoclonal antibodies, the spatial organisation of human and mouse 




  Figure 3.1.5. Human immunophenotypic HSCs, MPPs and MLPs in the bone marrow 
of NSG recipient mice engrafted with early human embryonic HSCs. Representative 
flow cytometry plots show the flow cytometry analysis performed with bone marrow cells 
from recipient mouse 4 engrafted with AGM region HSCs from a CS 17 human embryo. To 

























), the cells 
were immunolabelled with anti-human CD34, CD38, Thy-1 and CD45RA monoclonal 
antibodies and analysed by flow cytometry (A). Cell populations of interest were gated 




  Figure 3.1.6. Assessment of human CFU-C activity in the bone marrow of NSG 
recipient mice engrafted with early human embryonic HSCs. Seven months after 
transplantation, bone marrow cells from an NSG mouse repopulated with AGM region 
HSCs from a CS 17 human embryo were plated into methylcellulose medium supplemented 
with human cytokines. This resulted in the formation of human haematopoietic colonies of 
different types (A–D). Representative flow cytometry plots confirm the human origin of 




Table 3.1.5. Human CFU-C frequency in the bone marrow of NSG recipient mice 
engrafted with early human embryonic HSCs. Data shown are the number±SD of human 
CFU-Cs per 10000 input bone marrow nucleated cells. The bone marrow was obtained from 
NSG mice repopulated with HSCs from the human AGM region, the yolk sac or the 




microscopy. In recipient mouse 3, in which 45% of bone marrow CD45
+
 cells were 
of human origin, human and mouse haematopoietic cells in the bone marrow were 
segregated and formed well-demarcated areas (Figure 3.1.7 A). Only between these 
areas, human and mouse haematopoietic cells have been found intermixed. In the 
recipient mouse 6, in which 93% of total bone marrow CD45
+
 cells were of human 
origin, human haematopoietic cells almost completely superseded mouse 
haematopoietic cells in the bone marrow (Figure 3.1.7 B). The above observations 
suggest that upon the xenogeneic transplantation of HSCs from the human AGM 
region, discrete areas of human and mouse haematopoiesis persist in the recipient 
mouse bone marrow. It would be of interest to test if this is also the case in human 
umbilical cord blood and adult bone marrow HSC xenotransplantation. 
 
3.1.9. Early Human Embryonic HSCs Self-Renew and Are Retransplantable 
It was tested whether HSCs from the human AGM region, the yolk sac and the 
embryonic liver can be serially transplanted. In all eleven experiments with the AGM 
region, two experiments with the yolk sac and one experiment with the embryonic 
liver, the transplantation of the bone marrow from one primary recipient mouse into 
six to 20 secondary recipient mice resulted in sustainable human long-term 
multilineage haematopoietic engraftment (Figure 3.1.8). In these experiments, 96% 
(108 out of 113) of secondary recipient mice transplanted were found engrafted with 
human HSCs. Since the vast majority of primary recipient mice were transplanted 
with approximately one or two early human embryonic HSCs (see section 3.2.3), 















Figure 3.1.8. Human long-term multilineage haematopoietic engraftment in secondary 
NSG recipient mice upon the retransplantation of early human embryonic HSCs. 













) in the peripheral blood (A) and the bone 
marrow (B) of an NSG mouse transplanted with bone marrow cells from a primary recipient 
engrafted with HSCs from a CS 15 AGM region. Secondary transplantation was performed 
7 months after primary transplantation. The analysis of secondary recipient mice was 
performed 7 months later. In total, 14 independent secondary transplantation experiments 
were performed. 
 
Figure 3.1.7 (on the previous page). Human haematopoietic areas in the bone marrow 
of NSG recipient mice engrafted with HSCs from the human AGM region. Femurs were 
obtained from two NSG recipient mice exhibiting human long-term multilineage 
haematopoietic repopulation upon the transplantation with HSCs from the human AGM 
region. Recipient mice 3 (A) and 6 (B) were used in this experiment (see Tables 3.1.2, 3.1.3 
and 3.1.4 for the details on these recipients). After the bones were fixed, decalcified, snap-
frozen and sectioned, tissues were stained with anti-human and anti-mouse CD45 
monoclonal antibodies, followed by nuclear counterstaining with DAPI. Images were 
obtained employing confocal microscopy. A control for anti-human CD45 monoclonal 




bone marrow of primary recipient mice, which is discussed in more detail in the next 
result subchapter. 
 
3.1.10. HSCs in the Human Placenta Appear Later than in the AGM Region 
It has recently been reported that the human placenta harbours HSCs from at least 
week 6 of gestation (Robin et al., 2009). In that study, 17 human placentas from 
human embryos and foetuses between weeks 6 and 19 of development were screened 
for HSC activity by transplantation into sublethally irradiated NOD/SCID mice. It 
has been reported that human haematopoietic repopulation of recipient mice was 
achieved at least in five independent experiments. However, among these five cases 
there were only one placenta from a 6-week-old human embryo and one placenta 
from an 8-week-old human embryo. Since Robin et al. (2009) used postmenstrual 
gestational age, which exceeds by approximately 2 weeks postovulatory gestational 
age employed in the Carnegie staging system, 6–8-week-old human embryos in their 
study are comparable to CS 12–17 human embryos in the present study. Juxtaposing 
the data of Robin et al. (2009) with the data on the timing of HSC emergence in the 
human AGM region presented in section 3.1.3, one can conclude that in the early 
human embryo HSCs appear in the placenta simultaneously with or even earlier than 
in the AGM region. 
 
To validate the above claims regarding the presence of HSCs in the early human 
placenta, 19 independent transplantation experiments were performed with cells 
obtained from CS 12–17 human placentas (Table 3.1.1). Prior to transplantation, in 
six experiments, placental tissues were subject to enzymatic digestion and Ficoll 
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density gradient separation as described by Robin et al. (2009) or Barcena et al. 
(2009). In 13 cases, Ficoll density gradient separation step was omitted to minimise 
cell losses. Despite this and the fact that in the present study placental cells were 
transplanted into NSG mice, which are more receptive for human HSCs than 
NOD/SCID mice (McDermott et al., 2010), in none of the experiments human long-
term multilineage haematopoietic engraftment could be achieved. However, in seven 
experiments, 12 out of 22 mice transplanted with human placental cells were found 
repopulated exclusively with human T cells and showed signs of graft-versus-host 
disease (Table 3.1.1). If the recipient mice did not develop graft-versus-host disease, 
T cells could hardly be detected in recipient haematopoietic tissues at month 4–5 
after transplantation (Figure 3.1.9). If the recipient mice developed graft-versus-host 
disease, human T cells propagated and in some cases constituted virtually 100% of 
recipient blood leukocytes by the time of animal death. 
 
It has previously been reported that T cells from human blood expand easily after 
transfer into immunodeficient mice (van Rijn et al., 2003), and placenta is always 
contaminated with maternal blood. To discriminate between maternal versus 
embryonic origin of human T cells in NSG recipient mice transplanted with human 
placental cells, DNA fingerprinting was carried out employing STR analysis. 
Genomic DNA was extracted from human embryonic donor tissues and peripheral 
blood, bone marrow and/or spleen cells from corresponding recipient mice. In all 
cases tested, human cells in the recipient mice exhibiting transient human unilineage 
T cell repopulation following the transplantation of placental cells were of maternal 




Tables 3.1.6–3.1.11 (on the following six pages). Results of the STR analysis performed 
to distinguish embryonic versus maternal origin of haematopoietic repopulation in 
NSG recipient mice transplanted with human embryo or placenta-derived cells. STR 
profiles (the array of alleles in multiple STR loci) were obtained for genomic DNA extracted 
from embryonic/foetal tissues and from long-term hematopoietic graft (peripheral blood, 
spleen and/or bone marrow cells from repopulated NSG recipient mice). Numbers denote 
the alleles in a given STR locus. When identical STR profiles were obtained for 
embryonic/foetal and graft samples, this confirmed the embryonic/foetal origin of 
haematopoietic graft. By contrast, in the case with CS 12–17 placentas (Table 3.1.6), the 
match of only one allele in the majority of STR loci for embryonic and graft samples 
indicated familial relationship only, thus demonstrating the maternal origin of engrafted 
cells. Amelogenin X and Y PCR products were used for gender determination. F, allele 
drop-out. Pm, match probability (the probability that a human genomic DNA sample that is 
chosen at random has a matching STR profile to the embryonic/foetal sample). 
 
Figure 3.1.9. Human transient unilineage T cell repopulation in NSG recipient mice 
transplanted with cells from the early human placenta.  Representative flow cytometry 




) in the peripheral blood of a recipient mouse 
transplanted with 0.33 e.e of a CS 16 placenta. Peripheral blood leukocytes from this 







































  Figure 3.1.10. Human long-term multilineage haematopoietic repopulation in NSG 
recipient mice engrafted with HSCs from the midgestation human placenta. (A) 
Representative flow cytometry plots show the presence of human CD45
+
 haematopoietic 
cells in the peripheral blood of three NSG recipient mice each transplanted with ~1/30 of 
total placental cells from a 15-week-old human foetus. Recipient peripheral blood was 













) in the peripheral blood are shown for one 
of the recipients. The analysis was performed 4 months after transplantation. Two 
independent experiments were performed. 
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upon the transplantation of human AGM region, yolk sac or liver cells were always 
of embryonic origin (Tables 3.1.7–3.1.10). 
 
To prove that the failure to detect HSCs in the early human placenta was not due to 
some technical problems in employing the protocol of Robin et al. (2009), placental 
tissues from two 15-week-old (postmentrual gestational age) human foetuses were 
obtained and processed exactly in the same way as it had been done for the early 
human placentas. In each of these two experiments, placental cells were transplanted 
into three sublethally irradiated NSG recipient mice at the dose of 1/30 of total 
placenta cells per recipient. All recipient mice achieved human long-term 
multilineage haematopoietic engraftment of foetal origin (Figure 3.1.10 and Table 
3.1.11). 
 
3.1.11. Postmenstrual Gestation Age Should Not Be Used in Studies on Early 
Human Embryos 
To obtain consistent results in developmental biology studies, it is important to use 
internationally accepted embryo staging systems. Embryo staging systems exist for 
the zebrafish, frog, chicken, mouse, rat, rhesus macaque and some other animal 
embryos (Hamburger and Hamilton, 1951; Hendrickx and Sawyer, 1975; Kimmel et 
al., 1995; Nieuwkoop and Faber, 1956; Theiler, 1989; Witschi, 1962). To stage 
human embryos, the Carnegie staging system has been introduced (O’Rahilly and 
Muller, 1987). Nevertheless, CSs are often substituted with postmenstrual gestational 
ages determined and provided by gynaecologists-obstetricians performing elective 
termination of pregnancy (Huyhn et al., 1995; Migliaccio et al., 1986; Oberlin et al., 
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2010; Oberlin et al., 2002; Robin et al., 2009; Tavian et al., 1996). Depending on the 
length of the woman’s menstrual cycle, postmenstrual gestational age of the human 
embryo exceeds by 1–3 weeks its postovulatory gestational age, which is the real age 
of the embryo. Since the difference between the two gestational ages cannot be easily 
established, postmenstrual gestational age is an unreliable indicator of the 
developmental stage of the human embryo (O’Rahilly and Muller, 2000). In contrast, 
the Carnegie staging system, which was used in the present study, is based on a 
complex of both external and internal morphological criteria and is not directly 
linked to gestational age (O’Rahilly and Muller, 1987). 
 
To determine the correlation between CSs and postmenstrual gestational age, 
information on a woman’s menstrual history was collected for the vast majority 
(n=89) of human embryos obtained for the study. The human embryos were split into 
six groups based on the CS they belonged to. A mean postmenstrual gestational age 
and a 95% CI were calculated for each group. For CS 12–15, 95% CIs overlapped 
between the four groups, indicating that postmenstrual gestational age cannot be used 
to distinguish between CS 12–15 human embryos. However, based on postmenstrual 
gestational age, it was possible to distinguish between CS 16 and 17 human embryos 
at a confidence level of 95% (Figure 3.1.11). Additionally, CS and postmenstrual 
gestational age of CS 12–15 human embryos did not correlate with each other 
(r=0.251; P=0.101). In contrast, the correlation between CS and postmenstrual 
gestational age of CS 16 and 17 human embryos was moderate and statistically 
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Figure 3.1.11. Relationship between postmenstrual gestational age and Carnegie stages. 
Human embryos obtained for the present study were split into groups depending on the 
Carnegie stage they belonged to. For each group, a mean postmenstrual gestational age in 
days (open circles) and a 95% CI (error bars) were calculated and plotted against 
corresponding Carnegie stages. The number of human embryos obtained for each Carnegie 
stage is indicated above the error bars. 
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highly significant (r=0.536; P<0.001). Thus, postmenstrual gestational age cannot be 
used to judge about the developmental stage of the human embryos under CS 16, 
which is crucial since the first human HSCs are detected in the human embryo 
starting from CS 14. 
 
3.1.12. Discussion  
Although the embryonic development of HSCs has been studied in various vertebrate 
species, the generation of the first HSCs during human embryogenesis remains an 
unexplored topic. The present concept of the embryonic development of the human 
haematopoietic system is primarily based on morphological and in vitro studies 
(Oberlin et al., 2002; Tavian et al., 1996; Tavian et al., 1999; Tavian et al., 2001). 
Here, systematic analysis of the spatio-temporal distribution of HSCs in the early 
human embryo was performed by employing the in vivo long-term repopulation 
assay. It has been shown that the AGM region, more specifically the dorsal aorta, is 
the first generator of HSCs in the human embryo. Interestingly, while in the mouse 
embryo definitive HSCs appear concomitantly in the AGM region, yolk sac, 
umbilical cord and placenta (de Bruijn et al., 2000; Gekas et al., 2005; Kumaravelu 
et al., 2002; Muller et al., 1994; Ottersbach and Dzierzak, 2005); in the human 
embryo, the timing of HSC appearance in these sites is clearly resolved, possibly due 
to considerably longer development of the human embryo. Additionally, in contrast 
to the mouse embryo (de Bruijn et al., 2000), early human embryonic HSCs have 




As expected, HSC activity in the AGM region precedes that in the liver, which 
emerges there not before CS 17. The present data highlight the importance of in vivo 
long-term repopulation assays, since previous immunohistological and in vitro 
studies suggested that HSCs appear in the human embryonic liver around CS 13 
(Tavian et al., 1999). Recent transplantation experiments have shown that HSCs 
colonise the human embryonic liver around week 7–8 of development (Oberlin et al., 
2010), which corresponds to the findings of the present study. 
 
Upon transplantation into NSG mice, early human embryonic HSCs could easily 
provide long-term multilineage haematopoietic engraftment. An unexpected finding 
was the progressive growth in the levels of repopulation with human haematopoietic 
cells. The percentage of human CD45
+
 cells could reach up to 90% of total recipient 
mouse blood leukocytes by month 8 after transplantation. Previous reports have 
shown that transplantation of many human umbilical cord blood or adult bone 
marrow HSCs into immunodeficient mice results in blood chimerism below 50% at 
week 10 after transplantation and frequently decreases after several months 
(Cashman et al., 1997; Ishikawa et al., 2005; Liu et al., 2010). A recent study from 
John Dick's laboratory has shown that 10–20 umbilical cord blood HSCs 
transplanted per NSG recipient mouse are able to provide up to 40% repopulation in 
the blood by month 8 after transplantation (Notta et al., 2011). In the next result 
subchapter, data are provided showing that in the majority of experiments early 
human embryonic HSCs have been transplanted in a limiting dose (one or two HSCs 
per recipient mouse). This suggests that early human embryonic HSCs are much 
more potent in terms of long-term multilineage repopulation than their counterparts 
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from neonatal and adult tissues. The progressive growth in the levels of repopulation 
with human haematopoietic cells upon the transplantation with early human 
embryonic HSCs might be the result of the gradual productivity enhancement of one 
or two transplanted HSCs or the result of the amplification of HSC numbers. The 
data in section 3.1.9 suggest that early human embryonic HSCs amplify in the bone 
marrow of primary recipient mice. In more detail the question on the regenerative 
potential of early human embryonic HSCs is addressed in result subchapter 3.2. 
 
The findings of the present study contradict a recent report that the human placenta 
harbors HSCs already from week 6 of development (Robin et al., 2009) and 
demonstrate that the human placenta acquires HSC activity long after the emergence 
of the first HSCs in the AGM region. Of note, in the mouse embryo, definitive HSCs 
appear in the placenta concomitantly with the AGM region (Gekas et al., 2005; 
Ottersbach and Dzierzak, 2005). In their study, Robin et al. (2009) have not provided 
sufficient evidence that placentas from early human embryos contained HSCs. To 
claim that some tissue possesses HSC activity, it is required to show that candidate 
HSCs within this tissue are capable of long-term multilineage haematopoietic 
differentiation and self-renewal. Robin et al. (2009) do not provide these data for the 
experiments with the early human placenta since in these cases the authors used PCR 
analysis to detect human haematopoietic engraftment in NOD/SCID recipient mice. 
Considering the sensitivity of the PCR analysis employed (one human cell in 100000 
mouse cells) and a very early time point of donor contribution analysis (starting from 
week 5 after transplantation), a persistence of small numbers of some placenta-
derived haematopoietic progenitor or nonhaematopoietic cells in recipient mice could 
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not be excluded. However, the presence of HSCs in the human placenta was 
convincingly shown starting from week 9 of development. In those experiments, the 
authors employed the long-term repopulation assay and flow cytometry but not PCR 
analysis to detect human multilineage haematopoietic engraftment in mice 




3.2. Regenerative Potential of Early Human Embryonic HSCs 
3.2.1. Introduction 
From clinical studies, it is known that patient survival after HSC transplantation is 
improved by increasing the transplanted cell dose, which can be explained by the 
faster haematological and immunological recovery, lower chance of the bone marrow 
failure and a more robust graft-versus-leukaemia effect (Mehta et al., 1996). If we 
assume that the human HSC pool is as heterogeneous as that in the mouse (Benz et 
al., 2012; Dykstra et al., 2007a; Sieburg et al., 2006), the better survival of patients 
transplanted with higher cell doses may also be explained by engraftment with 
sufficient numbers of HSCs possessing a high regenerative potential. Although it is 
of an enormous clinical significance, at present nothing is known about low- and 
high-level repopulating human HSCs. Transplantation of single HSCs may elucidate 
this question. For obvious reasons, this can be done only in xenotransplantation 
experiments. 
 
Analysing the results of studies which involved the transplantation of human HSCs 
into immunodeficient mouse recipients in a limiting dose, one could conclude that 
human high-level repopulating HSCs do not exist since only low-level engraftments 
with human haematopoietic cell levels far below 1% of total recipient blood 
leukocytes were observed (Majeti et al., 2007; Notta et al., 2011). However, it is 
possible that human HSCs with a high regenerative potential cannot be revealed in 
mouse recipients due to suboptimal self-renewal and differentiation signals as a 
result of the incompatibility between mouse cytokines and corresponding human 
HSC receptors and/or inadequate levels of compatible mouse cytokines (reviewed by 
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Manz, 2007). It is still not clear how to explain human high-level haematopoietic 
engraftments in which upon the transplantation with 10–20 umbilical cord blood 
HSCs the level of human CD45
+
 cells in the recipient mouse peripheral blood may 
reach up to 40% of total leukocytes by month 8 after transplantation (Notta et al., 
2011). This may be a cumulative repopulation effect of the transplantation with many 
low-level repopulating HSCs. 
 
In the preceding result subchapter, it has been shown that the high-level human 
haematopoietic repopulation of NSG recipient mice can easily be achieved upon the 
transplantation of human AGM region, yolk sac or embryonic liver HSCs. In these 
experiments, the percentage of human CD45
+
 cells could reach up to 90% of total 
recipient mouse blood leukocytes by month 8 after transplantation, suggesting that 
the early human embryonic haematopoietic tissues may contain high-level 
repopulating HSCs. An alternative explanation for the above observations may be a 
cumulative repopulation effect due to the presence in the human AGM region, yolk 
sac or embryonic liver of many low-level repopulating HSCs. These two possibilities 
are explored below. 
 
3.2.2. Experimental Approach 
The main goal of this part of the study was to quantify HSCs in the early human 
embryo and to assess their regenerative potential. To achieve this, the long-term 
repopulation assay was combined with the limiting dilution analysis. When it was 
required to calculate numbers of daughter HSCs produced by early embryonic HSCs 
in the bone marrow of primary recipient mice, the secondary repopulation assay was 
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performed in conjunction with the limiting dilution analysis. Secondary 
transplantations were also performed to establish the immunophenotype of daughter 
HSCs and to assess their migratory abilities. Since the vast majority of the human 
embryos used in the present study were very early human embryos containing HSCs 
only in the AGM region, this result subchapter is mainly focused on human AGM 
region HSCs. 
 
3.2.3. Human AGM Region Contains One or Two HSCs at a Time 
Upon transplantation, a single HSC can restore haematopoiesis of a myeloablated 
recipient, which has been shown for both mouse and human HSCs (Notta et al., 
2011; Osawa et al., 1996). This allows estimating the frequency of HSCs in a cell 
population of interest using the limiting dilution analysis (Conneally et al., 1997; 
Szilvassy et al., 1990). Given that some HSCs, for example, cycling (Fleming et al., 
1993) are not able to engraft a recipient, the term ‘competitive repopulating unit’ has 
been introduced to distinguish between the true frequency of HSCs and the 
frequency of HSC determined by transplantation (Szilvassy et al., 1990). It is also 
not clear whether all human HSCs or just a subset called SCID-repopulating cells are 
able to engraft immunodeficient mice (Larochelle et al., 1996). Therefore, evaluating 
the frequency of HSCs in the human AGM region or in any other tissue of interest, it 
is required to keep in mind that the true frequency of HSCs may be higher than that 
determined by the long-term repopulation assay and the limiting dilution analysis. 
 
In my experiments, a single cell suspension prepared from the human AGM region 
was split into equal portions and transplanted into two to four sublethally irradiated 
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NSG recipient mice. In 16 out of 17 experiments, HSC transplantations were 
performed at a limiting dose as only some recipients showed human long-term 
multilineage haematopoietic repopulation. Only in one experiment, both recipients 
have been found engrafted with human HSCs (Table 3.2.1). To perform limiting 
dilution analysis, a software programmed to handle small number of replicates and 
nonlinear situations was used (Hu and Smyth, 2009). Before the limiting dilution 
analysis was carried out, it had been confirmed that the data fitted the single-hit 
Poisson model (χ 
 
=0.087, P=0.768), demonstrating consistency between the 17 
experiments and justifying the pooling of the data to calculate the frequency of HSCs 
in the human AGM region (Hu and Smyth, 2009). The model calculations showed 
that CS 14–17 human AGM regions contain on average 1.7 (95% CI: 1.1–2.6) HSCs 
per e.e (Figure 3.2.1). Remarkably, in the mouse AGM region at comparable 
developmental stages the number of detectable HSCs is very close to that in the 
human AGM region (Kumaravelu et al., 2002). 
 
3.2.4. Early Human Embryonic HSCs Possess an Enormous Regenerative 
Potential 
Statistically, human long-term multilineage haematopoietic repopulation in each 
engrafted recipient mouse transplanted with human AGM region cells must have 
arisen mainly from one HSC. As it has been shown in section 3.1.9., the transfer of 
the bone marrow from one primary recipient mouse into six to 20 secondary recipient 
mice resulted in sustainable human HSC engraftment, suggesting that human AGM 
region HSCs propagated in the bone marrow of primary recipients. However, there 
might be an alternative possibility that the human AGM region contained some 
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Table 3.2.1. Primary data used for the limiting dilution analysis to establish the 
frequency of HSCs in the human AGM region. Data shown are the number of engrafted 
NSG mice compared to the number of transplanted NSG mice in the long-term repopulation 






Figure 3.2.1. Results of the limiting dilution analysis establishing the frequency of 
HSCs in the human AGM region. In each experiment in which AGM region HSCs were 
detected, the natural logarithm of the fraction of nonengrafted mice was plotted against the 
dose of donor tissues transplanted per recipient. This is shown by the open circles. The 
down-pointing triangle represents the data value with zero negative response (two out of two 
recipients were found engrafted with human HSCs). The solid diagonal line indicates the 
mean value of HSC per cell dose transplanted. The dotted lines show the 95% CI. The 
limiting dilution model was fitted to the data in Table 3.2.1. Note that λ, a number of HSCs 
transplanted per recipient mouse, can be calculated from the formula λ=–ln(Fraction of 
nonengrafted mice). From here, –ln(0.37)≈1, which means that the dose of transplanted cells 
yielding ≈37% of nonengrafted recipient mice contains one HSC. To establish the dose of 
human AGM region cells containing a single HSC, draw an imaginary horizontal line from 
the y axis at –1 to intercept the solid diagonal line. Then, draw an imaginary vertical line 
from the point of interception of the imaginary horizontal line and the solid diagonal line 
until it cuts the x axis at ≈0.6, which is the dose of human AGM region cells containing one 
HSC.    
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HSCs which remained dormant in the bone marrow of primary recipient mice but 
could be activated upon retransplantation. To test this, bone marrow cells from two 
coxal bones, two femurs and two tibiae were collected from nonrepopulated primary 
recipient mice (Figure 3.2.2 A, mice a and b) from five independent experiments in 
which at least one other recipient mouse had been found engrafted with human AGM 
region HSCs (Figure 3.2.2 A, mouse c). In each case, the cells were transplanted into 
sublethally irradiated secondary NSG recipient mice. None of the secondary 
recipients showed human haematopoietic engraftment, confirming that the human 
AGM region contained only one or two HSCs and that these rare HSCs propagated 
in the bone marrow of primary recipients. This explains the observed progressive 
growth in the levels of repopulation with human haematopoietic cells. Other 
embryonic haematopoietic tissues have also been assessed for the presence of 
dormant HSCs. Secondary transplantations of the bone marrow from nonengrafted 
recipient mice transplanted with yolk sac, liver, umbilical cord and placental cells 
were also unsuccessful. For each tissue, two to five independent experiments were 
performed. 
 
To evaluate the number of daughter HSCs generated by a single transplanted human 
AGM region HSC, primary recipient mouse bone marrow cells were subject to the 
limiting dilution analysis performed in conjunction with the secondary repopulation 
assay. The bone marrow from engrafted primary recipients was harvested from the 
sternum, humeri, ulnae, radii, coxal bones, femurs and tibiae, which composes 
approximately 2/5 of total bone marrow (Boggs, 1984), pooled and transplanted in 








Figure 3.2.2. Experimental strategy employed to confirm the expansion of human 
AGM region HSCs in the bone marrow of primary recipient mice. (A) AGM region 
cells obtained from a CS 15 human embryo were transplanted into three sublethally 
irradiated NSG recipient mice (0.33 e.e. per recipient). Only one of the three recipients 
showed human long-term multilineage haematopoietic repopulation (mouse c). It was 
confirmed by secondary transplantation that the other two recipients (mice a and b) 
contained no activatable HSCs. To test if the single human HSC that repopulated mouse c 
had generated daughter HSCs which could spread across the recipient bone marrow, bone 
marrow cells from two coxal bones, two femurs and two tibiae were harvested and 
separately transplanted into six secondary recipients (mice 1–6). Secondary transplantations 
were performed 4 months after the primary transplantation. BM, bone marrow. (B) 
Representative flow cytometry plots show haematopoietic repopulation of human origin in 
the peripheral blood of the 6 secondary recipients 3 months later. Two independent 
experiments were performed. 
136 
 
performed 8 months after primary transplantation, the lowest dose transplanted per 
secondary recipient mouse was 1/75 of total primary recipient mouse bone marrow. 
All secondary recipients achieved human long-term multilineage haematopoietic 
repopulation. In the second experiment, the dose was decreased further to 1/300 of 
total primary recipient mouse bone marrow per secondary recipient mouse. The 
experiment was performed 7 months after primary transplantation. Again, all 
secondary recipients showed engraftment with human HSCs. In this experiment, a 
secondary transplantation of primary recipient mouse spleen cells was also 
performed, resulting in human long-term multilineage haematopoietic repopulation 
in four out of four secondary recipient mice transplanted. Thus, one HSC from the 
human AGM region is capable of generating at least 300 daughter HSCs upon 
transplantation into sublethally irradiated NSG mice (data are not shown since more 
definitive data are presented below for similar experiments). 
 
Since a limiting dose had not been found in the two above experiments, three 
additional independent experiments were performed at a larger scale to assess the 
regenerative potential of a single human AGM region HSC. Primary recipient mice 
used as donors in these secondary transplantations were chosen from experiments in 
which only one out of three primary recipients transplanted with equal numbers of 
human AGM region cells had been found repopulated with human haematopoietic 
cells. This condition was introduced to decrease the probability that the primary 
recipient mice had been engrafted with more than one HSC, which could skew the 
calculations of daughter HSC numbers. As a result, the probability was decreased to 
6.3%, as computed using the Poisson distribution formula and the theory of 
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probability (P(x>1;λ=0.406)=1–          –           , where x is a Poisson random 
variable, e is the base of the natural logarithm, which is 2.718, and λ is an average 
number of HSCs transplanted per recipient mouse, which was calculated from the 
formula λ=–ln(Fraction of nonengrafted mice)). In each secondary transplantation 
experiment, 20 sublethally irradiated NSG recipient mice were split into four 
experimental groups and transplanted with primary recipient mouse bone marrow 
cells at doses ranging from 1/20 to 1/1620 of total bone marrow per mouse. Starting 
from month 2 after transplantation, the recipient mice were bled by tail vein nicking 
every month, and the percentage of human CD45
+
 cells was assessed. The limiting 
dilution analysis was performed with the values obtained at month 4 after 
transplantation, when the progeny of human short-term repopulating haematopoietic 
cells is not detectable any more (Notta et al., 2011). The mice were considered as 
engrafted with human HSCs if at least 0.1% of total recipient blood leukocytes were 
of human origin, with both myeloid and lymphoid cells present. Often, others employ 
less stringent criteria for human HSC engraftment and consider NSG mice as 
engrafted if at month 4 after transplantation the bone marrow but not blood content 
of human CD45
+
 cells is at least 0.1% (Notta et al., 2010). 
 
The first large-scale secondary transplantation experiment was performed 5 months 
after primary transplantation of AGM region cells. At that time point, the percentage 
of human CD45
+
 cells in the blood and the bone marrow of primary recipient mouse 
was 5% and 31% cells, respectively. As assessed at month 4 after transplantation, all 
secondary recipients transplanted with primary recipient mouse bone marrow cells at 
doses 1/20, 1/60 or 1/180 of total bone marrow per mouse achieved human long-term 
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multilineage haematopoietic engraftment with average percentages of human 
leukocytes in the blood 31±14%, 14±10% and 3.6±3.8%, respectively. Two out of 
five secondary recipient mice transplanted with 1/540 of total primary recipient 
mouse bone marrow per mouse were found nonrepopulated with human 
haematopoietic cells. The percentage of human leukocytes in the blood of the other 
three secondary recipients was on average 1.1±0.058% of total blood leukocytes 
(Figure 3.2.3 A). Employing the limiting dilution analysis, it has been computed that 
during a 5-month period a single human AGM region HSC produced 604 (95% CI: 
254–1440) daughter HSCs (Figure 3.2.3 B). 
 
The second large-scale secondary transplantation was carried out 9 months after 
primary transplantation of AGM region cells. At that time point, the percentage of 
human CD45
+
 cells in the blood and the bone marrow of the primary recipient was 
50% and 96%, respectively. As assessed at month 4 after transplantation, all 
secondary recipient mice transplanted with bone marrow cells from the primary 
recipient mouse at doses 1/60 and 1/180 of total bone marrow per mouse achieved 
human long-term multilineage haematopoietic engraftment with average percentages 
of human leukocytes in the blood 6.7±7.5% and 5.0±7.9%, respectively. One out of 
five secondary recipient mice transplanted with 1/540 of total primary recipient 
mouse bone marrow per mouse was found nonrepopulated with human 
haematopoietic cells. The percentage of human leukocytes in the blood of the other 
four secondary recipients was on average 0.23±0.068% of total blood leukocytes. In 
group 4, secondary recipient mice were transplanted with 1/1620 of total primary 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































group, and neither of them were found engrafted with human HSCs. Employing the 
limiting dilution analysis, it could be computed that during a 9-month period a single 
human AGM region HSC produced 729 (95% CI: 313–1699) daughter HSCs. 
 
The third large-scale secondary transplantation experiment was performed 6 months 
after primary transplantation of AGM region cells. At that time point, the percentage 
of human CD45
+
 cells in the blood and the bone marrow of primary recipient mouse 
was 62% and 92%, respectively. As assessed at month 4 after transplantation, all 
secondary recipients transplanted with primary recipient mouse bone marrow cells at 
doses 1/60, 1/180, 1/540 and 1/1620 of total bone marrow per mouse achieved 
human long-term multilineage haematopoietic repopulation with average percentages 
of human leukocytes in the blood 54±16%, 44±6.1%, 29±12% and 16±6.8%, 
respectively. Thus, during a 6-month period a single human AGM region HSC 
produced at least 1620 daughter HSCs (Figure 3.2.4). 
 
3.2.5. Regenerative Potential of Human HSC Gradually Decreases During 
Ontogeny 
To evaluate the regenerative potential of human HSCs from sources other than the 
AGM region, four large-scale secondary transplantation experiments were performed 
with the bone marrow from primary recipient mice engrafted with HSCs from the 
human embryonic liver (1 experiment), the midgestation placenta (1 experiment) and 
the umbilical cord blood (2 experiments). As in the above experiments, bone marrow 
cells from the primary recipients were harvested from the sternum, humeri, ulnae, 













































































































































































































































































































































































































































































sublethally irradiated secondary NSG recipient mice. Primary recipient mouse bone 
marrow cell doses ranged from 1/20 to 1/1620 of total bone marrow per secondary 
recipient mouse. The mice were considered as engrafted with human HSCs if at 
month 4 after transplantation at least 0.1% of total recipient blood leukocytes were of 
human origin, with both myeloid and lymphoid cells present. 
 
In section 3.1.3, it has been reported that in one primary transplantation experiment 
HSCs could be detected both in the AGM region and in the embryonic liver from the 
same human embryo. This was a single opportunity to compare the propagation 
capacity of HSCs sharing the same genetic background but derived from different 
human embryonic haematopoietic sites. For this, two secondary transplantation 
experiments combined with the limiting dilution analysis were performed in parallel 
using the bone marrow from primary recipient mice engrafted with human HSCs 
from the AGM region and the embryonic liver. It has been found that a single human 
AGM region HSC produced at least 1620 daughter HSCs (see the results of the third 
large-scale secondary transplantation experiment in the previous section, Figure 
3.2.4). Unfortunately, it was not possible to estimate precisely the productivity of a 
single human embryonic liver HSC since the primary transplantation had not been 
performed in a limiting dose. Two out of two NSG recipient mice, each transplanted 
with 0.5 e.e. of human embryonic liver cells, achieved human long-term multilineage 
haematopoietic repopulation, suggesting that each of them had been engrafted with 
one or more human HSCs. If one assumes that in this particular case the human 
embryonic liver contained just two HSCs that have been equally distributed between 
two primary recipient mice in the transplantation course, the probability of such an 
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outcome would be 14%, as computed using the Poisson distribution formula and the 
theory of probability (P(Equal distribution of two HSCs between two recipients)=(         
2
, where x 
is a Poisson random variable, e is the base of the natural logarithm, which is 2.718, 
and λ is an average number of HSCs transplanted per recipient mouse, which in this 
case is assumed 1). Thus, it is very likely that the human embryonic liver contained 
more than two HSCs. It is required to recognise this fact when evaluating the 
expansion capacity of human embryonic liver HSCs. 
 
An assessment of human HSC numbers in the bone marrow of one of the two 
primary recipient mice engrafted with human embryonic liver HSCs has suggested 
that AGM region HSCs possess a higher regenerative potential than their 
counterparts in the embryonic liver. At month 6 after transplantation, the percentage 
of human CD45
+
 cells in the blood and the bone marrow of the primary recipient 
mouse was 40% and 94%, respectively. As assessed at month 4 after transplantation, 
all secondary recipient mice transplanted with primary recipient mouse bone marrow 
cells at doses 1/60 and 1/180 of total bone marrow per mouse achieved human long-
term multilineage haematopoietic engraftment with average percentages of human 
leukocytes in the blood 11±3.7% and 3.8±2.4%, respectively. One out of five 
secondary recipient mice transplanted with 1/540 of total primary recipient mouse 
bone marrow per recipient mouse was found nonrepopulated with human 
haematopoietic cells. The percentage of human leukocytes in the blood of the other 
four secondary recipients was on average 0.49±0.39% of total blood leukocytes. 
Three out of five secondary recipient mice transplanted with bone marrow cells from 
the primary recipient mouse at a dose 1/1620 of total bone marrow per mouse were 
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found nonengrafted with human HSCs. The percentage of human leukocytes in the 
blood of the other three mice was on average 0.28±0.47% of total blood leukocytes 
(Figure 3.2.5 A). Employing the limiting dilution analysis, it has been computed that 
at month 6 after primary transplantation 883 (95% CI: 401–1941) human HSCs 
could be detected in the primary recipient mouse bone marrow (Figure 3.2.5 B). 
Unfortunately, the bone marrow from the second primary recipient could not be used 
to confirm the above observations in a similar secondary transplantation experiment 
since the mouse had developed graft-versus-host disease at month 5 after primary 
transplantation with human embryonic liver HSCs, possibly due to occasionally 
observed defects in the negative selection of human T cells in the recipient mouse 
thymus (reviewed by Shultz et al., 2007). 
 
In one secondary transplantation experiment, the propagation capacity of human 
HSCs from the midgestation placenta was assessed. As it has been reported in 
section 3.1.10, placental cells from a 15-week-old (postmentrual gestational age) 
human foetus were transplanted into three sublethally irradiated NSG recipient mice 
at a dose of 1/30 of total placenta cells per recipient. In two such experiments, all 
recipient mice achieved human long-term multilineage haematopoietic engraftment 
of foetal origin, suggesting that each of them had been engrafted with one or more 
human HSCs. One of these primary recipients was used as a bone marrow donor for 
secondary transplantation performed 8 months after primary transplantation. At this 
time-point, the percentage of human CD45
+
 cells in the blood and the bone marrow 
of the primary recipient was 3% and 23%, respectively. As assessed at month 4 after 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































primary recipient mouse bone marrow cells at a dose 1/20 of total bone marrow per 
mouse achieved human long-term multilineage haematopoietic engraftment with 
percentages of human leukocytes in the blood 0.42% and 0.37%. All secondary 
recipient mice transplanted with lower bone marrow cell doses were found 
nonengrafted with human HSCs. Employing the limiting dilution analysis, it has 
been computed that at month 8 after primary transplantation 6.7 (95% CI: 1.7–26) 
human HSCs could be detected in the bone marrow of the recipient mouse engrafted 
with HSCs from the human midgestation placenta. 
 
Finally, the regenerative potential of human umbilical cord blood HSCs was 
evaluated. In two independent experiments, sublethally irradiated NSG recipient 
mice were transplanted with 2500 of human umbilical cord blood CD34
+
 cells each. 
As reported by others, this cell dose contains one or two HSCs (McDermott et al., 
2010). In one experiment, all five recipient mice have been found engrafted with 
human HSCs. In the other experiment, three out of five recipients achieved human 
long-term multilineage haematopoietic repopulation. The average percentage of 
human leukocytes in the blood of the recipients engrafted with human umbilical cord 
blood HSCs was 0.59±0.45%, as assessed at month 4 after primary transplantation. 
Two of these recipients (one from each experiment) were used as bone marrow 
donors for secondary transplantation experiments performed 4 months after primary 
transplantation with a goal to estimate human HSC numbers in the bone marrow of 
the primary recipients. The percentage of human CD45
+
 cells in the blood and the 
bone marrow of these two mice was 0.19% and 5.1% (mouse 1) and 0.54% and 6.2% 
(mouse 2), respectively. In both secondary transplantation experiments, human 
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haematopoietic cells were absent in all secondary recipient mice, suggesting that in 
the xenotransplantation settings human umbilical cord blood HSCs transplanted in a 
limiting dose possess a poor regenerative potential if compared to their embryonic 
counterparts. Limited self-renewal capacity of HSCs from the human umbilical cord 
blood have been previously reported by others (Guenechea et al., 2001; Liu et al., 
2010; McKenzie et al., 2006). 
 
3.2.6. Extensive Dissemination of Daughter HSCs in Primary Recipient Mice 
The engraftment of one or two HSCs from the human AGM region results in 
considerable amplification of the HSC pool. It was tested if daughter HSCs stayed at 
one site where the lodging of the parental HSC had occurred or if they migrated and 
disseminated throughout the entire recipient bone marrow. Two primary NSG 
recipient mice repopulated with different AGM regions were euthanised. From each 
recipient, the bone marrow from two coxal bones, two femurs and two tibiae was 
harvested separately. Bone marrow cell suspensions from each bone were 
transplanted individually into sublethally irradiated secondary NSG recipient mice 
(Figure 3.2.2 A). In experiment 1, all transplanted mice showed human long-term 
multi-lineage haematopoietic engraftment (Figure 3.2.2 B). Consistent with this, in 
experiment 2, all secondary recipient mice except one were repopulated with human 
haematopoietic cells. Thus, one or two early human embryonic HSCs colonise the 
entire recipient mouse bone marrow not only through the substantial production of 
daughter HSCs but also through the mobilisation, migration and homing of daughter 




3.2.7. Daughter HSCs Are of the Canonical Phenotype 





(Bhatia et al., 1997; McKenzie et al., 2006). Due to a number of reasons, it is not 
feasible to determine the immunophenotype of HSCs in the human AGM region 
using conventional high-pressure FACS. Firstly, the frequency of HSCs in the human 
AGM region is low (one or two HSCs per e.e.). Secondly, conventional FACS is 
always associated with cell losses and embryonic HSC functional damage as has 
been shown for the mouse AGM region (Medvisnky et al., unpublished data). 
Thirdly, it is almost impossible to obtain at the same time and pool for a cell sorting 
AGM regions from several fresh human embryos at the appropriate developmental 
stages (CS 14–17) to overcome the above two issues. However, due to substantial 
self-renewal of early human embryonic HSCs in the bone marrow of engrafted 
primary recipient mice, it was possible to determine the immunophenotype of 
daughter HSCs. The bone marrow was harvested from the sternum, humeri, ulnae, 
radii, coxal bones, femurs, and tibiae of primary recipients engrafted with a single 
HSC from the human AGM region. Then, the bone marrow was immunolabelled and 
sorted into four cell populations based on the expression of human CD34 and CD38 
antigen (Figure 3.2.6 A). Finally, each cell population was transplanted into four to 
five sublethally irradiated secondary NSG recipient mice. In two independent 





population (Figure 3.2.6 B). The fact that HSCs from the human AGM region give 
rise to daughter HSCs with an immunophenotype similar to that of human adult-type 
HSCs is a strong evidence that in the human embryo the AGM region is the primary 







Figure 3.2.6. Immunophenotype of daughter human AGM region-derived HSCs in the 
bone marrow of primary recipient mice. (A) Seven months after primary transplantation, 
the bone marrow of NSG recipient mice repopulated with CS 16 and 17 AGM regions was 
sorted into four cell populations based on expression of human CD34 and CD38 antigens. 
Two independent experiments were performed. (B) Cells of each sorted population were 
injected into sublethally irradiated secondary recipient mice. The peripheral blood of 
secondary recipients was analysed for human CD45
+
 cell contribution 2 months after 
transplantation. The circles show individual recipient mice. Two independent experiments 




The data presented in this result subchapter show that human AGM region HSCs 
possess a considerably higher regenerative potential than human HSCs at later 
ontogenetic stages. Despite some variability in experiments, which was most likely 
due to genetic differences between individual human embryos, it has been 
demonstrated that upon transplantation into sublethally irradiated NSG mice a single 
HSC from the human AGM region usually produces around 600 daughter HSCs 
during a period of 5–9 months. This unprecedented self-renewal capacity has not 
been previously described for human or for mouse HSCs. It is likely as a result of 
this the percentage of human leukocytes in the recipient mouse blood progressively 
increased, reaching up to 90% of total blood leukocytes (see section 3.1.5). To 
achieve the same effect with human umbilical cord blood or adult bone marrow 
HSCs, considerably higher numbers of HSCs need to be transplanted. More recent 
data suggest that ≈40% content of human CD45
+
 cells in the recipient mouse blood 
can be achieved 8 months after transplantation of 10–20 human umbilical cord blood 
HSCs per NSG mouse (Notta et al., 2011). 
 
Based on the observations from the previous experiments with human umbilical cord 
blood and adult bone marrow HSCs (Cashman et al., 1997; Guenechea et al., 2001; 
Ishikawa, 2005; Liu et al., 2010; McKenzie et al., 2006), it has been suggested that 
the incompatibility between mouse cytokines and corresponding human HSC 
receptors and inadequate levels of compatible mouse cytokines are the two main 
reasons for a poor expansion of human HSCs in the recipient mouse organism 
(reviewed by Manz, 2007). Strikingly, upon transplantation into immunodeficient 
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mice, human AGM region HSCs have been shown to perform considerably better 
than their counterparts from neonatal and adult cell sources, showing extensive self-
renewal and amplification of HSC numbers. Thus, it is very likely that due to a very 
high propagation capacity early human embryonic HSCs can surmount the effects of 
the suboptimal recipient mouse bone marrow microenvironment. These may also 
suggest that the expansion potential of human AGM region HSCs in physiological 
conditions is likely to be higher than assessed by the xenotransplantation assay. 
However, one may propose another explanation for the robust propagation capacity 
of early human embryonic HSCs. Due to suboptimal microenvironment in the 
recipient mouse organism, it is possible that the true regenerative potential of human 
umbilical cord blood and adult bone marrow HSCs simply cannot be revealed by 
xenotransplantation and may be considerably higher than it has previously been 
reported (Cashman et al., 1997; Guenechea et al., 2001; Liu et al., 2010; McKenzie 
et al., 2006). Indeed, umbilical cord blood and adult bone marrow HSCs can 
successfully be used for transplantation in clinical settings (Gluckman et al., 1989; 
Good et al., 1969). As for early human embryonic HSCs, their requirements for 
supportive cytokines may differ from those of ontogenetically older HSCs; hence, 
NSG mice may be more optimal recipients for them than for human HSCs from the 
umbilical cord blood and adult bone marrow. Although the xenotransplantation assay 
may be a misleading approach for the comparison of the expansion potential of 





The assessment of the regenerative potential of human HSCs from different sources 
has suggested that during embryo- and foetogenesis the propagation capacity of 
human HSCs declines. It has been found that upon transplantation into sublethally 
irradiated NSG mice HSCs from the human embryonic liver, midgestation placenta 
and umbilical cord blood produce smaller number of daughter HSCs than HSCs from 
the human AGM region. This is consistent with AGM region HSCs being founders 
of the adult haematopoietic system in the human. Since the few first HSCs emerging 
in the human AGM region around day 35 of development are ancestors for thousands 
of HSCs residing in the adult human bone marrow, it may well be imagined that 
during this massive expansion the daughter HSCs through some unknown 
mechanism lose the huge regenerative potential of the parental HSCs. Similar 
conclusions can be drawn from the secondary transplantation experiments. While in 
primary recipient mice transplanted with a single human AGM region HSC there was 
observed a progressive growth in the levels of repopulation with human 
haematopoietic cells, most likely related to the propagation of this single HSC, this 
was not observed to the same extent in secondary recipients transplanted with 
daughter HSCs. It is possible that this reflects the loss of the regenerative potential 
observed during human embryo- and foetogenesis. However, this may not be a 
replication of a biological phenomenon but just an experimental artifact due to 
prolonged exposure of human HSCs to suboptimal microenvironment in the recipient 
mouse bone marrow. 
 
Using stochastic analyses, it has been shown that adult human HSCs replicate every 
40 weeks (Catlin et al., 2011). If one assumes that human AGM region HSCs do not 
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lose their propagation capacity upon transplantation into the mouse and undergo cell 
divisions regularly, it can be speculated that the extensive expansion of early human 
embryonic HSCs occurs through replication every 2–3.5 weeks or even more 
frequently, considering that HSCs also produce mature blood cells. However, this 
view on the behaviour of human HSCs in the recipient mouse organism is rather 
simplified, and it is possible that human AGM region HSCs in the mouse undergo 
cell divisions irregularly, for example, the main expansion steps occur shortly after 
transplantation, and then HSCs self-renew less frequently. In this case, the length of 
the cell cycle shortly after transplantation would be even shorter than discussed 
above, which is consistent with AGM region HSCs being founders of the adult 
haematopoietic system in the human. 
 
Mathematical simulations performed by Catlin et al. (2011) have suggested that to 
prevent bone marrow failure after myeloablation before clinical HSC transplantation 
a minimum of 100 HSCs should be transplanted. For comparison, a single human 
AGM region HSC produces about 600 daughter HSCs. To alleviate the problem of 
the shortage of HSC donors in the absence of HSC ex vivo expansion strategies, it is 
theoretically possible to use the bone marrow from germ-free NSG mice engrafted 
with human AGM region HSCs as a source of high numbers of clinically 
transplantable human HSCs and haematopoietic progenitors. Moreover, these cells 
have been shown to be easily engraftable due to their outstanding capability to 




3.3. Localisation and Immunophenotypic Characterisation of 
Human AGM Region HSCs 
3.3.1. Introduction 
The observations reported in the above two result subchapters suggest that human 
AGM region HSCs possess an unprecedented propagation capacity considerably 
superseding that of human HSCs from other cell sources. Therefore, this is not only 
of academic interest but also of clinical importance to understand the mechanism 
underlying the high regenerative potential of early human embryonic HSCs. One of 
the ways to clarify this is by studying differential gene expression in human AGM 
region HSCs versus human umbilical cord blood HSCs. Although the latter can be 
enriched to a comparatively high purity (Notta et al., 2011), at the moment there are 
no methods to purify HSCs from the human AGM region. 
 
A number of reasons preclude the use of conventional high-pressure FACS to study 
the immunophenotype of human AGM region HSCs and to purify them. Firstly, the 
frequency of HSCs in the human AGM region is very low (one or two HSCs per 
e.e.). Secondly, conventional FACS is always associated with cell losses and 
embryonic HSC functional damage, as it has been shown for the mouse AGM region 
(Rybtsov et al., unpublished data). Thirdly, it is practically impossible to overcome 
the above two obstacles by obtaining at the same time and pooling for a cell sorting 
AGM regions from several fresh human embryos at the appropriate developmental 





The on-chip microfluidic FACS may be an appropriate substitute for conventional 
FACS. By employing this technique, it is possible to exclude cell losses using a 
closed-loop sorting strategy. Additionally, cell functional damage is prevented by 
low-pressure cell sorting. The main disadvantage of the on-chip microfluidic cell 
sorting is a comparatively low cell sorting speed (100 events per second), which 
limits the input cell number (Wang et al., 2005). The precise anatomical localisation 
of HSCs within the human AGM region would overcome this limitation since the 
tissues free of HSC activity could be removed before cell sorting, decreasing the 
input cell number. 
 
In section 3.1.4, it has been reported that the dorsal aorta but not the UGRs is the 
source of HSC activity within the human AGM region. In the mouse embryo, the 
vast majority of definitive HSCs were found in the AoV (Taoudi and Medvinsky, 
2007). Therefore, it was reasonable to ask if this could also be extended to the human 
embryo. Beside the observations of the distribution of intra-aortic haematopoietic 
cell clusters (Minot, 1912; Tavian et al., 1996), no data to support the existence of 
the dorso-ventral polarity in haematopoietic activity within the human dorsal aorta 
has been presented so far. If the dorso-ventral polarity in HSC activity within the 
human dorsal aorta does exist, this would allow us to progress with the on-chip 
microfluidic cell sorting experiments in order to find the immunophenotype of 
human AGM region HSCs. More notably, this would also permit us to address a 
number of important biological questions, the very first of which could be related to 
gene expression in the early human embryonic HSC niche (differential gene 
expression in the AoV versus the AoD). 
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3.3.2. Experimental Approach 
To establish the existence of the dorso-ventral polarity in haematopoietic activity 
within the human embryonic dorsal aorta, the dorsal aorta and the surrounding 
mesenchyme were subdissected along the midline into the AoV and the AoD, as 
previously described for the mouse embryo (Taoudi and Medvinsky, 2007). The 
main goal of this part of the study was to assess the dorso-ventral polarity in HSCs 
activity. For this, single cell suspensions prepared from the ventral and the dorsal 
parts of the human embryonic dorsal aorta were individually transplanted into 
sublethally irradiated NSG recipient mice. To increase the success rate of these 
experiments, CS 15–17 human embryos were used. Flow cytometry and CFU-C 
analyses were also performed to obtain additional evidence to support the existence 
of the dorso-ventral polarity in haematopoietic activity within the human embryonic 
dorsal aorta. 
 
3.3.3. Spatial Distribution of Haematopoietic Cells within the Human AGM 
Region 
Five independent experiments were performed with CS 15–17 human embryos to 
establish the spatial distribution of haematopoietic cells within the human AGM 
region. The expression of CD45, a marker of all haematopoietic cells except 
erythrocytes and megakaryocytes, and CD34, a marker of human HSCs and 
haematopoietic progenitors, was assessed by flow cytometry analysis performed with 
the cells from the AoV, the AoD and the UGRs. The AoV and the AoD included the 
ventral aortic endothelium and the dorsal aortic endothelium, respectively, and the 
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surrounding mesenchyme. The UGRs included the gonads, the mesonephros and a 
portion of the mesenchyme adjacent to the aorta laterally. 
 
The average absolute number of CD45
+
 cells in the AoV, the AoD and the UGRs 
was 7280±5490, 3370±1900 and 7490±6460 cells per e.e., respectively (Figure 3.3.1 
A). Although the AoV and the UGRs contained on average twice as many CD45
+
 
cells as the AoD, the difference between the data sets was not statistically significant 
when assessed with the parametric Paired-Samples T Test. The probability values P 
for the pairs the AoV versus the AoD, the AoV versus the UGRs and the AoD versus 
the UGRs were 0.086, 0.897 and 0.159, respectively. The use of the parametric 
statistical test was formally dictated by the normal distribution of the data sets, as 
determined with the Kolmogorov-Smirnov Test. Knowing that with small data sets 
the Kolmogorov-Smirnov Test may have little power to discriminate between 
normally and not normally distributed data (Motulsky, 2010), the nonparametric 
Wilcoxon Signed Ranks Test was additionally performed to compare the data sets. A 
statistically significant difference in the absolute number of CD45
+
 cells was only 
found between the AoV and the AoD (P=0.043). 
 
Performing flow cytometry analysis of subdissected human AGM regions, it became 




cells (Figure 3.3.2). In 
the AoD and the UGRs, these cells were underrepresented or, in some embryos, even 




 cells in the AoV, the AoD 
and the UGRs was 1480±860, 150±210 and 420±460 cells per e.e., respectively 




  Figure 3.3.1. Absolute numbers of CD45+ and CD34hiCD45lo cells and CFU-Cs in the 
AoV, the AoD and the UGRs dissected from early human embryos. AGM regions from 
five CS 14–17 human embryos were subdissected into the AoV, the AoD and the UGRs, and 







 cells (B) per e.e. was assessed by flow cytometry using counting 
beads as an internal control. The number of CFU-Cs per e.e. was evaluated plating AoV, 
AoD and UGR cells into methylcellulose medium supplemented with human cytokines (C). 
Each symbol (●, ■, ▲, + and ♦) represents the same individual human embryo. The 





Figure 3.3.2. Expression of CD34, CD144 and CD45 by human AoV, AoD and UGR 
cells. The human AGM region was subdissected into the AoV, the AoD and the UGRs, and 
individual single cell suspensions were prepared from these tissues. After immunolabelling 
with anti-human CD34, CD144 and CD45 monoclonal antibodies, cells were analysed by 







population identifiable only in the AoV but not in the AoD and the UGRs. CD144
+
 cells are 
overlaid and shown in red. 
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cells that the AoD and the UGRs. The 
P values for the pairs the AoV versus the AoD and the AoV versus the UGRs were 





cells between the AoD and the UGRs (P=0.094). 
 
3.3.4. Spatial Distribution of CFU-Cs within the Human AGM Region 
Since the cells with HSC and haematopoietic progenitor immunophenotype had been 
found predominantly in the AoV, it was of interest to assess functionally the spatial 
distribution of haematopoietic progenitors within the human AGM region. To this 
end, five independent experiments were performed with subdissected AGM regions 
from CS 14–17 human embryos. Single cell suspensions prepared from the AoV, the 
AoD and the UGRs were plated into the methylcellulose medium supplemented with 
human cytokines. After 14 days of culture, human erythroid, myeloid and mixed 
haematopoietic colonies were enumerated. The average number of CFU-Cs in the 
AoV, the AoD and the UGRs was 210±130, 30±20 and 40±30 CFU-Cs per e.e., 
respectively (Figure 3.3.1 C). The Paired-Sample T Test showed a statistically 
significant difference in the number of CFU-Cs only between the AoV and the AoD 
(P=0.032). The probability values P for the pairs the AoV versus the UGRs and the 
AoD versus the UGRs were 0.056 and 0.486, respectively. Since the P value for the 
pair the AoV versus the UGRs was just slightly above 0.05 and due to the possibility 
that the Gaussian assumption might be violated, the Wilcoxon Signed Ranks Test 
was additionally performed to compare the data sets. A statistically significant 
difference in the absolute number of CFU-Cs between the AoV and the UGRs was 
confirmed with the nonparametric statistical test (P=0.043). 
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3.3.5. Spatial Distribution of HSCs within the Human AGM Region 
In section 3.1.4, it has been reported that the dorsal aorta but not the UGRs possess 
HSC activity within the human AGM region. Considering the above data on the 
dorso-ventral polarity in the distribution of haematopoietic cells, cells with HCS 
immunophenotype and CFU-Cs within the human dorsal aorta, the last step was to 
assess the dorso-ventral polarity in HSC activity. This was tested in 10 independent 
transplantation experiments performed with CS 15–17 human embryos. In each case, 
the human dorsal aorta was subdissected into the AoV and the AoD, as previously 
described for the mouse AGM region (Taoudi and Medvinsky, 2007). Single cell 
suspensions prepared from these tissues were individually transplanted into 
sublethally irradiated NSG recipient mice. In 10 experiments performed, HSCs were 
detected on six occasions in the AoV and never in the AoD (data not shown). 
 
3.3.6. On-Chip Microfluidic Cell Sorting of Human AGM Region Cells 
Characterisation of the immunophenotype of the earliest human HSCs is crucial to 
elucidate the molecular mechanisms underlying the high regenerative potential of 
these cells. As discussed in the introduction to this result subchapter, conventional 
high-pressure FACS is not a method of choice to study the immunophenotype of 
human AGM region HSCs. The on-chip microfluidic FACS can be employed 
instead. However, the limitations of this method are a comparatively low cell sorting 
speed and, as a consequence, a limited number of input cells. After it had been 
established that the human AGM region HSCs reside in the ventral wall of the dorsal 
aorta, it became feasible to study the immunophenotype of the earliest human HSCs 
overcoming the issue with the limited number of input cells by removing the AoD 
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and the UGRs before cell sorting. The AoV from CS 14–17 human embryos contains 
on average 162480±125970 cells per e.e. Considering that the maximum speed of the 
on-chip microfluidic cell sorting is 100 events per second, it can be estimated that the 
isolation of a population of interest from the AoV requires about 30 min to complete. 
This is a reasonable duration for a cell sort and is unlikely to severely compromise 
cell viability and functionality. 
 
To perform the on-chip microfluidic FACS, a Celula mvs360b instrument was 
employed. The machine was equipped with a 488 nm laser, a forward scatter detector 
and four fluorescence detectors. Due to difficulties in the compensation of the 
spectral overlap between different fluorochromes, only three fluorescence detectors 
could be used in practice (525/40, 575/25 and 624/40). The instrument could only 
perform a two-way sorting, which was determined by the design of the Celula 
mvs360b sorting chip (Figure 3.3.3). 
 
In view of the immunophenotype of mouse AGM region HSCs (Taoudi et al., 2005) 
and the fact that the human AoV, which exclusively harbours HSC activity within 









 cells from the human AoV and tested 
them in the long-term repopulation assay. To this end, human AoV cells were 
immunolabelled with anti-human CD45-FITC and CD144-PE monoclonal 





 cells and all the other remaining cells. The cell 
populations were individually transplanted into sublethally irradiated 
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Figure 3.3.3. Design of the disposable Celula mvs360b chip for microfluidic FACS. 
Cells are loaded into a sample cup. Driven by a low hydraulic pressure gradient, the cells 
enter the system of microchannels to become focused in the centre of the sheath fluid stream 
and separated from each other. Entering the analysis and sorting area, the cells are exposed 
to the laser. In the case a target cell is detected, hydraulic pressure is applied to deviate the 
cell towards a target cell chamber. Irrelevant cells flow into a waste cell chamber by default. 
Scale bar, 10 mm. 
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NSG recipient mice. In total, five independent transplantation experiments were 
performed with sorted AoV cells from CS 15–17 human embryos. Strikingly, in all 
five experiments HSCs could be detected in none of the two sorted populations. 
Statistically, every second CS 15–17 human embryo should contain HSCs in the 
AGM region (see Table 3.1.1 and sections 3.1.4 and 3.3.5). The failure to detect HSC 
in the long-term repopulation assay might be explained by the functional impairment 
of human AGM region HSCs following the on-chip microfluidic cell sorting. Among 
the possible factors that could contribute to the loss of HSC activity might be HSC 
damage by the laser or due to toxic effects of some substances released by the chip. 
To test this, three technical experiments were set up with AGM region cells from day 
11.5 Ly5.2/Ly5.2 mouse embryos. The unlabelled cells were run through the Celula 
mvs360b chip with the maximum sorting speed and the laser turned on. Afterwards, 
the cells were transplanted into sublethally irradiated Ly5.1/Ly5.1 recipient mice at 
the dose 1 e.e. per recipient. Unmanipulated mouse AGM region cells were used as a 
control. No difference in HSC activity between the experimental and control groups 
was found (data not shown). This indirectly suggested that the on-chip microfluidic 
FACS did not functionally affect human AGM region HSCs. Thus, the loss of HSC 
activity due to immunolabelling should also be considered. 
 
3.3.7. Immunophenotype of Human AGM Region HSCs 
Since the on-chip microfluidic cell sorting approach was not successful in 
establishing the immunophenotype of human AGM region HSCs, the magnetic cell 
separation was employed as an alternative approach. To this end, AGM region cells 
from CS 15–17 human embryos were sorted based either on CD45 or CD144 
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expression using magnetic beads. Antigen-positive and negative cell populations 
were isolated and individually transplanted into sublethally irradiated NSG mice. In 
two out of three independent experiments performed with anti-human CD45 
magnetic beads, HSC activity was detected exclusively within the CD45
+
 cell 
population (Figure 3.3.4). As for cell separation based on the expression of CD144, 





cell population. More experiments need to be performed to obtain more stringent 
statistical evidence, but the above observations suggested that anti-CD144 antibody 
may functionally impair human AGM region HSC. Interestingly, the anti-CD144 
antibody used in the present study (clone TEA 1/31) has been shown to possess a 
moderate CD144 blocking activity, as assessed in vitro by changes in paracellular 
permeability of human umbilical vein endothelial cells (Corada et al., 2001). 
 
Due to a limited availability of human embryonic tissues, it was not feasible to 
estimate the effect of CD144 blockade on human HSC function in a systematic 
experiment. Therefore, mouse AGM region HSCs were used to test the hypothesis 
that CD144 blocking antibodies attenuated HSC activity. To this end, cell 
suspensions prepared from AGM regions from day 11.5 Ly5.2/Ly5.2 mouse embryos 
were labelled with either anti-mouse CD144, CD45 or both CD144 and CD45 
monoclonal antibodies and individually transplanted into sublethally irradiated 
Ly5.1/Ly5.1 recipient mice at the dose 1 e.e. per recipient. Unlabelled mouse AGM 
region cells were transplanted to serve as a positive control. In total, three 







Figure 3.3.4. Xenotransplantation experiments revealed that human AGM region 
HSCs are CD45
+
. (A) AGM region cells from two CS 17 human embryos were 





 cell populations, each of which was individually transplanted into sublethally 
irradiated NSG recipient mice. (B) Representative flow cytometry plots show the presence 
of human CD45
+
 haematopoietic cells in the peripheral blood of two NSG recipient mice 
from two independent experiments (mouse 1 from experiment 1 and mouse 2 from 




 human AGM 




these experiments (clone 11D4.1) was a blocking antibody (Gotsch et al., 1997). 
Assessing recipient mouse peripheral blood 2 months after transplantation, it was 
found that in the experimental variants where mouse AGM region cells had been 
treated with the anti-CD144 blocking antibody alone or in a combination with an 
anti-CD45 antibody, two out of eight and two out of nine recipients, respectively, 
were found engrafted with donor HSCs. For comparison, in the experimental variant 
where cells had been exposed to an anti-CD45 antibody alone and in the control 
variant, five out of nine and five out of eight recipients, respectively, were found 
repopulated with donor haematopoietic cells (Figure 3.3.5). From the above data, it 
was concluded that CD144 blockade caused considerable functional impairment of 
mouse AGM region HSCs. It is very likely that CD144 blockade was a reason why 
human AGM region HSCs could not be detected in the long-term repopulation assay 
following the cell purification based on the expression of CD144 antigen using both 
the on-chip microfluidic FACS and the magnetic cell separation. 
 
Although it has not formally been shown that human AGM region HSCs are 
CD144
+
, several pieces of indirect evidence suggest that the first human HSCs do 





 cell population. The finding that the blockade of 
CD144 considerably attenuates HSC activity hints that human AGM region HSCs 
reside within the CD144
+
 cell population with a high probability. Secondly, the vast 




 cells reside in the AoV, which has 





 cells express a number of antigens expressed by human 
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Figure 3.3.5. Anti-mouse CD144 blocking monoclonal antibody attenuates HSC 
activity of mouse AGM region cells. A single cell-suspension was prepared from day 11.5 
Ly5.2/Ly5.2 mouse AGM regions and split into four equal parts. Each of the three parts of 
the cell suspension was incubated for 30 min with either anti-mouse CD144, CD45 or both 
CD144 and CD45 monoclonal antibodies, washed and individually transplanted into 
sublethally irradiated Ly5.1/Ly5.1 recipient mice. One part of the cell suspension was left 
unmanipulated and transplanted as a control. Recipient peripheral blood was assessed for the 
presence of Ly5.2/Ly5.2 CD45
+
 cells by flow cytometry 2 months after transplantation. In 









cell population contains almost all human AGM region CFU-Cs. 
In four independent experiments, human AGM region cells were immunolabelled 
and sorted into four cell populations based on the expression of CD144 and CD45 
(Figure 3.3.7 A). Each of the sorted populations was individually plated into the 
methylcellulose medium supplemented with human cytokines. After 14 days of 
culture, human haematopoietic colonies were enumerated. The average number of 
















 cell populations was 0.3±0.5, 3.8±3.0, 89.5±49.9 and 17.8±21.5 CFU-Cs per 




cell population contained statistically significantly more CFU-Cs than each of the 
other three sorted cells populations (P<0.05) (Figure 3.3.7 B and Tables 3.3.1 and 
3.3.2). To make the data more representative, the normalisation against the total 
number of CFU-Cs per e.e. was performed for each individual human embryo used 





cell populations contained 83±7.8% of total human AGM region 
CFU-Cs. Taken together all the above, it can be claimed with a high confidence that 















In this result subchapter, it has been shown that there exists the dorso-ventral polarity 
in haematopoietic activity within the human embryonic dorsal aorta. In the human 
embryo, the AoV contains statistically significantly more CD45
+
 cells, cells with 
HSC immunophenotype and CFU-Cs than the AoD. More importantly, the AoV 
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 cells from 
the human AGM region. Human AGM region cells from one human embryo were split 
into several parts and immunolabelled with anti-human CD144-PE, CD45-FITC and either 
CD34, c-Kit, Thy-1 or CD105 APC-conjugated monoclonal antibodies. Based on the FMO 









Figure 3.3.7. Immunophenotype of human AGM region CFU-Cs. (A) Human AGM 
region cells from four human embryos were sorted into four cell populations based on the 
expression of CD144 and CD45 antigens. (B) Each population was individually plated into 
methylcellulose medium supplemented with human cytokines, and after 14 days human 
















Table 3.3.1. Absolute live cell numbers obtained per e.e. sorting cells  from four 

















 cells populations.  

















 cell populations sorted from four different human AGM regions.  
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possesses the entire human AGM region HSC activity. Thus, it is reasonable to 
assume that the AoV contains the niches in which the first human HSCs emerge. In 
future, the identification and characterisation of such niches would facilitate our 
understanding of the key factors required for the generation of adult-type HSCs. This 
knowledge would not only be of academic interest but also of enormous practical 
value in the development of the methods for in vitro differentiation of human 
pluripotent stem cells into transplantable HSCs. 
 
According to current views, it is possible that intra-aortic cell clusters budding from 
the ventral wall of the embryonic dorsal aorta and underlying mesenchyme are 
constituted from the mentioned above HSC niches (Jaffredo et al., 1998; Taoudi et 
al., 2008; Yokomizo and Dzierzak, 2010). Due to a number of reasons discussed 
below, one should not underestimate other locations for HSC niches within the AoV. 




 cell clusters occurs between CS 12 
and 16 (Tavian et al., 1996; Tavian et al., 1999). In section 3.2.3, it has been shown 
that one human AGM region contains between one and three HSCs; however, the 
number of intra-aortic cell clusters is much higher (Tavian et al., 1996; Tavian et al., 
1999), suggesting that not every cluster contains HSCs. Secondly, although HSCs are 
still detected at CS 17, intra-aortic cell clusters are reported to disappear by that stage 
(Tavian et al., 1996; Tavian et al., 1999), indicating that the link between HSCs and 
haematopoietic cell clusters needs to be elucidated further. Thirdly, it has been 
shown that the maturation of definitive HSCs in the mouse embryo also occurs 
underneath the luminal layer of the dorsal aorta (Rybtsov et al., 2011). Taking 
together all the above, the identification of exact HSC location will be a rather 
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challenging task. One of the possible initial approaches to this scientific question 
would be a detailed characterisation in situ of the cells surrounding human AGM 
region HSCs. For this, the first requirement is to establish a precise 
immunophenotype which would allow separating the earliest human HSCs and more 
differentiated haematopoietic progenitors present in the AGM region. 
 
If one compares the dorso-ventral polarity in haematopoietic activity within the 
human versus the mouse dorsal aorta, it should be noted that in the day 11.5 mouse 
embryo there only exists the polarity in pre-HSC and HSC activity. Mouse mature 
haematopoietic cells and CFU-Cs are uniformly distributed in the wall of the dorsal 
aorta (Taoudi and Medvinsky, 2007). In contrast, in the human embryo, the dorso-
ventral polarity in haematopoietic activity within the dorsal aorta is absolute. 
Therefore, studying the differential gene expression in the AoV versus the AoD can 
identify potential factors regulating the emergence of HSCs, and it is possible that a 
result obtained by using human but not mouse embryonic tissues will be ‘cleaner’. 
This, of course, does not mean that the data obtained for the human embryo should 
be blindly and fully extended to the mouse embryo since there is a possibility that the 
mechanism regulating the formation of definitive HSCs in the human and the mouse 
are indeed different. 
 
The preliminary long-term repopulation assay data on the immunophenotype of 
human AGM region HSCs presented in this result subchapter strongly suggest that 




. Remarkably, HSCs from the mouse 




(Taoudi et al., 2005). Using flow cytometry 
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cell population from the 
human AGM region is entirely positive for CD34, c-Kit and Thy-1, which all are 
markers of human adult HSCs. Thus, the immunophenotype of human AGM region 
HSCs can be extended further without a need to perform transplantation experiments. 
Unfortunately, this does not help much in addressing the two important biological 
questions raised in the present thesis. The first question is related to the identification 
and characterisation of HSC niches in the AoV. The second question touches on the 
mechanism underlying the high regenerative potential of early human embryonic 
HSCs. To answer both of these questions, it is crucial to separate human AGM 
region HSCs and more differentiated haematopoietic progenitors. As it has been 




cell population from the human AGM region 
contains both HSCs and CFU-Cs. Unluckily, it was not possible to separate these two 





cells from the human AGM region also expressed CD34, 
c-Kit, Thy-1 and CD105. Currently, this is the aim of my ongoing work to find ways 




4. SUMMARY AND PERSPECTIVES 
Prior to this study, nothing was known about the development of haematopoietic 
stem cells in the human embryo. Medvinsky and Dzierzak (1996) have shown that 
the AGM region is the prime site for the generation of HSCs in the mouse embryo. I 
tested whether this could be extended to the human embryo. Since HSCs can be 
assessed only by transplantation into preconditioned recipients, the long-term 
repopulation assay was rigorously employed in the present study. Transplanting 
sublethally irradiated NSG mice with single cell suspensions prepared from various 
intra- and extra-embryonic tissues obtained from human embryos at different 
developmental stages, the spatio-temporal mapping of HSC activity within the 
human embryo has been performed. It has been found that, similar to the mouse 
embryo (Muller et al., 1994; Taoudi et al., 2005), the earliest human embryonic 
HSCs are detected in the AGM region (around week 5 of development), specifically 
in the ventral wall of the dorsal aorta. Approximately one week later, the human yolk 
sac and embryonic liver also acquire HSC activity. In contrast to the mouse embryo 
(de Bruijn et al., 2000; Gekas et al., 2005; Ottersbach and Dzierzak, 2005), umbilical 
cords and placentas from early human embryos do not contain HSCs. It was reported 
by others that the human placenta acquires true HSC activity around week 9 of 
development (Robin et al., 2009). Thus, although the development of HSCs is 
mainly conserved between the mouse and the human embryo, there are a number of 
substantial differences between the two species. 
 
Although a key role of the AGM region in the production of definitive HSCs is 
widely acknowledged in the field of mouse embryonic haematopoiesis, there still 
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remains a controversy regarding the origin of the first definitive HSCs. The main 
reason for this is that in the mouse embryo the first definitive HSCs are detected at 
approximately the same time in the dorsal aorta, the yolk sac, the umbilical and 
vitelline arteries and the placenta (reviewed by Medvinsky et al., 2011). Therefore, it 
is very difficult or maybe even impossible to set up experiments in a way that would 
provide a final answer to the question, ‘In which tissue do the first mouse definitive 
HSCs emerge?’ In the quest for the answer to this question one should consider that 
it is also possible that HSCs may arise independently in different intra- and extra-
embryonic sites, which is equally difficult to prove. In the human embryo, the 
appearance of HSCs in different tissues is clearly resolved, with the AGM region 
being the first site where HSC are detected. Thus, while the issue of the origin of 
definitive HSCs is not resolved in the mouse embryo and nonmammalian vertebrate 
embryos, the data obtained in the experiments with human embryos shift the balance 
further towards the priority of the AGM region in the generation of the first HSCs. I 
believe that this essential result became possible due to extended time required for 
the development of the human embryo. 
 
Now, it is clear that the first human HSCs emerge in the AGM region. However, this 
does not necessarily mean that the human definitive HSC lineage (pre-HSCs and yet 
undescribed earlier HSC precursors) arises in the AGM region. It is still possible that 
human HSC precursors emerge, for example, in the yolk sac and then migrate to the 
AGM region to become there the first definitive HSCs. Although I did make attempts 
to address the question on the existence of human pre-HSCs employing the ex vivo 
AGM region and yolk sac explant, reaggregate and coaggregate culture systems 
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developed in our laboratory to study mouse pre-HSCs (Rybtsov et al., 2011; Taoudi 
et al., 2008), the experiments with human embryonic tissues were not successful, and 
even the maintenance of HSC activity could not be reproducibly achieved (data not 
shown). Due to a limited availability of human embryonic tissues and an unclear 
approach how to address the question, these experiments have been postponed in 
order to put as a priority other fundamental questions on the embryonic development 
of human HSCs. Hopefully, the ongoing work in the laboratory, for example, the 
derivation of stromal cell lines from the human AGM region will provide additional 
tools for identifying and manipulating human pre-HSCs. 
 
An unexpected but very important finding of this study was that human AGM region 
HSCs possess an unprecedented regenerative potential. Upon transplantation into 
sublethally irradiated NSG mice, a single HSC from the human AGM region 
produces around 600 daughter HSCs during a period of 5–9 months. Although it is 
unlikely that early human embryonic HSCs will ever be used in clinical haematology 
as a transplant, the above finding has potential clinical applications. Exploring the 
mechanisms underlying the high propagation capacity of human AGM region HSCs, 
it may be possible to develop methods to increase the regenerative potential of 
human umbilical cord blood and adult bone marrow HSCs, which are currently used 
in the clinic. To begin addressing this issue, we are planning to perform the whole 
transcriptome analysis to establish the list of genes differentially expressed between 
human AGM region and umbilical cord blood HSCs. For this, it is required first to 
establish the precise immunophenotype of the earliest human HSCs to be able to 
purify the cells for the gene expression analysis. In the course of the present study, it 
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. Although this immunophenotype 
provides up to 1000-fold enrichment of HSCs if compared to unseparated human 
AGM region cells, it does not segregate HSCs from more differentiated 
haematopoietic progenitors. Therefore, the aim of my current experimental work is to 
find cell surface markers permitting the separation of embryonic HSCs and CFU-Cs. 
 
In parallel, we are planning to perform gene expression analysis in the human 
embryonic HSC niche. This may provide important information on potential key 
factors involved in the generation and maintenance of HSCs. I have shown that 
HSCs within the human AGM region reside exclusively in the AoV. In cell sorting 
and xenotranplantation experiments, data on the immunophenotype of early human 
embryonic HSCs have been obtained. This will allow me to localise cells with HSC 
immunophenotype within the AoV. It is reasonable to think that the cells surrounding 
immunophenotypic HSCs are the cells forming the early embryonic HSC niche. 
Based on the data of others (Tavian et al., 2010), it is likely that the cells with HSC 
immunophenotype will be found mainly in the intra-aortic cell clusters budding from 
the AoV. I will first try to carefully localise intra-aortic cell clusters using the whole-
mount immunostaining technique and confocal microscopy. Then, cells within and 
underneath the intra-aortic cell clusters and cells from the AoD (negative control) 
will be microdissected using the laser capture technique and will be used for the 




In summary, this study has provided a systematic spatio-temporal picture of HSC 
emergence in the early human embryo and identified the AGM region as the primary 
source of HSCs with unprecedented self-renewal capacity. Future comparative 
studies of early human embryonic HSCs and their foetal, neonatal and adult 















  Figure A.1. Flow cytometry controls. Considering disadvantages of isotype controls 
(Keeney et al., 1998), cell populations of interest were usually gated based on 
autofluorescence of cells from sublethally irradiated NSG mice injected with DPBS. The 
cells from such control mice were treated with antigen-specific anti-human monoclonal 
antibodies in parallel with the cells from mice transplanted with human cells. Representative 
flow cytometry plots show gates used for designation of human B cells (A), T cells (B, C), 
NK and NKT cells (D), granulocytes and monocytes/macrophages (E), erythroid cells (F) 
and platelets (G) in the peripheral blood, bone marrow, spleen and/or thymus of NSG 
recipient mice, as shown on Figure 3.1.4. BM, bone marrow. 
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mCD45 Alexa Fluor 546 
DAPI 
Figure B.1. Confocal microscopy control for anti-human CD45 monoclonal antibody 
staining. To test the specificity of anti-human CD45 monoclonal antibody, femurs from 
sublethally irradiated NSG mice injected with DPBS were used. After the bones were fixed, 
decalcified, snap-frozen and sectioned, tissues were stained with anti-human and anti-mouse 
CD45 monoclonal antibodies, followed by nuclear counterstaining with DAPI. Images were 
obtained employing confocal microscopy.  
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7. APPENDIX C: PUBLICATION 
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